Ascorbic acid and the hepatic drug metabolising system. by Sutton, Judith L.
ASCORBIC ACID AND THE HEPATIC 
DRUG METABOLISING SYSTEM
by
JUDITH L. SUTTON
A thesis submitted in accordance 
with the requirements of the 
University of Surrey for the 
degree of Doctor of Philosophy.
Department of Biochemistry 
University of Surrey, 
Guildford,
Surrey.
September,
ProQuest Number: 10804550
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 10804550
Published by ProQuest LLC(2018). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106- 1346
To my Parents
ABSTRACT
In recent years, there have been many reports of the 
beneficial effects derived from the taking of large, i.e. gram, 
doses of ascorbic acid. These reports have stressed the harmless 
nature of the vitamin, due largely to its water-solubility. 
However, these reports have been countered by a smaller number 
describing adverse effects of large doses of ascorbic acid.
Such reports have been given considerable publicity in spite 
of the fact that few of the effects have been systematically 
investigated.
When gram doses of ascorbic acid are consumed, it 
is probably no longer possible to consider the substance as a 
vitamin for the doses are pharmacological and the substance 
itself becomes a drug and like other drugs becomes involved 
in the detoxification system of the liver.
The activity of the drug metabolising enzymes is known 
to be reduced by ascorbic acid deficiency. The bulk of the 
work described in this thesis involves a series of experiments 
designed to investigate the effects and mechanisms of action of 
large doses of ascorbic acid over periods of 4 and 28 days.on 
the hepatic drug metabolising enzymes, using the guinea pig as 
an animal model, since this species, like man, is unable to 
synthesise the vitamin. The relative importance of the effects 
found is discussed together with possible mechanisms of action.
In the doses given, which correspond approximately to 
4.5g/day in man, ascorbic acid had an inhibitory effect on 
the mixed function oxidase system, which was not. extended to a 
generalised effect on the endoplasmic reticulum or the liver cell, 
but was characterised by altered haem synthesis.
The activities of cytochromes P450 and bp. and the 
concentrations of microsomal haem were decreased as was hydroxy- 
lation of type I substrates. However, type II substrates were 
unaffected, suggesting that specific species of cytochrome P450 
may have been involved. The concentrations of the phospholipid, 
phosphatidylcholine and its precursor, phosphatidylethanolamine, 
were also decreased.
A dose dependent relationship was apparent, with decrease
in the concentrations of the cytochromes first occurring with 
dose levels of 200mg/day, with exacerbation of the effect with 
300mg/day.
Phase II metabolism of drugs was also affected, with 
the activity of l~naphthol glucuronyl transferase showing a 
decrease. Another membrane-bound enzyme, glucose-6-phosphate, 
was unaffected, as was the cytosolic enzyme, glucose-6-phosphate 
dehydrogenase. The extent of lipid peroxidation also remained 
unchanged.
Activity of the(rate-limiting enzyme in haem synthesis, 
delta-amino laevulinic acid synthetase, was significantly 
increased, whereas the activity of the degradatory enzyme, haem 
oxygenase, was decreased, suggesting an attempt to conserve 
haem.
The possible involvement of transition metals, such 
as copper, zinc and iron, was investigated but no significant 
trends were seen in the concentrations of these metals in 
either the serum or liver of control and treated animals.
Ascorbic acid also appears to be capable of augmenting 
the action of the natural superoxide anion scavenger, superoxide 
dismutase. This finding is perhaps significant since such ions 
may be involved in the hydroxylation of xenobiotics, perhaps 
as precursors of the active oxygen species associated with 
cytochrome P450.
Both deficiency and large quantities of ascorbic acid 
appear capable, therefore, of exerting a similar inhibitory effect 
on the hepatic mixed function oxidase system of the guinea pig. 
Hence results of these studies suggest that large doses of 
ascorbic acid can no longer be considered to be totally innocuous 
and. care should be taken when prescribing large doses of the 
vitamin to at least some groups of the population*.
Finally, it should not be forgotten that other adverse 
effects, besides those affecting the drug metabolising system, 
have been reported in the literature, including increased 
excretion of uric acid and oxalate. Although reports of these 
effects have been used to counter the claim that the use of 
large doses of ascorbic acid is without risk, this argument is 
no longer valid since these effects have recently been shown to
be negligible. However, the results presented in this thesis 
provide strong new evidence of a possible adverse effect 
of large doses of the vitamin.
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C H A P T E R  1.
I N T R 0 D U C. T I O N
I. HISTORICAL REVIEW.
The early history of ascorbic acid is intimately 
connected with its deficiency disease, scurvy, which was 
first described with certainty at the time of the crusades 
in the thirteenth century (Sharman, 1974). With the 
development of the sailing ship, long oceanic voyages became 
possible and as a result scurvy was the cause of more deaths 
amongst naval crews than resulted from all other causes.
In the mid eighteenth century, James Lind demonstrated 
that the juice of fresh citrus fruit cured scurvy (Lind 1753). 
Nearly half a century, however, was to elapse before his 
proposals were adopted in 1795 at the instigation of Sir 
Gilbert Blane.
In 1907, Holst and Frolich (1907) produced scurvy, 
experimentally, in guinea pigs by feeding them a restricted 
diet. Soon afterwards, Hopkins (1912) introduced the concept 
of 'acessory food factors’ and in the same year, Funk (1912) 
postulated the existance of 'special substances which are 
of the nature of organic bases, which we will call vitamines?.
Ascorbic acid was isolated in the late 1920’s by Albert 
Szent-Gyorgyi (1928) and by the mid 1930's, the structure of the 
vitamin (Figure I) had been elucidated (Haworth ert al, 1934). 
Many methods for its synthesis were to follow and the vitamin 
soon became widely available at low cost.
CH OH 
2
HC H
FIGURE I The accepted structural configuration of ascorbic
acid, an a-ketolactone with the formula C„H 0„, a
6 8 6
molecular weight of 176.13 and containing an acid
ionising group in water with pK 4.19.
a
II PHYSIOLOGY AND METABOLISM
a) Recommended Intake of Ascorbic Acid.
Throughout the world there is a wide variation in both 
the daily dose of the vitamin that is recommended (Figure II) 
and the parameters on which this decision is made. Although 
the pathological lesions of ascorbic acid deficiency have been 
accurately defined, the explicit- biochemical functions of the 
vitamin remain unclear. For many years it has been recognised 
that lOmg/day will prevent scurvy in the adult man (Chatterjee, 
1978) although plasma levels remain low at this intake.
The United Kingdom Panel on Recommended Allowances of 
Nutrients (DHSS, 1969) recommended a daily allowance of 30mg 
ascorbic acid for adult men and non-pregnant women, based on 
a study carried out in Sheffield (Bartley et^  al, 1953). Twenty 
male volunteers were divided into three groups and received 
diets containing no ascorbic acid, lOmg/day or 70mg/day. On 
the basis of this study it was concluded that the League of 
Nations figure of 30mg ascorbic acid was a safe allowance to 
adopt, since physical fitness tests left some doubt as to 
whether lOmg was an optimal dose and there were--small differences 
in favour of 70mg.
Unlike the United Kingdom, the United States took tissue 
saturation as their criterion and 60mg/day was advised (National 
Research Council, 1968). However, in 1974, the situation was 
reviewed and a recommended intake of 45mg/day was agreed upon 
(National Research Council, 1974). This figure was derived 
from the observations that man has a body pool of ascorbic.acid, 
which is approximately 1.5g in size and that the daily turnover 
of this pool is about 3% i.e. 45mg (Baker et^  a]L, 1971a; Hodges 
et al, 1971). It was calculated that on this intake, serum 
ascorbic acid would be maintained at approximately 0.6mg/100ml, 
that the leucocyte level, which is considered to represent the 
tissue level, would be about 20mg/100ml cells and that the body 
pool would remain close to a maximum of 1.5g (Harper, 1975).
Serum ascorbic acid levels below 0.2mg/100ml are generally 
considered to indicate a deficiency state (Sauberlich, 1975).
3.
The DHSS has recently reviewed recommended daily 
nutrient intakes (DHSS, 1979) but has retained the 30mg/day 
recommendation for ascorbic acid, in spite of the fact that 
an intake of lOOmg/day has recently been recommended (Kallner 
et al, 1979).
FIGURE II ASCORBIC ACID REQUIREMENTS (mg/day) FOR MEN IN 
DIFFERENT COUNTRIES (1964-1973) 
from the 19 countries report reviewed by IUNS *
Australia, Canada, Finland, Malaysia,
Thailand, U.K., West Pacific, W.H.O., 30
USA (1974) 45
Colombia, India, Netherlands, Turkey 50
INCAP (Institute of Nutrition of
Central America & Panama) 55
East Germany 60
West Germany, Phillipines 70
USSR 70 - 100
* IUNS - Committee on International Dietary Allowances 
of the International Union of Nutritional 
Sciences, 1975.
b) Evolution and Biosynthesis
There are five vertebrate species known which are unable 
to synthesise _i3scorbic acid, these are man, the primates, the 
guinea pig, fruit eating bats and the red-vented bul bul bird. 
The ability to synthesise ascorbic acid can be followed through 
evolution and is thought to have always been absent in the 
insects, invertebrates and fishes (Chatterjee, 1978). In 
amphibians, the biosynthetic capacity started in the kidney, and
4r-emained there in reptiles. In mammals, biosynthesis was 
transfered to the liver but finally disappeared in the species 
mentioned above (Chaterjee, 1978). A similar transition was 
observed to occur in the evolution of birds, such that the 
highly evolved passeriforms also require dietary ascorbic acid.
It is nowadays generally assumed that the inability of 
man and other species to synthesise ascorbic acid is due to 
an inability to carry out the metabolic steps in which 
D- glucurono- y -lactone and L-gulono-y-lactone are involved 
(Figure III). As a result it has been suggested (Lewin, 1976) 
that the biosynthetic deficiency is due to a ’missing step' 
or ’gene mutation' involving one or more of the following :
a) the microsomal enzyme D-glucurono-y- 
lactone reductase.
b) L-gulono-y-lactone oxidase
c) Aldonolactonase (Uronolactonase)
Chatterjee et_ al (1960) have suggested that the absence 
of L-gulono-y-lactone oxidase is a general characteristic of 
all the species which are unable to synthesise L-ascorbic acid. 
However, more recently it has been proposed that the inability 
to synthesise ascorbic acid by some species is governed by a 
lack of more than one enzyme. Guinea pig microsomes seem to 
lack both D-glucuronolactone reductase activity and L-gulono-y- 
lactone oxidase (Chaterjee, 1970).
Stone (1965) has provided a genetic explanation for the 
biochemical generalisation made by Chaterjee et al (1960) and 
suggests that the entire human race and some of the primates 
carry a defective gene which renders them unable to synthesise 
the enzyme, L-gulono-y-lactone oxidase. Hence Stone (1966) 
regards scurvy as the result of an inborn error of metabolism 
rather than a nutritional disorder and names the condition * 
hypoascorbaemia.
5Despite the general acceptance of the fact that the guinea 
pig is unable to synthesise the vitamin, a few isolated reports 
indicate that a very small number of animals are capable of 
at least limited synthesis. Williams and Deason (1967)3 
compared survival times and evidence of scurvy in guinea pigs 
on a scorbutic diet with varying degrees of ascorbic acid 
supplementation. Although they did not differentiate their 
animals by sex, they found at least a 20-fold variation between 
individuals in their vitamin C requirements. From their 
experiments, they concluded that the guinea pig and man have 
varying abilities, previously undetected, to produce ascorbic 
acid endogenously. However, unlike other mammals such as the 
rat, the guinea pig and man are unable to produce the vitamin 
in sufficient quantities to maintain health.
Other experiments suggest that the sex of the animal is 
of relevance. Odumosu arid -Wilson (1973) compared survival times 
of male and female guinea pigs and measured ascorbic acid -i 
concentrations in the survivors. Male guinea pigs all tended 
to die by 28 days of a scorbutic diet, whereas females survived 
for at least 30 days. By day 24, the animals could be divided 
into two groups on the basis of weight loss. Those which were 
later to die were still losing weight, but weight loss had 
ceased in those which were destined to survive. Of 50 .female 
guinea pigs, 9 were still alive at 36 days, one existed for 
98 days on a scorbutic diet and another continued to live on a 
scorbutic diet after the experiment had finished.
Similar results have also been reported by Ginter (1976) 
with male guinea pigs. Three animals manifested no signs of 
scurvy despite 4 - 8  months on a scorbutic diet, and gained 
weight normally. After 8 months on a scorbutic diet, one of the 
animals was found to have a liver ascorbic acid concentration 
which was more than twice that of an animal receiving a daily 
intake of lOmg ascorbic acid.
Hence it is apparent that certain guinea pigs are capable 
of synthesising ascorbic acid, although the incidence of such 
animals is probably extremely small, perhaps 1:1000 (Ginter 1976).
FIGURE III. THE BIOSYNTHETIC FORK OF L-ASCORBIC ACID AND L-XYLULOSE.
(Lewin, 1976)
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7c) Absorption
Exogenous ascorbic acid is absorbed through the 
buccal mucosa, from the stomach and through the mucous membrane 
of the small intestine, the latter being the most important.
Oral administration of ascorbic acid to guinea pigs resulted 
in an increased concentration of the vitamin in the walls of 
the stomach and the large and small intestines (Penney & Zilva, 
1946). A linear logarithmic relationship was found to exist 
between the dose of ascorbic acid administered and the con­
centration of the vitamin attained in the wall of the alimentary 
canal.
In man, ascorbic acid is rapidly absorbed through the 
buccal mucosa, the degree of absorption being dependent on 
the local pH and concentration of the vitamin (Odumosu & Wilson, 
1971) and, in addition, gastric absorption is more efficient 
than in the guinea pig (Penney & Zilva, 1946).
In both man and the guinea pig, ascorbic acid is absorbed 
in the gastrointestinal tract by an energy-requiring sodium 
ion-dependant active transport mechanism (Hornig, 1975; Iwamoto 
et al, 1976). The mode of carrier system is thought to be 
similar in nature to, but functionally distinct from the sodium- 
gradient mechanism postulated to effect sugar and amino acid 
transport in the mammalian ileal mucosa (Iwamoto et^  al, 1976; 
Mellors et al, 1977). It is of interest, however, that Mann 
and Newton (1975) have demonstrated "that the addition of sugars 
impaired the transport of ascorbic acid, suggesting that the 
absorptive mechanisms for ascorbic acid and sugars are not 
functionally distinct. In addition, Rose and Nahrwold (1978) 
provide evidence that the transport mechanism may respond to 
circulating levels of the vitamin, since intramuscular injection 
of ascorbic acid reduced the rate of influx of ascorbic acid 
but not choline.
In species which demonstrate endogenous production of 
ascorbic acid, for example the rat and hamster, passive transport 
was observed (Hornig, 1975).
8An active transport mechanism implies a saturable process 
and hence relative absorption may be expected to decrease with 
the administration of increasingly large doses of the vitamin. 
Access to radioactive-labelled ascorbic acid has allowed 
detailed examination of metabolism, half-life, turnover rates, 
elimination rates and size of the body pool of ascorbic acid.
Pool sizes and turnover rates have been estimated from 
urinary excretion of radioactively labelled metabolites in 
volunteers, who had been given labelled ascorbic acid orally 
(Baker et aJ, 1966; Tolbert ert al, 1967; Baker e^t a!L, 1969;
Baker et al, 1971b;Sauberlich, 1975). Data obtained from these 
studies, using ascorbic acid free diets, revealed that in a 
depleted state, about 3% of the total body pool is degraded 
daily. Furthermore, orally ingested ascorbic acid appeared 
in the urine only when the body pool of ascorbic acid approached 
the size of approximately 1.5g. The first signs of scurvy 
appeared when the pool size reached 300 - 400mg. and , upon 
repletion, the last signs of scurvy, hyperkeratosis, did not 
disappear until a pool size of about lg. had been achieved 
(Hodges et_ al, 1971). However, Kallner et^  al (1977) suggested 
that in these experiments over-estimations of the pool size 
were made, mainly due to the false assumption that ascorbic 
acid was completely absorbed.
Using healthy non-smoking volunteers, Kallner and
colleagues (1979) followed the time-course of radioactivity
in plasma and urine after oral administration of a single dose 
14of (1- C) ascorbic acid. The investigation was carried out 
under steady state conditions with regard to ascorbic acid 
intakes in the range 30-180mg/day. They found that the half- 
life was inversely related to the dosage and that the pool size 
could be increased to about 20mg/kg bodyweight by increasing 
the dosage. This work is in agreement with that of Kuebler and 
Gehler (1970), who showed that by increasing the dose of 
ascorbic acid from 1.5 - 12g. the relative absorption decreased 
from 49.5% to 16.1%. An average absorption of 70% was 
extrapolated for intakes of up to 180mg.
4 Kallner et al_ (1979) concluded that a total turnover
of 60mg/day of ascorbic acid should be aimed at, and taking 
into account the incomplete absorption of ascorbic acid (Kallner 
et al, 1977), the amount of ascorbic acid which should be 
ingested in order to reach this total turnover would be in the 
range of 70-75mg/day. Since the group investigated were 
healthy and non-smoking, two standard deviations should be added 
in order that 95% of the population is accommodated. Hence 
these authors recommend a daily intake of lOOmg/day (Kallner 
et al, 1979).
In a pilot study (Hornig at al, 1980) the absorption
of large single oral ascorbic acid doses was investigated.
The urinary excretion of unmetabolised unlabelled ascorbic
acid per day was taken as an index for the absorption of
ascorbic acid. It decreased from 75% of a lg. ingested dose
to 20% of a 5g. dose, and of the latter 80-90% of the excreted
label remained unchanged. The linearisation of the relationship
between ingested dose and the .excreted amount in urine yielded
a figure of 1.16g. ascorbic acid, this being the maximum which
can be absorbed in 24 hours under the experimental conditions.
However, some discrepancies were found, since although on a
daily dose of 5g. only 22.2% of the dose was absorbed, only 2.8%
was found in the faeces up to 117 hours following ingestion of
the label. Thus, about 75% of the administered radioactivity
14could not be recovered. Respiratory excretion of C0o had 
not been monitored since this is not usually considered to be 
a major catabolic pathway in man. However, it is possible that 
with large doses, this assumption is no longer valid. Another 
possibility may be microbial destruction of ascorbic acid to 
gaseous products including CO and methane. Other suggestions 
proposed by the authors are combination of ascorbic acid with 
nitrite and decomposition due to the instability of ascorbic 
acid in the alkaline environment of the intestine.
d) Transport and Tissue Distribution
Ascorbic acid is the preferred form of transport of the 
vitamin in pituitary and adrenal glands, lungs, liver, kidneys, 
bone, skin and nasal mucosa (Hornig, 1975). On the other hand
10
dehydro-ascorbic acid (DHAA) is the preferred form of uptake 
by neutrophils, erythrocytes and lymphocytes (Bigley & Stankova, 
1974), In the erythrocyte, DHAA is enzymatically reduced-to 
ascorbate by the reduced glutathione-dependant DHAA reducing 
enzymes (Hughes, 1964; Hornig, 1975).
It has been reported that uptake of ascorbic acid by the 
various tissues is an energy requiring process, whereas uptake 
of DHAA follows simple diffusion (Hornig, 1975). With regard to 
tissue distribution, both the guinea pig and man show similar 
patterns, whereas in species capable of endogenous synthesis 
of the vitamin, tissue contents are far higher (Hornig, 1975).
In the human, the highest concentrations of ascorbic acid were 
observed in adrenal and pituitary glands, with appreciably high 
contents occuring in the brain, liver, spleen, pancreas, eye 
lens, kidney and heart muscle. The tissue contents generally 
decline with age (Chatterjee, 1978). Plasma ascorbic acid 
depends on many factors, including dietary intake, and it may 
vary from trace to 1.4mg/100ml.
e) Catabolism and Excretion
The catabolic fate of ascorbic acid in man and experi­
mental animals has been studied using labelled ascorbic acid.
The main excretory products are ascorbic acid, dehydroascorbic 
acid, oxalate and ascorbic acid-2-sulphate, the latter being 
the most recently discovered and accounting for about 3% of 
the ascorbic acid metabolised daily (Baker, et al, 1971a)# Figure IV 
indicates the metabolites and excretory pathways of ascorbic 
acid. These excretory compounds have been demonstrated in 
the rat, guinea pig, trout, monkey and man. However, Baker 
and his colleagues (1971a) suggest* that other metabolites, as 
yet undiscovered and possibly of importance in the understanding 
of ascorbic acid metabolism, may exist.
The relative importance of the different metabolites 
shows a species variation. CC>2 is of minor significance in 
man, as is diketogulonate, contributing only about 1% towards 
the total excretion of ascorbic acid (Baker et al, 1962; Tolbert 
et, al, 1967). However, in the rat, the guinea pig and the monkey 
CO^ has been shown to contribute a far larger proportion of the
11
excretory products, and in the monkey CO  ^production and its 
excretion via the lungs appeared to account for the larger part 
of a labelled ascorbic acid dose (Baker et al, 1975).
With regard to ascorbic acid-2-sulphate, there is some
controversy as to whether it is a mere catabolic end-product
or whether it functions in sulphate transfer. Verlangieri and
35Mumma (1973) reported an approximate 50-fold elevation of ( S)-
labelled cholesterol sulphate excretion in the faeces of rats
35 2-following intracardial injection of SO. . The administration
35 2-of ascorbic acid together with SO. caused a 2-fold increase
35in the excretion of ( ;S)-sulphate. This data was taken as 
evidence of the existence of sulphate transfer to cholesterol. 
However, Hornig et al, (1974) were unable to confirm any signif­
icant enhancement of cholesterol sulphate excretion, using
35intravenous administration of ( S)ascorbic acid sulphate, 
although they were able to demonstrate that a limited part of 
the sulphate moiety of ascorbic acid sulphate was transferred 
onto cholesterol.
Verlangieri and Mumma (1973) proposed that the quoted 
hypocholesterolaemic effect of ascorbic acid may be due to 
the intermediate synthesis of ascorbic acid sulphate. However, 
the results of Hornig et al (1974), tend to suggest that no 
such regulatory role of ascorbic acid sulphate exists in the 
catabolism of cholesterol to bile salts.
In fact, in the guinea pig following either oral or 
parenteral administration of ascorbic acid-2-sulphate, it has 
been demonstrated that there is limited tissue uptake and rapid 
elimination of mostly unaltered ascorbic acid-2-sulphate in 
the urine and faeces, with only a minute conversion of ascorbic 
acid-2-sulphate to inorganic sulphate, suggesting only a low 
potency of ascorbic acid-2-sulphate to combat scurvy (Hornig,1974).
The most recently discovered metabolite, ascorbic acid- 
2-sulphate, has also featured in discussion linking ascorbic 
acid with drug metabolism. In man and many mammals, inorganic 
sulphate in the diet is poorly absorbed and hence the major 
source of sulphate tends to be the sulphur containing amino 
acids, cysteine and methionine (Baker et al, 1971a).
EXOGENOUS ASCORBATE
1
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FIGURE IV. SCHEMATIC REPRESENTATION OF INPUT AND EXCRETION OF BODY ASCORBATE 
(after Lewin, 1976).
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Sulphate transfer is also important in the biotrans­
formation of phenolic compounds (Williams, 1959) and this path­
way, being dependant on the availability of sulphate, is of 
limited capacity in man and is therefore subject to competitive 
inhibition (Levy et al, 1967). Hence one could hypothesise 
that in the presence of both non-physiological concentrations 
of ascorbic acid and a phenolic compound e.g. salicylamide, 
competitive inhibition might occur, leading to an increase in 
the plasma half-life of the latter if an alternative pathway 
is not immediately available. Indeed, work by Houston and 
Levy (1975) has demonstrated competitive inhibition when 2g 
ascorbic acid and 150mg salicylamide were administered con­
comitantly. Due to this competition., the fraction of the dose 
excreted as the sulphate was significantly decreased whilst 
that excreted as the glucuronide was enhanced.
This problem could be further exacebbated if the 
sulphate source was depleted. Basu (1977) reported that the 
excretion of certain amino acids could be reduced by large 
doses of ascorbic acid. Healthy volunteers who took 3g of the 
vitamin daily over a period of weeks showed progressive 
decreases in cysteine excretion, suggesting an increased 
requirement of the amino acid in the presence of large amounts 
of ascorbic acid.
Experimental and clinical evidence (Wokes, 1958: Sfcith , 
1961) suggest that the detoxification of cyanide takes place 
by conversion to thiocyanate and this reaction may also require 
cysteine. Basu (1977) showed that the urinary excretion of 
thiocyanate was decreased in subjects treated with high doses 
of ascorbate, but the concomitant daily administration of lOmg 
cysteine restored the thiocyanate levels to normal. Thus 
detoxification of cyanide as well as that of phenolic compounds, 
may be impaired due to lack of available sulphate.
In conclusion, despite the quantity of information
accumulated, mainly through studies with labelled ascorbic acid,
there are still many gaps in our knowledge, especially with
regard to a realistic recommended daily intake and the nature
of the minor metabolites of the vitamin and their relevance to
\
ascorbic acid intermediary metabolism. In addition, since 
many people now choose to regularly ingest doses far exceeding 
the recommended intake, it is of paramount importance that we 
understand how these doses are being metabolised in the body.
Ill BENEFICIAL EFFECTS OF LARGE DOSES OF ASCORBIC ACID
In recent years, reports of the beneficial effects of 
large doses of ascorbic acid, stressing its water-solubility 
and consequent non-toxic properties, have been ubiquitous and 
some of these will be briefly reviewed since it is against 
this background that concern has arisen about possible toxic 
or adverse effects of the vitamin.
a) The Common Cold
Early inconclusive studies of the effects of ascorbic 
acid on the common cold, for example, Cowan et &1 (1942), have 
tended to be disregarded (Pauling, 1970; Stone 1972) on the 
basis that relatively low doses were used.
Since 1970, a number of large clinical trials (Anderson' 
et 'al, 1972a; Wilson & Loh, 1973; Anderson et^  al, 1974; Coulehan 
et al, 1976, Elwood et_ al, 1976; Asfora, 1977) have been 
conducted using gram doses of the vitamin. In addition 
volunteers have been given gram doses of ascorbic acid and then 
innoculated with various viruses (Walker et aT, 1967; Schwartz 
et al, 1973).
The results of these trials indicate that any benefit 
of ascorbic acid is modest and cannot be consistently replicated, 
that a dose response pattern is not evident and that specific 
subsets of symptoms or of persons benefitting from the vitamin 
cannot be identified. Furthermore, benefits seen are, in some 
cases, quite likely to be due to a placebo effect since despite 
attempts to make.studies double blind, volunteers were quite 
often able to determine which protocol they were on by difference 
in taste of the formulations used.
b) Cancer
In cancer patients there is often an accompanying 
desaturation with respect to ascorbic acid (Bodansky et al, 1951; 
Krasner & Dymock, 1974). Both plasma and leucocyte levels are 
decreased in patients with leukaemia, pulmonary, skin and 
prostatic cancers (Kakar_et jT, 1974; 1975; 1976) and examination 
of both primary and secondary tumours in man and experimental
animals has shown that ascorbic acid is actively concentrated 
in malignant tumours at the expense of the surrounding tissue 
(Musulin et al, 1936; Moriarty et^  al, 1977). Large oral doses 
of ascorbic acid have been suggested to be of some value in 
the management of cancer patients (Cameron & Baird, 1973;
Krasner & Dymock, 1974), possibly by inducing the production 
of hyaluronidase inhibitors, which would prevent the break­
down of glycosaminoglycans in surrounding ground substance 
and consequently prevent spread of the tumour (Cameron, 1966).
(kmeron and Campbell (1974) gave lOg of ascorbic acid 
to terminal cancer patients and reported an extended survival 
period and relief from bone pain. Criticism of the non- 
random nature of the controls in the study was met by a further 
report (Cameron & Pauling, 1978), which again showed a palliative 
effect with matched controls.
A subsequent random, prospective, double-blind study 
(Creagan et' al, 1979) of 150 patients with advanced cancer 
showed no therapeutic effect of the vitamin.
Work concerning chemically induced carcinogenesis in 
experimental animals is equally inconclusive. Experiments 
with guinea pigs exposed to carcinogens (Russel, 1952; Migliozzi, 
1977) suggest that ascorbic acid does not suppress tumour growth, 
whereas work with rats (Mirvish et al, 1976) demonstrated a 
lower incidence of tumours and an absence of lung metastases 
following sodium ascorbate treatment.
The formation of nitrosamines from nitrite and various 
amines at the pH of the mammalian stomach has been shown to be 
prevented by ascorbic acid (Kamm et_ al, 1973), thus forestalling 
the formation of carcinogens (Cardesa et_ al, 1974; Mirvish 
et al, 1975). However, other workers have suggested a non- 
uniform action of the vitamin such that there is inhibition of 
the formation of some nitrosamines, whilst others are acceler­
ated (Chang et_ al, 1979).
Finally it has been noted that exposure of rats and 
mice to chemical carcinogens such as 3-methyl-cholanthrene and 
1,2-5-6-dibenzanthracene, evokes a multifold increase in ascorbic 
acid synthesis, a process of which man is incapable.
Hence it is still to be determined whether ascorbic 
acid has any role to play in the management of malignant 
disease.
The common feature linking the reported use of ascorbic 
acid in the treatment of the common cold and cancer is the ; 
proposed role the vitamin plays in the body’s immune processes . 
As previously mentioned, both these disease states, together 
with others, demonstrate' ascorbate depletion in both plasma 
and leucocytes (Rinehart et al, 1936; Wilson, 1975; 1977). 
Research on the effects of vitamin C on host defence has 
proceeded in a piece-meal fashion and as a result, the literature 
is bedevilled with controversy and lack of confirmation. Never­
theless, recent reviews (Leibovitz & Siegel, 1978; Thomas &
Holt, 1978) refer to many studies which have demonstrated that 
cellular immune functions, both ’in vivo’ and ’in vitro’, and 
humoral factors can be altered by ascorbic acid. In addition 
effects of ascorbic acid have been noted on expression and 
induction of hypersensitivity (Zweiman et al, 1966; Wilson et 
al, 1975) and on interferon production (Siegel, 1974; 1975).
Despite these reports, there is still little positive 
evidence, in the form of clinical trials, demonstrating a 
therapeutic effect of the vitamin via enhanced immunocompetance, 
although high concentrations of the vitamin are found in the 
cells’of the immune system and rapid utilization of the vitamin 
during infection and phagocytosis has been reported, together 
with a claimed relationship between leucocyte ascorbic acid 
and severity of illness (Wilson & Loh, 1973).
c) Relief of Bone Pain
One of the beneficial effects noted in the studies of 
ascorbic acid and cancer (Cameron & Campbell, 1974; Cameron & 
Pauling, 1976) was relief of bone pain and consequent decreased 
dependence on opiates. Basu and his colleagues (1974) observed 
that a one gram loading dose of ascorbic acid reduced the 
elevated excretion of hydroxyproline found in metastatic patients 
over a period of twelve hours, suggesting that the vitamin may 
have modified bone dissolution. A possible explanation for the 
relief of bone pain in such patients is that ascorbic acid is
capable of exerting an effect of tyrosine metabolism, leading 
to production of L-dopa, which in turn reduces bone pain 
(Dickerson & Basu, 1977).
Similar effects have been reported in patients with 
Paget’s disease (Basu et al, 1978), suggesting that the vitamin 
may be of general therapeutic value in disorders of bone 
metabolism.
d) Blood Histamine Concentrations and Predisposition 
to Miscarriage.
In guinea pigs (Chatter.jee et al, 1975), raised blood 
histamine levels are reduced by ascorbic acid and thus it 
has been predicted (Clemetson,. 1980) that ascorbic acid 
deficiency may be a common cause of an elevated blood histamine 
level. In addition, Chatterjee et al (1975) have suggested that 
the vasodilatory action of histamine on small blood vessels may 
be responsible for some of the manifestations of scurvy. It 
is generally accepted that plasma ascorbic acid levels below 
0.2 mg/100 ml. are symptomatic of scurvy, however histamine 
begins to accumulate in the blood long before plasma ascorbic 
acid levels have fallen to this low level and consequently 
ascorbic acid levels below 0.7mg/100ml should perhaps be 
considered to represent deficiency (Clemetson, 1980).
In the "Vanderbilt University co-operative study of 
maternal and infant nutrition in Nashville (Martin et^  al, 1957), 
it was found that nine out of ten cases of premature separation 
of the placenta occurred in women who had consistently low 
serum ascorbic acid levels, that is below o.4mg/100ml, in the 
> second and third trimesters of pregnancy. A mean plasma 
ascorbic acid level of 0.16mg/100ml has been reported in women 
who had suffered a miscarriage (Clemetson, 1964), however there 
was no correlation between incidence of miscarriage and ascorbic 
acid intake, suggesting the existance of a metabolic disturbance 
rather than a simple dietary deficiency. Clemetson (1980) 
suggested that there may be an interference in absorption of 
ascorbic acid by trace elements, such as copper and iron in the 
water .supply, or indeed by iron supplements and consequently 
it is suggested that ascorbic acid supplements should be given
in conjunction with a natural plant polyphenol, such as 
rutin, which acts as an indirect antioxidant by chelating 
metals.
Hence, if ascorbic acid deficiency and histamine 
intoxication do predispose to miscarriage, a need for a larger 
supplement of the vitamin during pregnancy is perhaps 
indicated.
Finally, it is of interest that Bouhuys (1974) 
suggested that any beneficial effect of ascorbic acid on the 
common cold may be mediated by its anti-histaminic action, 
since a 500mg supplement of the vitamin decreased airway 
constriction induced by inhalation of histamine.
e) Atherosclerosis
For ascorbic acid to be of any benefit in atherosclerosis, 
it must either prevent or heal damage to the ground substance 
of the arteries, or prevent accumulation of lipids in pre­
existing lesions and in this respect, the vitamin seems to hold 
a position of importance by virtue of its involvement in two 
systems ; the maintenance of vascular integrity and metabolism 
of cholesterol to bile acids (Krumdieck & Butterworth, 1974), 
Ginter dt alfl979 a) have hypothesised, on the basis of animal 
experiments, that a 'chronic latent deficiency’ of ascorbic 
acid, brought about by a life-long marginal intake of the vitamin 
is the cause of an abnormal metabolic situation, which can lead 
to atherogenesis (FIGURE V).
There are many contradictions in the literature as to 
whether ascorbic acid can modify human hyperlipidaemia, due 
partly to inadequate definition of experimental conditions. The 
most striking hypocholesterolaemic effect was achieved in 
institutionalised elderly people and in hypercholesterolaemic 
maturity-onset diabetics (Ginter et al, 1977; 1978). Similar 
effects have been described in atherosclerotic patients (Willis, 
1954; Kothari eb aJ, 1977; Norden et al, 1977) and in young 
adults (Spittle, 1973). However, other authors have reported 
elevation of serum cholesterol in both normal individuals 
(Anderson et al,1972 b; Morin, 1972) and young male baboons
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baboons (kotze et_ aJ, 1975) receiving large doses of the vitamin, 
whilst others have not found evidence of a therapeutic effect 
(Elwood et'. al, 1970; Bradley et al, 1973) . Regardless of 
which view is taken most authors agree that individuals with 
serum cholesterol concentrations below about 200mg/100ml 
are unaffected by ascorbic acid therapy.
Hanck and Weiser (1977) reported a marked effect of 
ascorbic acid on a range of lipids, together with increased 
lipolysis and suggested that the mode of action of the vitamin 
was through a stabilising action on noradrenaline, thus pro­
longing noradrenaline induced lipolysis. A positive correlation 
between leucocyte ascorbic acid and high density lipoproteins 
(HDL) has also been demonstrated in elderly hospitalised men 
but not in elderly women (Bates et al, 1977; Horsey et^  al, 1981) 
and this was suggested to be partly attributable to an effect 
of the vitamin on lipoprotein lipase activity (Sokoloff et al, 
1966; Horsey et al, 1981).
Finally, several authors have reported a moderate
hypocholesterolaemic effect of pectin (Keys et al, 1961;
Jenkins et al^ , 1975; Kay & Truswell, 1977) and when used in
conjunction with ascorbic acid (Ginter et al, 1979b) serum
/
cholesterol levels fell dramatically in subjects with mild 
hypercholesterolaemia or hyperlipidaemia. Pectin has been 
reported to both lower the absorption of exogenous cholesterol 
and bind bile acids in the gastrointestinal;tract, thereby 
accelerating- cholesterol-transformation to bile acids (Kay & 
Truswell, 1977; Miettinen & Tarpila, 1977) (FIGURE VI).
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FIGURE V Scheme for the potentiation of atherogenesis following 
a chronic marginal intake of ascorbic acid; after 
Ginter (1979).
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FIGURE VI Interaction of pectin with cholesterol and bile 
salt metabolism
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f) Trace Elements
Trace elements have been implicated in an ’in::vitro’ 
mutagenic effect of ascorbic acid (Stich crt a!L, 1979).
However, 'in vivo' effects of the vitamin are more complex 
since they can influence both gastrointestinal absorption 
and distribution of the metals within the tissues. In 
addition, the effect can either be direct or indirect 
perhaps through a thiol group.
A true evaluation of the situation is complicated by the 
fact that'ascorbic acid may influence the physiological fate 
of trace elements and the metals themselves may influence 
the distribution and concentration of ascorbic acid.
Ascorbic acid aids the absorption of iron (Van Campen, 
1972; Hughes, 1974) and Mazur and co-workers (1955) have 
demonstrated that certain reducing agents, including ascorbic 
acid and reduced glutathione, release ferrous iron from 
ferritin. In addition, Lochhead and Goldberg (1959) suggested 
that ascorbic acid and reduced glutathione take part in the 
transfer of iron from ferritin and haemosiderin to protoporphyrin 
in haem biosynthesis.
In contrast, the absorption of copper is decreased by an 
ascorbate supplement and an existing copper deficiency can be 
exacerbated (Carlton & Henderson, 1965; Simpson ert al, 1971)
In addition, Hill and Starcher (1965) reported decreased growth, 
increased mortality or decreased elasticity of the aorta in 
copper deficient chicks fed an ascorbic acid supplemented diet.
There:' is some evidence that ascorbic acid may protect an 
organism against the toxic action of some metals, such .as 
arsenic (Bundesen et al, 1941) and cadmium (Fox & Fry, 1970;
Maji & Yoshida, 1974; Suzuki & Yoshida, 1978). A protective 
effect of ascorbic acid and dietary iron has been proposed 
in rats suffering from a moderately long-term lead toxicity 
of 56 days duration (Suzuki & Yoshida, 1979). In contrast 
large doses of the vitamin have been reported to enhance the 
deposition of orally ingested mercury in the tissues of the 
guinea pig (Blackstone_et a1, 1974) as a result of increased 
mercury absorption in the gastrointestinal tract (Murray &
-Hughes, 1976).
g) Catecholamines
Ascorbic acid is a cofactor for dopamine- ^ -hydroxylase 
(KaufmanFriedman, 1965) and may have a role in the induction 
of tyrosine hydroxylase (Nakashima et al, 1976).
Both large amounts of ascorbate given by injection and 
deficiency of the vitamin* cause alterations in levels of 
neurotransmittors, including catecholamines, in the brain 
and other organs oi the guinea pig (Thoa et al, 1965;
Dashman et al, 1973). However, high ascorbic acid intakes 
cause no significant differences in the levels of noradrenalin 
in a number of different rat tissues, including the brain 
(Behrens & Madere, 1980). Hence, effects of the vitamin in 
this instance seem to be restricted to an animal species 
unable to synthesise the vitamin.
The vitamin specifically inhibits the dopamine-sensitive 
adenyl-cyclase in the brain (Tolbert et al, 1979) and this 
suggests that it may be a potential therapeutic agent in 
treating disorders like schizophrenia, Huntington’s Chorea 
and tardive dyskinesia, which have in common a functional 
dopamine excess.
h) Urinary Acidif icatiop,
Acidification of urine is an adjunct in the therapy
of chronic urinary tract infection and gram quantities of
ascorbic acid have often been used for this purpose. However,
Travis and co-workers (1965) reported that even at daily dose 
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levels of 8g/m , normal subjects did not consistently demonstrate 
effective lowering of the urinary pH, despite the fact that 
the dose was given as four equal portions throughout the day.
IV TOXIC EFFECTS OF ASCORBIC ACID
The probability that large doses of ascorbic acid 
may have adverse effects has been reviewed in a series of 
isolated reports. TABLE 1 shows a list of such effects 
(Barness, 1977) and others such as altered growth and mortality 
rates in guinea pigs; effects on protein and amino acid, bone 
and drug metabolism; increased lysis of erythrocytes; inter­
actions with trace elements and mutagenic effects could be 
added.
TABLE 1. Reported toxic effects of :ascOrbic 
acid (Barness 1977).
ACIDOSIS 
OXALURIA 
RENAL STONES 
GLCOSURIA
RENAL TUBULAR DISEASE 
G. I. DISTURBANCES 
SENSITIVITY
CONDITIONED NEED
PROTHROMBIN
CHOLESTEROL
B DESTRUCTION 
12
LABORATORY ERRORS
FATIGUE
STERILITY
Since this list suggests that most systems of the 
body can be affected, it should not be taken lightly, especially 
when the recipients of supplementary ascorbic acid are often 
growing children. Inspite of the implications of these 
reported toxic effects of a water soluble vitamin, few of them 
have been systematically investigated.
a) Bone Metabolism
Ascorbic acid is required for the synthesis of collagen 
and mucopolysaccharides, the principal constituents of bone 
matrix and it might be expected that large doses of the vitamin 
could have a beneficial effect on bone. However, work from 
several laboratories suggests that this is not the case.
Thus Thornton (1970) reported increased mobilisation of calcium 
and phosphorus in the skeletons of chicks given a diet containing 
220mg ascorbic acid per kg. Similarly, an increase in the
urinary excretion of hydroxyproline, a constituent of collagen, 
was seen in 26 day old weanling pigs given lg ascorbic acid 
per day for 32 days (Brown et al, 1971).
Hence, growing children, those recovering from bone 
injury and the elderly with their relatively high risk of 
osteoporosis, may be subject to adverse effects with respect 
to bone metabolism if they are concurrently taking gram doses 
of ascorbic acid.
b) Renal Stones
Large doses of ascorbic acid may cause an increased 
excretion of oxalate in the urine of susceptible individuals 
(Lamden & Chrystowski, 1954; Briggs et al, 1973) and this 
could result in> an increased probability of calculi formation. 
However, the number of healthy individuals producing urinary 
calculi is small (Briggs et_ aJ, 1973) and Takiguchi et^  al (1966) 
found no significant increase in urinary oxalate excretion 
following the administration of up to 2g ascorbic acid daily 
for a period of up to six months. Moreover, ingestion of 
less than 4g ascorbic acid per day produces, on average, an 
insignificant rise in urinary oxalate excretion (Lamden & 
Chrystowski, 1954; Takenouchi et al, 1966). In fact, studies 
with labelled ascorbic acid (Atkins et al, 1963) had previously 
shown that ascorbic acid does not contribute to any great 
extent to the production of oxalate in hyperoxaluria.
Stein et al (1976) reported uricosuria and decreased 
plasma concentration of uric.acid in subjects given 4-8g/day 
ascorbic acid. However, the subjects were a small number of 
hospital inpatients and a very large dose (8g) was required 
to produce uricosuria.
c) Conditioned Need
An ’ascorbic acid dependency’ in the young, induced by 
exposure to high levels of the vitamin ’in utero’ in both the 
human (Cochrane, 1965) and the guinea pig (Norkus & Rosso,
1975) has been reported. Guinea pigs were fed either a control 
diet or a high ascorbic acid diet, containing 0.5% of the
vitamin, during the latter half of pregnancy. When the pups
were examined at 5 and 10 days after birth, the ascorbic
14acid group demonstrated a marked increase in C0o excretion
compared to controls following an intraperitoneal injection of 
14C-labelled ascorbic acid. When the animals were weaned .. 
onto an ascorbic acid deficient diet, signs of scurvy appeared 
earlier in the pups from the ascorbic acid group and their 
survival time was shorter. It was suggested that the earlier 
appearance of signs of scurvy in the experimental group was 
secondary to an increased rate of ascorbic acid catabolism.
Similarly, two cases of infantile scurvy have been 
reported (Cochrane, 1965) following a maternal supplement of 
about 400mg/day during pregnancy. Both infants received, 
from their diet, apparently adequate intakes of at least 
60mg/day ascorbic acid. The author attributed the scurvy to 
systemic conditioning 'in utero'.
Several groups of workers (Mas'ek & Hruba, 1964;
Rhead & Schrauzer, 1971; Schrauzer & Rhead, 1973; Angel et 
al, 1975) have also presented data which indicate that long 
term ingestion of gram quantities of ascorbic acid can result 
in adaptation with increased urinary excretion and a progressive 
fall in plasma ascorbic acid concentration subsequent to the 
initial increase in blood level.
Angel and co-workers (1975) reported that following 
cessation of treatment with increasing quantities of ascorbic 
acid, from l-5g per day, over a period of 7-weeks, plasma and 
whole blood ascorbic acid fell dramatically over a period of 
24 hours. However, urinary excretion only returned to normal 
after 4 days. In fact, Schrauzer performed a self-experiment 
in which he consumed 10-15g of the vitamin daily over a period 
of two weeks and then abruptly returned to his original, purely 
dietary, intake of the vitamin. Four weeks later, classical 
symptoms of scurvy appeared, which persisted until a vitamin 
supplement was taken 10 days later (Schrauzer & Rhead, 1973).
d) Growth and Mortality
Large doses of ascorbic acid cause growth retardation 
in experimental animals (Nandi _et al, 1973). These workers 
demonstrated that the daily administration of 50mg ascorbic 
acid to guinea pigs fed an unfortified wheat flour diet 
resulted in a significant decrease in growth rate compared 
to that obtained on 5-20mg ascorbic acid per day. This 
decrease was accompanied by a 50% mortality in 16 days and 
100% mortality in 25 days. The effect was still more dramatic 
with a daily dose of lOOmg, with all animals dying within 
16 days. Lysine is the limiting amino acid in wheat and 
supplementation with this counteracted the toxicity of the 
large doses of ascorbic acid.
This work could be considered to be of limited importance' 
when considering the human situation, since lysine intakes 
would only be marginal in a diet consisting mainly of cereals.
e) Lysis of Erythrocytes
Mengel and Greene (1976) reported an increase in the 
incidence of ’in vitro’ red cell haemolysis, in the presence 
of hydrogen peroxide, in blood samples from healthy individuals 
who had been taking 5g ascorbic acid daily. Individuals with 
a glucose-6-phosphate dehydrogenase deficiency are especially 
susceptible. This is illustrated by the case of a 60 year 
old negro, whose death was partly attributed to ascorbic acid.
He was suffering from acute renal failure following second 
degree burns for which he had been treated with massive 
quantities of ascorbic acid. The patient was oliguric, with 
excessive haemolysis and a urinary excretion of haemoglobin 
of 4mg/100ml. The patient also had a deficiency of the enzyme 
glucose-6-phoshate dehydrogenase.
Haemolysis has been reported in the erythrocytes of 
rats treated intraperitoneally with lOOmg ascorbic acid per 
lOOg body weight, following exposure to hydrogen peroxide. 
However, orally dosed rats (150mg/100g) showed no such effect 
(Jayanthi Bai et al, 1979).
f) Hyperglycaemia and Glycosuria
Work with guinea pigs fed an unfortified wheat diet 
suggests that large doses of ascorbic acid may cause marked 
increases in dehydroascorbic acid (DHAA), the oxidised form 
of the vitamin, in the blood, urine and liver (Chatterjee 
et al, 1975), together with a concomitant increase in blood 
glucose. The increase in blood glucose appeared to be 
dependant on the increase in DHAA but not on the ascorbic 
acid content of the blood.
It is of interest that comparable results to those 
described above can be produced in guinea pigs by a dose of 
ACTH (liu/day), small enough not to cause hyperglycaemia, 
which in effect causes a non-specific stress situation.
The same workers (Chatterjee _et al, 1975) conducted 
experiments with human subjects on a diet composed chiefly 
of cereals, such that lysine intake could be marginal. A 
daily dose of 4g ascorbic acid for fifteen days produced 
elevated blood DHAA concentrations in all 10 volunteers.
The same pattern was seen with a smaller dose of 2g per day 
over a period of 20 days. In addition, some of the group 
had raised post-prandial blood sugar levels. Ten days after 
the treatment had ended, blood concentrations had returned to
normal, confirming the results found earlier in guinea pigs.
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These observations are of importance because it has 
been demonstrated that, in contrast to ascorbic acid, DHAA 
is extremely neurotoxic and diabetogenic when administered 
intravenously to rats (Patterson, 1950; Patterson & Mastin, 
1951; Sjostrand, 1970). In fact, Chatterjee eit al^  (1975) 
noted persistently high blood DHAA levels in patients with 
both juvenile and maturity-onset diabetes mellitus, irres­
pective of age, sex, family history or duration of the disease 
and it has been postulated that a cause of diabetes in man 
may be a jnetabolic disorder leading to \accumulation of DHAA 
in the blood,. Further evidence for this idea is provided 
by the fact that gross degeneration of the B'-cells of the 
islets of Langerhans in the pancreas has been observed 
following D H A A  treatment of rats (Patterson, 1949;
.1950). Slight to moderate increases in blood DHAA have been 
reported in other illnesses e.g. hypertension, influenza, 
pneumonia and physical trauma; but these, unlike those in 
diabetes, return to normal during convalescence.
The rate of breakdown of DHAA to 2,3-diketogulonic: 
acid in the red blood cells of diabetics is remarkably low, 
suggesting a deficiency of the enzyme 2,3-diketogulonic acid 
decarboxylase. In addition, DHAA reacts with sulphur amino 
acids and -Chatterjee et al (1975) suggest that since insulin 
requires such amino acids for its synthesis, this may be a 
mode of action.
Consequently, on the basis of this work the adminis­
tration of large doses of ascorbic acid to diabetics is perhaps 
contraindicated, since it may exacerbate a pre-existing problem 
namely elevated DHAA levels. However, contrary to the findings 
of these workers, others suggest a hypoglycaemic effect of 
the vitamin when taken in large quantities (Dice & Daniel, 1973), 
based on experiments on the first author who is, himself, a 
.juvenile-onset diabetic. With this subject, progressive 
increases in ascorbic acid intake from one to fifteen grams was 
shown to be capable of partially replacing insulin and controlling 
hyperglycaemia.
Losert et al (1980) found comparable results. They 
reported that in guinea pigs, the blood glucose lowering effect 
of exogenous insulin (liu/kg,intravenously) was increased by 
concomitant administration of high doses of ascorbic acid (10mg/ 
kg intravenously). Similar results were provided by investiga­
tions carried out on healthy male volunteers, where the lowering 
of blood glucose by exogenous insulin (0.05 iu/kg) was augmented 
by oral pretreatment with 50mg ascorbic acid per kg body weight. 
Since in both the guinea pig and man, there was no improvement 
in glucose tolerance after a loading dose, these authors conclude 
that the action of ascorbic acid must be to enhance peripheral 
utilization of glucose.
g) High Altitude Resistance
Prior to World War II, moderate doses of ascorbic 
acid were recommended as a means of temporarily increasing 
the ’high altitude resistance' of pilots, aeroplane passengers 
and mountaineers (Peterson, 1941). However, other workers 
(Doerholt, 1938; Pfannenstiel, 1938) reported that larger 
doses of the vitamin actually diminish high altitude resistance 
in rabbits and human volunteers. More recent work by Schrauzer 
et al (1975) at pressures simulating an altitude of 25,000 
feet above sea level has shown that whilst with a dose of 
2g/day for 6 days there was. no significant effect, at 3g/day 
for 6 days there was a significant loss of resistance to high 
altitude, which returned to normal two weeks after termination 
of the regimen.
It is unlikely that large doses of ascorbic acid 
interfere with oxygen economy under normal conditions, however, 
this work provides another reason to regard current concepts 
concerning the alleged beneficial effects of massive doses 
of ascorbic acid with caution.
h) Mutagenic Potential
Earlier demonstration (McCarty, 1954; Bode, 1967) that 
ascorbic acid can form free radicals and interact with both viral 
.and bacterial DNA has recently raised a suspicion of a possible 
mutagenic potential. This effect is particularly evident in 
the presence of copper (Stich et_ al, 1976). Under these con­
ditions, cultured human fibroblasts showed DNA fragmentation,
DNA repair synthesis and chromosome aberrations, including 
chromatid breaks and exchanges. Copper alone, and ascorbic acid 
flushed with nitrogen immediately prior to use, showed no such 
pattern. Interestingly, it was noted that the range of concen­
trations at which.effects were seen was rather narrow. Similar 
events have been demonstrated using manganese, ferrous and ferric 
ions (Stich et al, 1979).
The precise molecular nature of the ultimate mutagenic 
metabolite of ascorbic acid is unknown. Hydroxyl radicals are 
generated in the interaction of Cu with hydrogen peroxide, 
which is in turn produced by the oxido-reductive activity of
- the ascorbic acid - dehydroascorbic acid system (Wong at al,
1974). V/hether these are responsible for the observedcDNA 
fragmentation and the genetic changes has yet to be determined.
Working with Chinese hamster ovary cells, Rosin at al. 
(1980) demonstrated both mutagenic and toxic effects of the 
vitamin. Addition of catalase prevented both effects, 
suggesting that the mutagenic metabolite of ascorbic acid may 
involve peroxide radicals. Stich and colleagues (1979) noted 
a similar effect with catalase.
It is difficult to determine the degree of genetic 
hazard posed by the vitamin and its metabolites in man.
However, the severity of the chromosome aberrations induced 
by ascorbate and metal mixtures was comparable to that seen 
after exposure to highly potent mutagens and carcinogens, 
including aflatoxin B,N-methyl-N'-nitro-N-nitroguanidine and 
4-nitroquinoline-l-oxide (Stich et aT, 1979). ■
This work must be considered in the light of that 
previously discussed (Cameron & Pauling, 1974; Mirvish et al, 
1975; Cameron al, 1979) which suggests that ascorbate can 
reduce tumour incidence or inhibit their development, and 
evidence for a capacity to reduce the mutagenic and chromosane 
damaging activity of some carcinogens when administered 
concurrently with ascorbic acid to cultured mammalian cells 
(Lo & Stich, 1978). The inhibitory action of ascorbic acid 
on the formation of nitrosamines in the gut from primary and 
secondary amines has also been discussed and a comparable 
effect on benzpyrene carcinogenesis has been described 
(Kalliastratos & Fasske, 1980) following concurrent oral 
administration of ascorbic acid to rats.
i) Superoxide Dismutase Function
Hirata and Hayaishi (1975) demonstrated that ascorbic 
acid could replace the xanthine - xanthine oxidase system as 
a generator of superoxide anions in an enzyme system, by under­
going autoxidation. However, this may be a feature of the pH 
of the enzyme system since other authors have reached the 
contradictory conclusion that the vitamin is capable of 
scavenging these toxic anions (Nishikimi, 1975; Bielski et al,
1975; Bodannes & Chan, 1979) and hence behaves in a similar 
manner to superoxide dismutase, the body's natural defence 
mechanism against oxygen toxicity.
Superoxide dismutase is an ubiquitous enzyme among 
aerobic organisms, unique in that its substrate is an unstable 
free radical (Fridovich, 1978). In the mammalian liver two 
types of superoxide dismutase have been described and charac­
terised. One is a copper and zinc containing enzyme with a 
molecular weight of 32,000 daltons, localised in the cytosol 
and the second type, a manganese containing enzyme with a 
molecular weight of 80,000 daltons, is located in the 
mitochondrial matrix. The copper-i-zinc enzyme is sensitive 
to cyanide inhibition, whereas the manganese - containing 
dismutase is not (Fridovich, 1978). Deficiency of manganese 
has been shown to significantly decrease the activity of the 
manganese enzyme in chickens (De Rosa ert <al> 1980) and 
similarly, deficiency of copper has been found to influence 
the activity of the cytosolic enzyme in swine (Williams et^  al,
1975) and rats (Bohnenkamp & Weser, 1977).
Superoxide anions can be produced by a number of naturally 
occuring compounds, such as thiols, oxyhaemoglobin, ferredoxins, 
adrenaline and tetra-hydropteridines (Fridovich, 1975) and a 
role for superoxide dismutase and the superoxide anion in 
inflammation (Johnston & Lehmeyer, 1977) and in neutrophil 
mediated cytotoxicity (Simchowitz & Spilberg, 1979; Yamanaka et^  
al, 1979) has been described. Ascorbic acid appears to potentiate 
the cytotoxic effect of nitro-aromatic compounds, perhaps by 
increasing the toxicity of the drug, via the creation of a more 
-anaerobic environment by scavenging oxygen (Koch et^  al, 1979).
An involvement of the superoxide anion in the mixed 
function oxidase, system has also been alluded to (Strobel & Coon, 
1971). These workers reported that superoxide dismutase inhibited 
benzphetamine hydroxylation in a reconstituted liver microsomal 
enzyme system and that a superoxide generating system, consisting 
of xanthine and xanthine oxidase, coupled with cytochrome P450 
to support the hydroxylation of benz:phetamine and ethyl-morphine- 
N-demethylase in the absence of cytochrome P450 reductase and 
NADPH. The superoxide radical has also been suggested to be an
intermediate in the oxidation of hydroxylamines by mixed 
function amine oxidase (Raukman ert al, 1979).
Metal ions, especially copper arid iron, are knownto 
enhance ascorbate oxidation (Halliwell & Foyer, 1976) and both 
enzymic and non-enzymic lipid peroxidation have been shown to 
be induced by transistion metals such as iron (Sharma, 1979; 
Rehncrona et al, 1980), especially when in combination with 
ascorbic acid. Lipid peroxidation is a complex process known 
to occur in both plants and animals, involving the formation 
and propagation of lipid radicals, the uptake of oxygen, a 
rearrangement of the double bonds in unsaturated lipids and 
the eventual destruction of membrane lipids, producing a 
variety of breakdown products including alcohols, ketones, 
ethers and aldehydes (Plaa & Witschi, 1976). Microsomal 
membranes are particularly susceptible to lipid peroxidation 
owing to the presence of high concentrations of polyunsaturated 
fatty acids.
Svingen et al (1978) have proposed that the mechanism 
of NADPH-cytochrome P450 reductase catalysed lipid peroxidation 
parallels that of xanthine oxidase in that initiation:;occurs 
through a superoxide dismutase sensitive reaction and that 
singlet oxygen is present during propagation of lipid peroxidation. 
Hence, this work provides further evidence for the involvement 
of superoxide anions in the mixed function oxidase system, of 
which cytochrome P450 reductase is a component.
Finally, 'in vitro' lipid peroxidation of liver, brain, 
kidney and spleen homogenates and their catalytic efficiencies 
for peroxidation of linoleic acid, were depressed in rats given 
large doses of ascorbic acid both orally and intraperitoneally 
(Jayanthi Bai et aJL, 1979).
Hence a critical balance exists between the superoxide 
anion and superoxide dismutase in which the enzyme prevents 
excessive accumulation of the anion whilst allowing the existence 
of sufficient to act as substrate for various reactions such as 
biosynthesis of some neurotransmittors (Bonneau ejt aT, 1977) 
and degradation of dimethyltryptamine, a hallucogen, by indolamine 
dioxygenase (Hirata & Hayaishi, 1975). If the process of
.scavenging is taken to excess by the ingestion of large 
quantities of ascorbic acid, problems might arise, since it 
has been noted that the addition of superoxide dismutase causes 
inhibition of ’in vitro1 benzphetamine hydroxylation (Strobel 
& Coon, 1971), possibly by compromising the active oxygen 
species involved in the microsomal drug hydroxylating system. 
Consequently, although ascorbic acid may function as a second 
means of defence against oxygen toxicity, there may be harmful 
underv-currents to this scavenging activity.
j) Other Effects
Other effects, probably of minor importance, have been 
cited in the literature, including acidosis, gastrointestinal 
disturbances and other allergic responses (Ruskin, 1945;
Anderson et al, 198Q), interferences with laboratory tests ?
carried out on an autoanalyser (Van Steirteghem et al, 1978) 
and interaction with vitamin B in food (Herbert & Jacobs,
1974).
The previous discussion illustrates the multiplicity 
of ways in which ascorbic acid, both in normal vitamin quantities 
and in pharmacological doses may affect metabolism. It is 
of interest that transition metals have often been seen to 
enhance such effects. The size of the dose of ascorbic acid 
appears to be critical in some instances, since different effects 
were seen at different dose levels. Whilst the mechanism of the 
effects of ascorbic acid on connective tissue are well known, 
that of some of the other effects is still obscure.
There are several factors which tend to occur frequently 
in the literature reviewed above. The involvement of transition 
metals has already been alluded to and it is of interest that 
three of the enzymes which have been implicated in adverse 
effects of the vitamin are copper containing enzymes, superoxide 
dismutase, uricase and dopamine-f3-hydroxylase. Amino acids, 
especially those containing sulphate, are a prominent feature 
as are functions of thiol groups. Oxygen economy, both with 
respect to superoxide dismutase activity and high altitude
resistance seems to be of importance and it should be noted that 
many of the respiratory proteins in the mitochondria are 
haemoproteins and as such may be subjected to some of the 
effects reported to occur with cytochrome P450, which will 
be discussed in the next section.
It is now becoming evident that the hepatic mixed function 
oxidase system plays a role in the metabolism of a wide range 
of substrates, both xenobiotics and natural body constituents.
It therefore seemed that studies of the effects of ascorbic 
acid on this system might be profitable, especially as in 
the amounts required to produce the effects discussed previously, 
ascorbic acid is no longer functioning as a vitamin but may well 
be considered a drug. Previous literature on the subject of 
drug metabolism will now be reviewed, with special reference 
to ascorbic acid.
V DRUG METABOLISM
Mammals have developed defence mechanisms capable of 
metabolising and subsequently excreting a wide range of 
xenobiotics such as drugs, pesticides, food additives, a 
multitude of environmental contaminants and also endogenous 
substances such as steroids, prostaglandins and fatty acids.
In the case of drugs, termination of pharmacological activity 
is achieved either via excretion through the kidney or bile, or, 
more commonly, via metabolism to a pharmacologically inert 
compound in the liver and other tissues, followed by excretion.
The enzymatic breakdown of drugs takes place in two 
distinct phases. The first phase, biotransformation, is 
asynthetic and results in the formation of a more polar compound 
by oxidation, reduction, hydroxylation, deamination or N- 
alkylation of a relatively lipophilic xenobiotic. The second 
stage is of a synthetic nature, involving conjugation of the 
polar compound with endogenous molecules such as glucuronic 
acid, sulphate, glutathione, glycine and acetate.
The enzyme system responsible for the asynthetic metabolism 
of drugs, the mixed function oxidases, is principally located 
in the endoplasmic reticulum of the hepatocyte and is somewhat 
unique in its ability to utilise a wide range of substrates.
The system is dependant on reduced nicotinamide adenine 
dinucleotide phosphate (NADPH), molecular oxygen, lipid and 
cytochrome P450, which acts as the terminal oxygenase (Parke,
1968). The oxidised cytochrome P450 present in the endoplasmic 
reticulum of hepatic cells forms a complex with the drug or 
anutrl'eht which is then reduced by NADPH dependant cytochrome 
P450 reductase. The reduced cytochrome then combines with mole­
cular oxygen to give an active oxygen complex and a subsequent 
breakdown of the oxygen compound produces oxidised cytochrome 
P450 and oxidised drug, (Figure VII).
The enzymes responsible for the metabolism of drugs through 
synthetic reactions (phase II reactions) are known as the trans­
ferases and are found in both the endoplasmic reticulum and the 
cytosol.
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By far the most common outcome of metabolism is 
deactivation of the compound and thus termination of its 
pharmacological effect. However, in some cases the opposite 
can happen. Hence a pharmacologically inert compound can be 
activated via metabolism by the same mixed function oxidase 
system or, indeed, a compound may be metabolised into toxic 
products, having adverse side effects. (TABLE 2).
TABLE 2. Examples of activation and deactivation of substrates
DEACTIVATION
phenobarbital
(sedative)
paracetamol
(analgesic)
oxygenation
glucuronide
conjugation
p-hydroxyphenobarbital
(inactive)
paracetamol glucuronide 
(inactive)
ACTIVATION
prontosil
(inactive)
reduction
sulphanilamide
(antimicrobial)
CHANGES IN ACTIVITY
methylatibh
codeine
(active)
iproniazid
(active
N-dealkylation
P morphine 
(active)
p isoniazid 
(active)
The activities of many of the enzymes that metabolise 
drugs have been shown to depend on a number of factors, such
-as age, sex, genetics, species but probably the most important 
factor is nutritional status. It should be remembered that 
just as nutritional status is capable of modifying the pharma­
cological effects of drugs, disease itself or the drug treatment 
of the sick may impair the nutritional status of the patient . 
with consequent effects upon the body's response to drugs.
a) Inter-Relationships of nutrition and the 
Metabolism of Drugs.
The ability of the body to metabolise drugs during 
concurrent nutrient deficiency has been extensively reviewed 
(Basu & Dickerson, 1974; Campbell & Hayes, 1974; Basu, 1977; 
Ioannides & Parke, 1979) and from these reports it is evident 
that deficiency of a great variety of nutrients affect drug 
metabolism and disposition and in general the duration of 
the pharmacological effect of xenobiotics is extended due to 
the decreased rate of detoxification of the compounds. 
Conversely, in the case of the minority of compounds in which 
metabolism results in activation, a nutrient deficiency might 
result in the diminished toxicity and/or loss of pharmacological 
.-activity. However, due to the fact that xenobiotics are 
metabolised through a number of pathways, some of which may 
be of an activating nature and others deactivating, the final 
response to the chemical is dependant on the relative rates 
of the different pathways, which may exhibit different sensi­
tivities to change in diet (Ioannides & Parke, 1979).
i) Since protein energy malnutrition is still prevalent 
in the children of developing countries, there has been con­
siderable interest in the interaction of protein deficiency arid 
drug metabolism. Dickerson et_ al (1976), using the weanling 
rat as an experimental model for protein energy malnutrition, 
reported depression of drug metabolising enzyme activities. 
Similarly, Campbell & Hayes (1976) described losses of up to 
75% of hepatic mixed function oxidase activity in weanling 
rats by the fifteenth day of low protein diet. Work with mature 
rats (Mclean and Mclean, 1966; Kato et_ aJ, 1968; Boyd & Taylor,
1969) and limited work with man (Wharton & McChesney, 1970; 
Kappas et al, 1976) has again indicated that drug metabolism is 
compromised by protein deficiency.
* ii) Strobel and co-workers (1970) demonstrated, in a
reconstituted enzyme system that the phospholipid, phosphatidyl"- 
choline,, is an integral component of the mixed function oxidase 
system. Rats fed a fat-free diet for three weeks showed 
depressed liver cytochrome P450 concentrations and rates of 
drug metabolism when compared with animals receiving a 3% 
corn-oil diet (Norred & Wade, 1972). The addition of olive 
oil (5-10%) to the diet, increased the activity of the mixed 
function oxidases; however, larger amounts of fat (25-30%) 
decreased hepatic oxygenases independantly of the degree of 
saturation of the fatty acids (Hietanen et_ _al, 1975). Lambert 
and Wills (1977) also demonstrated that the type, quantity 
and degree of saturation of fats in the diet of rats is of 
importance.
iii) Deficiencies in dietary calcium, magnesium, iron,
iodine, zinc, selenium and copper have all been reported to
affect the microsomal mixed function oxidase system to varying
degrees (Campbell & Hayes, 1974). Of these, iron might be
considered to be of major importance since it is a component
.of both cytochrome P450 and cytochrome b_. However, despite5
reports of effects of iron deficiency on various factors 
connected with drug metabolism, cytochrome P450 concentration 
appears to remain unchanged, even in severe iron deficiency 
anaemia (Catz et al, 1970; Becking, 1972).
iv) In general, vitamin deficiencies result in 
impairment of drug metabolic processes, but not in such a marked 
way as that seen in protein deficiency. Ascorbic acid has been 
the most extensively studied, but other vitamins such as 
riboflavin, retinol and tocopherol have also been implicated 
(Campbell & Hayes, 1974). Riboflavin is required for the 
synthesis of pyridine nucleotides and the flavoprotein, cytochrome 
C reductase, otherwise known as cytochrome P450 reductase,
and, in both weanling mice (Catz ejt _al, 1970) and adult rats 
Patel & Pawar, 1974), a significant decrease in the ability 
of the liver to metabolise drugs has been reported in prolonged 
riboflavin deficiency. Work by Carpenter (1972) had indicated 
that, in both male and female rats subjected to vitamin E 
deficiency, there is a decrease of about 50% in the N-demethylation
of codeine to nor-codeine, although the minor O-demethylation 
pathway remains unaffected. Becking (1973) reported effects 
of vitamin A deficiency on mixed function oxidase activity, 
specifically depressions in N-demethylation, N-hydroxylation 
and cytochrome P450 content, which he attributed to an effect 
on the endoplasmic reticulum structure, leading to an impairment 
of the closely integrated mixed function oxidase system.
Most of the reports cited involve deficiency of nutrients. 
For the mixed function oxidase system to operate it is necessary 
that all of its conponent parts are readily available. Hence 
any deficiency that directly or indirectly obstructs this 
availability will result in a decreased efficiency of the 
system. Similarly, any nutrient present in excess could also 
inhibit the availability of a second nutrient required for 
drug metabolism. This effect would be especially relevant if 
the second nutrient was, for example, an essential amino acid 
or lipid, and will be discussed in more detail later.
b) Effects of Ascorbic ^cid Deficiency.
Effects of ascorbic acid deficiency can only be 
investigated in those species that cannot synthesise the 
vitamin and therefore the guinea pig is the experimental 
animal of choice.
Studies from a number of laboratories have shown that 
ascorbic acid deficiency in the guinea pig results in decreased 
metabolism of a number of pharmacological agents. Richards et 
al (1941) found that pentobarbital sleeping time was prolonged 
in scorbutic guinea pigs and that this effect was reversed when 
the vitamin was administered. A three-fold increase in the 
plasma half-life of such compounds as aniline, acetanilide 
and antipyrine has been reported (Axelrod et al, 1954) in 
ascorbic acid deprived guinea pigs and on repleting the animals, 
the half-life of the drugs returned to normal. In the absence 
of clinical signs of scurvy, deficient guinea pigs were found 
to be more sensitive to the muscle relaxant, zoxazolamine, 
than controls (Conney et al, 1961). The increase in the 
duration of the response to the drug ’in: vivo' correlated with 
a decrease in its microsomal oxidation 'in vitro'
Degkwitz and Staudinger (1965) observed that p-hydroxy- 
lation of acetanilide as well as hydroxylation of coumarin 
(Degkwitz et al, 1968) was decreased in scorbutic animals 
and again reversal of this was achieved with ascorbic acid. 
Ethoxycoumarin demethylase activity was also found to be 
decreased to 50% of control values in both liver and lung 
but not in the intestines of scorbutic guinea pigs. Deficiency 
of the vitamin, however, had no effect on either epoxide 
hydrolase or benzpyrene hydroxylase activities in any of the 
organs studied (Kuenzig at al, 1976). On the basis of these 
results it was suggested that the effect of ascorbic acid 
deficiency is both substrate and tissue dependant in the guinea 
Pig.
Effects::of ascorbic acid on ’in vitro’ drug oxidation 
have also been reported. Leber and co-workers (1969) demon­
strated that liver microsomes from scorbutic guinea pigs showed 
significantly inhibited demethylation of aminopyrine and 
hydroxylation of acetanilide and had decreased cytochrome 
P450 contents, whereas cytochrome b^ remained unaffected. 
However, Degkwitz and Kim (1973), working in the same laboratory, 
later reported inhibition of both cytochromes P450 and b^.
Kato et_ al (1969) examined the effect of ascorbic 
acid deficiency on the metabolism of a variety of drugs and 
concluded that the hydroxylation of aniline, hexo.barbital 
and zoxazolamine was markedly decreased in ascorbic acid 
deficiency, whereas, in contrast, the N-demethylation of 
aminopyrine, diphenhydramine, meperidine and N-methylaniline 
was not significantly affected. Moreover, O-demethylation 
and reduction of substrates remained at control values. These 
results indicate that the affect of ascorbic acid deficiency is 
possibly specific to hydroxylating reactions.
In contrast, ’in vitro’ work (Zannoni at al, 1972) 
using weanling guinea pigs indicated a general marked decrease 
in drug metabolising activity, such that aniline hydroxylation, 
aminopyrine-N-demethylation and p-nitroanisole-O-demethylation 
were all affected. In addition, there was significant decrease 
in the quantity of cytochrome P450 and NADPH cytochrome P450 
reductase, effects not reported by Kato et al (1969). However,
the decreased activities occured only when the microsomal 
ascorbic acid concentration had reached 30% of control values. 
Reversal of these effects took six days of treatment with 
the vitamin. This lag period perhaps indicates a rather 
complex effect ’in vivo’ of ascorbic acid on microsomal 
enzyme activity, especially as several reports (Kato *rt al,
1969; Zannoni et_ al, 1972) have shown that direct addition 
of vitamin C to the incubation medium ’in vitro’ did not 
restore enzyme activity.
More recent studies (Sikic et al, 1976) have indicated 
that both cytochrome P450 and aminopyrine-N-dgmethylation 
are decreased to 60% of control values in liver microsomes 
at 21 and 25 days deficiency, whereas there was no significant 
change in other organs, such as the kidney and lung.
Wagstaff and Street (1971) reported that ascorbic 
acid was necessary in order to permit maximum induction of 
O-demethylating and hydroxylating enzymes in the presence of 
organochlorine pesticides. Other studies with inducers 
(Rikans ert al, 1978) indicated that ascorbic acid deficiency 
compromised the induction of delta-amino-laevulinic acid 
synthetase.
Various groups of workers (Kato et al, 1969; Wade et^  
al, 1972; Zannoni et_ al, 1972) have attempted to elucidate 
the mechanism of the effect of ascorbic acid deficiency by 
the determination of enzyme kinetic parameters together with 
activities of individual enzyme components, after the onset 
of deficiency. Kinetic studies with typical enzymes such as 
N-demethylase and O-demethylase (Zannoni, 1977) have indicated 
that there is no significant change in the affinity of the 
enzymes for their substrates in normal, deficient or supplemented 
(0-75mg/day) animals.
The length of the period of deficiency and the age of
the animals has been shown to be of relevance. Kato ert al
(1969) found no change after 12 days of feeding a deficient diet
to 400g guinea pigs in either the activity of NADPH-cytochrome
P450 reductase activity or in cytochrome P450 and b_ content
5
of the microsomes, whereas Zannoni et^  al (1972) observed a 
decrease in the activity of these same components in 250g
,animals following 21 days on a deficient diet. Studies by 
other workers (Leber et al, 1969; Wade et al, 1972) tend to 
be in agreement with the work of Zannoni's group. Hence 
younger animals may be at more risk than older ones.
Zannoni et^  al_ (1972) found an atypical aniline-cytochrome 
P450 binding spectra in deficient animals and hence proposed 
that the integrity of the microsomal phospholipid membrane 
associated with cytochrome P450 may be altered and may require 
ascorbic acid for its maintenance. These workers also draw 
attention to the demonstration (Staudinger et al, 1961;
Wade et_ al, 1972) that an ascorbic acid-dependant NADH oxidase 
system exists in hepatic microsomes, which may be an important 
auxiliary pathway for drug metabolism in the absence of a 
functioning microsomal NADPH-cytochrome P450 reductase system.
More recent studies by Sato and Zannoni (1976) suggest 
that the decrease in drug metabolism observed in ascorbic acid 
deficiency is not due to an increase in lipid peroxidation 
or a quantitative change in the essential phospholipid component 
involved in drug metabolism, phosphatidyl~choline and that the 
differences which exist between normal and ascorbic acid 
deficient microsomes include less stability of the ascorbic 
acid deficient microsomes to sonication, dialysis and treatment 
with ferrous iron metal chelators such as a - c?"-dipyridyl and 
O-pherunthroline. Losses of cytochrome P450 and O-demethylase 
activity could be prevented by the addition of ascorbic acid. 
Furthermore, a molar ratio of ascorbic acid to microsomal 
cytochrome P450 of the order of 2:1 was found to exist in both 
liver and adrenal tissue, during dialysis of both normal and 
deficient microsomes and during partial purification of the 
cytochrome. In addition, the vitamin protected cytochrome P450 
against inhibition by ferrous iron chelators. These studies 
suggest an interaction between ascorbic acid and cytochrome 
P450 involving haem iron. Hence another avenue of research 
has been the effects of ascorbic acid deficiency on haem bio­
synthesis.
Luft et_ al, (1972) demonstrated that cytochromes P450
and b_ could be raised to control values in deficient animals 5
within 48 hrs. of re-supplementation with ascorbic acid by the
concomitant administration of deita-amino laevulinic acid, thus 
providing evidence for the participation of the vitamin in 
the synthesis of haem. This same research group had earlier 
ruled out the possibility that cytochrome levels could be 
raised by ascorbic acid through an inhibition of cytochrome 
decomposition (Leber ert al, 1969). However, more recent 
studies (Rikans et al, 1978) have provided data which 
indicates that ascorbic acid deficiency does not affect the 
availability of haem for cytochrome synthesis and they suggest 
instead that the effect of the vitamin is on the apoprotein 
moiety of the haemoprotein. They based their argument on the 
finding that the key enzymes involved in haem synthesis, 
namely delta-amino laevulinic acid synthetase, delta-amino 
laevulinic acid dehydratase and ferrochelatase, were not 
decreased in the livers of ascorbic acid deficient animals.
In addition, Rikans et al (1978) have reported that 
ascorbic acid deficient microsomes consistently demonstrate 
reduction in three and increase in two polypeptide bands when 
the microsomal proteins which fall within the molecular weight 
range of 44,000 - 60,000 daltons are separated by polyacrylamide 
gel electrophoresis. These polypeptides were identified as 
species of cytochrome P450 using haem staining techniques and 
induction studies with phenobarbital and 3-methylcholanthrene.
It should not be forgotten that steroids, including 
cholesterol, are metabolised by the same system as xenobiotics. 
Zannoni et al (1977) reported that steroid and cholesterol 
metabolism are also inhibited in ascorbic acid deficient guinea 
pigs and restored by a supplement.
Hanck and Weiser (1977) found raised plasma and tissue 
lipids without concomitant increase in dietary intake of lipid, 
which could be reduced with an ascorbic acid supplement over 
an extended period of time in human subjects. In agreement 
with this work is that of Ginter (1977) who reported a decrease 
in 7 a-hydroxylation of cholesterol in ascorbic acid deficient 
guinea pigs, which promoted induction of hypercholesterolaemia, 
accumulation of cholesterol in the liver, an increase in the 
half-life of plasma cholesterol and a decrease in the size 
of the bile acid pool. Further experiments provided evidence
that the effect was exerted directly on 7-a hydroxylase. Hence 
it can be seen that a life-long marginal intake could provoke 
a rise in serum' cholesterol by an inhibitory effect on 
7-('a-hydroxylase.
In spite of the extent of the work investigating the 
effects of ascorbic acid deficiency on drug metabolism, the 
mechanism of action still remains elusive. It is evident 
that deficiency of the vitamin results in decreased activity of 
the components of the mixed function oxidase system, although 
the use of animals of different ages, exposed to varying degrees 
of deficiency has only served to cloud the issue. Hypotheses 
involving effects of vitamin deficiency on lipid peroxidation, 
substrate specificity, membrane phoshpholipids and protein 
synthesis tend to have been rejected in preferance to an 
effect on either the synthesis of the apoprotein moiety of 
cytochrome P450 or an effect on the incorporation of the 
component parts of the haemoprotein. Due to the extent of the 
involvement of the transition metals, it is perhaps not sur­
prising that Omaye and Turnbull (1980) have proposed a mechanism 
by which ascorbic acid deficiency exerts an indirect effect 
on the availability of ferrous ions for incorporation into 
haem by ferrochelatase via copper and ceruloplasmin. Cerulo­
plasmin, a ferroxidase, is capable of oxidising ferrous ions 
to the ferric form and hence rendering them unavailable for 
incorporation into protoporphyrin IX. This hypothesis will 
be discussed at length in subsequent chapters.
c) Effects of Large Doses of Ascorbic Acid.*— -   - -   ■   - ■ ■
There is a paucity of work on the effects of large doses 
of ascorbic acid on drug metabolism and with the exception of 
one experiment, studies have involved clinical trials.
Sato and Zannoni (1974) studied the effects of ascorbic 
acid supplements in the range 0-75mg/day in weanling guinea pigs, 
whose daily requirement of the vitamin to prevent scurvy has 
been reported to be l-2mg/day (Chaterjee, 1967), which is 
equivalent to a liver content of about 5mg/100g. They reported 
a significant increase in the enzymes and electron transport 
components of the mixed function oxidase system, together with
an increased dependency of the animals on ascorbic acid whilst 
on the diet. Figure VIII shows a reproduction of their 
results for NADPH cytochrome P450 reductase activity, following 
differing ascorbic acid supplements to weanling guinea pigs. 
Similar results for O-demethylation, cytochrome P450 and N- 
demethylation were also presented. However, it is clear from 
their data that the group with the highest activities of these 
various components and also the highest ascorbic acid 
content, is, in fact, the control group ahd not the 75mg/day 
supplemented group. Indeed, the liver ascorbic acid of the 
group receiving the 75mg supplement was half that of the 
control group, which received a chow diet supplemented with 
kale three times per week. Since kale contains 50-6.0mg/100g 
ascorbic acid, these two week old guinea pigs would have to 
have eaten 100-200g of kale per day to have equalled the 75mg 
supplement. Consequently, it would appear that the control 
group had, in fact, greater mixed function oxidase activity 
than the group receiving the highest supplement, suggesting 
an inhibitory effect of the vitamin rather than the inductive 
one suggested by the authors. One factor, apparently not 
considered by the authors, is the inductive effect of some 
green vegetables on cytochrome P450 (Pantuck eit al, 1976).
In humans, Basu (1977) reported decreased excretion 
of sulphur amino acids following large intakes of ascorbic 
acid and suggested that this demonstrated an increased 
requirement for the amino acids in the presence of ascorbic acid. 
As discussed earlier, sulphate conjugation is an important 
pathway in man, which is limited by the availability of 
sulphate (Levy et' al, 1967): A report by Houston and Levy
(1975) suggested that large doses of ascorbic acid competitively 
inhibit the sulphation of concomitantly ingested aspirin, since 
ascorbic acid treated subjects excreted a greater proportion 
of glucuronidated salicylamide and less salicylamide sulphate 
than controls receiving only aspirin. In addition, experimental 
and clinical evidence (Wokes, 1958; Smith, 1961) suggested 
that the detoxification of cyanide takes place by conversion 
to thiocyanate and this reaction may also require cysteine.
Basu (1977) has reported that the urinary excretion of "
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FIGURE VIII The effects of increase in ascorbic acid
supplement size on cytochrome P450 reductase 
activity in the weanling guinea pig 
(After Sato & Zannoni, 1974).
thiocyanate is decreased in subjects receiving gram doses 
of the vitamin, but that normal levels were restored by the 
daily administration of lOmg cysteine.
Finally, a significant increase in total body clearance 
of antipyrine has been reported (Houston, 1977) following 
treatment of human volunteers with lg ascorbic acid for one 
week. Whereas, Feetman et al (1975) demonstrated that even 
lOg/day ascorbic acid provoked no clinically significant 
antagonism of the hypoprothrombinaemic action of warfarin 
in human subjects. These results are contradictory to those 
reported with salicylamide (Houston & Levy, 1975), where 
the normal excretory pathway seemed to be compromised by 
ascorbic acid. However, it has been suggested that a dose 
response relationship exists, such that at ascorbic acid 
doses below 1.2 g/day, antipyrine clearance was significantly 
increased, whereas at higher levels, the total body clearance 
tended to decrease (Wilson et al, 1976).
IV AIMS OF THE STUDY
There has been much debate regarding the most appropriate 
daily intake of ascorbic acid to be advised to promote optimal 
health. Throughout the world, there is considerable difference 
in the dose recommended, ranging from 30mg in the United 
Kingdom and Canada to 70-100mg/day in the USSR. Indeed, recent 
studies by Kallner et^  al (1979) have led the authors to 
recommend a daily intake of lOOmg/day for non-smoking adults, 
which should be raised by 20mg/day for smokers, since the 
requirement of the vitamin is thought to be increased in such 
people. __
It has been assumed that since a little ascorbic acid protects the organism
from infection, large amounts would provide even better prevention. It is
perhaps only now being realised that the dose response relationship is not
linear and that just as deficiency has detrimental effects, so too has excess.
£
It seemed that this latter possibility was worthy of investigation, particularly 
in respect of its effects on drug metabolism.
In view of the existance of reports suggesting that, 
despite its water solubility, the vitamin may have adverse 
effects when taken in large quantities, it is of paramount 
importance that the 'in vivo' metabolism of large doses of 
ascorbic acid be systematically investigated. At the dose 
levels required to produce^ tjhese^  adverse effects, it could 
be suggested that ascorbic acid is no longer acting as a vitamin 
but as a drug, and as such it would require detoxification in 
the liver along with the other xenobiotics entering the body.
In this situation, it is possible that competitive inhibition 
could occur with respect to other compounds requiring the 
same pathway for excretion.
Although there have been a few studies investigating 
the interaction of large doses of ascorbic acid with the 
metabolism and excretion of various drugs, there has been no 
study designed to investigate the effects of large doses of 
the vitamin on the enzymes and the components of the hepatic
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mixed function oxidase system, which is now realised to 
play an essential role in the metabolism and eventual excretion 
of a wide variety of compounds of both endogenous and exogenous 
origin. Hence any compound interfering in any way with this 
function could produce widespread alteration in normal body 
metabolism.
As previously stated, ascorbic acid can readily be 
bought across the counter and hence interference of this 
vitamin with drug metabolism could pose a real problem to man 
and requires futher investigation. Ideally, such studies should 
be performed in human subjects, however the nature of the work 
does not permit this for a number of reasons. In the past 
(Labadarios et al, 1978), glucaric acid excretion has been 
used as an index of drug metabolising activity. However, this 
use can be criticised on the basis that glucaric acid excretion 
is only representative of phase II conjugation, specifically 
glucuronidation, and is not indicative of total hepatic drug 
metabolism. Consequently, liver biopsies would be required 
if human subjects were used, in order to assay components of 
the enzyme systems. This would cause many problems, both of 
an ethical nature and by virtue of the fact that large numbers 
of subjects would be required for statistical evaluation of 
the data. In addition, samples might not necessarily be 
representative of the total liver and confusion would be added 
to data collected by individual variation between subjects, 
which can be partially eliminated by the use of a specific 
strain of animal.
Due to size, availability and relatively low cost, the 
guinea pig is the species of choice, it being amongst the small 
group of mammals which, like man, require dietary ascorbic 
acid. The use of animals instead of human volunteers offers 
the advantage that age, sex, dietary intake and environment 
can be carefully controlled and, due to the fact that larger 
numbers can be used, statistical evaluation of the data can 
be performed.
It was therefore decided to undertake a series of studies 
of this problem, in the guinea pig, in an attempt to find the 
effects of large doses of ascorbic acid on the components of 
the hepatic drug metabolising system and to elucidate the 
mechanisms of such effects.
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I MATERIALS
Sigma Chemical Company, Poole, Dorset, was used as 
a supplier of the following compounds: NADP, NADH, NADPH,
glucose-6-phosphate, glucose-6-phosphate dehydrogenase, 
cytochrome C, serum albumen, 1-naphthol, uridine diphospho- 
glucuronic acid (UDPGA), Brij 35, Tris base, Coomassie blue G, 
hexobarbital, hemin, p-phenylene-diamine (PPD), delta-amino 
laevulinic acid and pyridoxal phosphate. The phospholipid 
markers for the isolation of phospholipids by thin layer 
chromatography were also obtained from Sigma.
Semicarbazide hydrochloride,biphenyl,bbiphenyl-4-
hydroxylase, potassium cyanide, 2-mercaptoethanol, bromophenol
blue, sodium dodecyl sulphate (SDS), acrylamide, NjN^-methylene-
bis-acrylamide, aniline, vanadium pentoxide, l-amino-2-
naphthol-4-sulphonic acid, ammonium molybdate, adrenaline,
xanthine, xanthine oxidase from unpasteurised cream, Dowex
)
50 resin (100-200 mesh), Drabkins reagent and haemoglobin 
standards were all obtained from British Drug Houses Ltd.,
Poole, Dorset.
Labelled compounds were bought from The Radiochemical 
Centre, Amersham, Bucks. and PPO was supplied by Fisons 
Scientific Apparatus, Loughborough, Leicestershire. Dimethyl- 
POPOP was obtained from Packard Instrument Company Inc.,
Zurich, Switzerland, and metapol (synperonic NX) from Durham 
Chemicals Distributors Ltd., Birtley, Tyne.and Wear. Hopkin 
and Williams, Chadwell Heath, Essex, supplied the Tween 80 
(polyoxyethylene sorbitan mono-oleate) and Bandrowski’s 
base came from ICN Pharmaceuticals, Cleveland, Ohio. 
Ethoxyresorufin and resorufin were both supplied by Pierce 
and Warrier, Chester and Koch and Light, Colnbrook, Bucks. 
was a source of l-naphthyl-3-D-glucuronide. The protein 
markers for gel electrophoresis were bought as a kit from 
Boehringer, Lewes, East Sussex. . Ethyimorphine was provided 
by May and Baker, Dagenham, Essex and 1,1,3,3-tetra methoxy 
propane, malonaldehyde bis-(dimethyl acetal), was obtained 
from Aldrich Chemical Company Inc., Milwaukee, Wisconsin.
II TREATMENT OF ANIMALS
Male Dunkin-Hartley guinea pigs, maintained on a stock 
diet (Table 4) (FDI pellets, Labsure Ltd.), plus water 
’ad libitum1, were divided into groups on a paired weight 
basis, following a period of equilibration in metabolic 
cages (Forth-Tech Services Ltd., Mayfield, Dalkeith, Scotland). 
One group received oral doses of 150mg ascorbic acid twice 
daily in buffered 20% sucrose for four successive days. The 
second group received an equal volume, 1ml., of sucrose 
solution and served as controls. The dosing was performed 
using a plastic syringe attached to a short dosing needle, 
the end of which was protected by a length of narrow plastic 
tubing. The animals were pair fed and killed on the fifth 
day by cervical fracture. The livers were quickly removed, 
chilled in ice-cold KC1 (1.15%), blotted and weighed. 
Homogenisation of the liver, using a Potter-Elvehjem 
homogeniser with a loose fitting pestle, then occurred to 
provide a 25% (w/v) homogenate in KCL (1.15%), containing tris 
buffer (20mM).
This was the normal procedure used and any deviations 
from this are discussed elsewhere.
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TABLE 4. Composition of the Guinea Pig Diet, FD1
crude oil 3.46 % manganese 25.0 ppm
crude protein 18.58 % copper 2.0 ppm
crude fibre 11.19 % cobalt 0.4 ppm
calcium 1.04 % iron 30.0 ppm
phosphorus 0.74 % iodine 1.3 ppm
salt
metabolisable
energy
1.27 % 
1960 Kcal/kg
magnesium 1000.0 ppm
Amino Acids (% of feed) Vitamins
threonine 0.72 % vitamin A 8000 i.u/kg
glycine 1.12 % vitamin D3
1000 i.u.
valine 0.95 % riboflavin 8 mg
isoleucine 0.78 % nicotinic acid 20 mg
leucine 1.28 % pantothenic acid 4 mg -
tyrosine 0.59 % vitamin B12
12 mg
phenylanaline 0.83 % vitamin E 25 i.u.
histidine 0.41 % vitamin K 10 mg
arginine 1.25 % folic acid 6 mg
tryptophan 0.28 %. choline chloride 200 mg
thiamine 2 mg
ascorbic acid 2000 mg
Ill PREPARATION OF LIVER FRACTIONS
Homogenates were spun at 10,00Cgav. for 10 mins. at 
4° C (M.S.E. High Speed 18, 8 x 50ml rotor, 11,000 rpm) to 
sediment nuclei and mitochondria. Aliquots of the supernatant 
were then spun at 105,000g av. for 1 hour (Beckman L5-65 
Ultracentrifuge, 8 x 35ml rotor, 40,000 rpm) and the microsomal 
pellet retained and resuspended in the original volume of 
buffer.
Washed microsomes were produced by a second 105,000g 
spin of the resuspended pellet. When storage of the microsomes 
was required, the pellet was resuspended at a concentration 
of lg original tissue per ml. and frozen at -40*C in sucrose 
EDTA buffer, containing 250rriM sucrose, 20mM tris-HCl and 
5mM EDTA, pH 7.4
IV METHODOLOGY FOR HEPATIC DRUG METABOLISM
a) Biphenyl-4-hydroxylase
Biphenyl-4-hydroxylase was measured in the 10,000g- 
fraction (Creaven et^  al, 1965). The incubation mixture 
contained 250mg tissue, 6pmoles biphenyl, lOmg Tween .80, 
o.25 jimoles NADP and 0.05Mtris-HCl buffer, pH 8.6, to a 
final volume of 2.7ml. Fluorescence measurements were made 
in a spectrofluorimeter at 338nm with an excitation wavelength 
of 280nm. At this wavelength there was no interference from 
the 24iydroxybiphenyl isomer.
b) Ethylmorphine-N-demethylase
Ethylmorphine-N-demethylase activity was measured in 
terms of rate of formaldehyde production following demethylation 
(Holtzman et al, 1968). The formaldehyde is trapped by 
semicarbazide in the incubation medium. The estimation was 
carried out by heating the deproteinised supernatant with Nash 
reagent, containing ammonium acetate and acetylacetone, which was 
prepared freshly. The incubation mixture of 2.0ml contained 
approximately 3mg microsomal protein, o.2ml neutralised semi­
carbazide hydrochloride (2%); ethylmorphine at a final con­
centration of 7.5 mM, 625^uM NADP; 7.5mM glucose-6-phosphate;
5mM magnesium sulphate and 2EU glucose-6-phosphate dehydrogenase 
in tris-HCl buffer, 0.15M pH8. For each sample, duplicate 
test and control tubes were assayed. In standard tubes, the 
ethylmorphine was replaced by an equal volume of lpM formaldehyde.
c) Ethoxyresoruf in-O-Deethylase
Ethoxyresorufin is a type II substrate, utilising
*
cytochrome P448, whereas the two previously mentioned enzymes 
require cytochrome P450, and are therefore classed as type I.
In the presence of NADPH and oxygen, ethoxyresorufin (7- 
ethoxy-phenazone) is converted to resorufin by the enzyme 
ethoxyresorufin-O-deethylase (Burke & Mayer, 1974). Concen­
trations of the enzyme were measured in microsomal suspensions 
(50% w/v) using a spectrofluorimeter at 586nm with an extinction
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wavelength of 510nm. The incubation mixture contained lpM
ethoxyresorufin, 2mg microsomal protein, and Q.1M tris-HCl
pH7.4, in a final volume of 2.5ml. A 10 pM solution was used
as a standard with the standard cell containing 0.2 nmoles.
It was found that activity was not lost by freezing samples
6
for periods of a few days at -40 C.
d) Cytochrome P450
In the measurement of cytochrome P450, use is made of 
its ligand binding properties. Carbon monoxide combines 
with the reduced form of cytochrome P450 in microsomes to 
form a single peak at 450nm. The reducing agent used was 
dithionate and an extinction coefficient of 91 cm  ^between
450nm and 490nm was used to calculate the P450 content of 
the samples (Omura and Sato, 1964).
e) Cytochrome b _^
The cytochrome b_ content of microsomes was determined5
from the difference spectrum between NADH-reduced and oxidised 
samples using an SP1800 spectrophotometer attached to a chart 
recorder (Ernste et aJ, 1962). An extinction coefficient 
increment between 424nm and 409nm of 185 cm  ^was used
to calculate the concentration of the haemoprotein.
f) Cytochrome C reductase
Cytochrome C reductase activity was determined by
monitoring the rate of reduction of cytochrome C at ambient
temperaturev. Measurements were made at 550 nm using a 3ml
incubation mixture containing O.lmg microsomal protein,
cytochrome C (100 pM)) NADPH (30mM) and phosphate buffer (0.05M)
pH 7.6, containing ImM KCN (Williams & Kamin, 1962). After
establishing a base line, the reaction was started by the
addition of NADPH and the initial velocity taken as a measure
of reductase activity. An extinction coefficient of 18.5cm ^mM  ^
was used.
g) Protein
The protein content of the different fractions was 
estimated by the method of Lowry et al (1951) using bovine 
serum albumen as a standard.
h) Glucuronyl-Transferase
Glucuronyl transferase activity was measured by a 
modification (Shirkey, 1977) of the method of Bock (1974), 
with 1-naphthol as substrate. Contained in a 0.5ml volume of 
tris-HClbuffer, 0.25M pH 7.6, was UDPGA, 5mM; 1-naphthol,
400pM; magnesium chloride, 5mM; Brij 35, 0.1% and tissue 
equivalent to approximately O.lmg microsomal protein.
Following a 5 min preincubation of the reaction mixture at 
37°C in 10ml sovirel tubes, the 1-naphthol was added in a 
lOOjil volume to start the reaction. After 4 mins, the reaction 
was stopped by the addition of 1ml ice-cold glycine-trichloro­
acetic acid buffer (0.5M, pH 2.2) and the tubes were 
placed in iced water. To each standard tube was added lOpl 
of aqueous l-naphthyl-6-D-glucuronide (lOnM) and naphthol 
was added to the blank and standard tubes to give a final 
concentration of 400pM. All tubes were rotary extracted for 
10 mins with 6ml chloroform, followed by centrifugation at 
2000 rpm for 15 mins in order to remove the unreacted naphthol 
and to precipitate the protein solubilized by the detergent. 
Finally, 1 ml of the aqueous layer was added to an equal volume 
of glycine-sodium hydroxide buffer, 1.0M pH 10.6 and the 
fluorescence of the samples read at an excitation wavelength 
of 303 nm and an emission wavelength of 334 nm.
It was found that UDPGA was without effect on the 
fluorometric assay and hence could be omitted from the blank 
and standard tubes. With regard to the standard, aliquots of 
lOnM concentration were frozen at -40 C and thawed at will.
i) Sodium Dodecyl Sulphate Polyacrylamide Disc
Gel Electrophoresis.
The washed microsomal suspensions were initially 
stabilised with sodium dodecyl sulphate (S*D.S.) and then’ 
separated on polacrylamide using a discontinuous buffer system 
(Laemmli, 1970; Fennel, 1980).
Reagents: Gel stock
Buffer I 
Buffer II 
Buffer III 
Buffer IV
30% (w/v) acrylamide containing 
0.8% (w/v) N,N’-methylene-bis- 
acrylamide.
1.5M tris-HCl (pH 8.8) 
containing 0.4% (w/v) SDS
500mM tris HC1 (pH 6.8) contain­
ing 0.4% (w/v) SDS.
25mM tris-HCl (pH 8.3) containing 
192mM glycine and 0.1% (w/v) SDS
62.5mM tris-HCl (pH 6.8) contain­
ing 2.3% (w/v) SDS, 15% (v/v) 
glycerol, 5% (v/v) 2-r-mercaptoe- 
thanol and 0.001% bromophenol blue 
ammonium persulphate 10% (w/v)
A vertical slab gel apparatus, made in the workshop of 
the Biochemistry Department was used. The gel was contained 
in a glass and perspex cuvette, with internal dimensions of 
120mm x 100mm x 1.5mm. Electrophoresis was carried out at 
room temperature.
The glass plates of the gel cuvette were washed in 
detergent, rinsed in tap water, distilled water, methanol 
and acetone and allowed to dry. The cuvette was assembled 
and sealed with 1:5% (w/v) molten agar and then clamped in a 
vertical position. The lower (or running) gel was prepared 
and the solution was poured into the cuvette to a height of 
80cm. A layer of distilled water was introduced above the 
gel mixture to ensure a flat interface between the separating 
gel and stacking gel after polymerisation. When polymerisation 
was complete, the water layer was removed and the upper (or 
stacking) gel was prepared and added to the cuvette. A perspex 
comb was introduced into the stacking gel prior to polymerisation
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to form the sample wells. The comb was removed when 
polymerisation was complete and a small amount of buffer 
III was introduced into the sample wells to keep them separate/ 
The lower spacer was removed from the cuvette, and the cuvette 
was then placed in the electrophoresis tank. Buffer III was 
added to the upper and lower reservoirs, and air bubbles 
trapped beneath the gel were removed using a syringe.
a final concentration of lmg protein/ml. Samples were placed 
in a boiling water bath for three minutes. The samples were 
cooled and applied to the stacking gel. Two samples of each 
protein were applied, one containing lOpg protein and the 
other 20pg. A constant current of 20mA was used until the 
bromophenol blue entered the stacking gel and then the current 
was increased to 40mA until the bromophenol blue was within 
5cm of the end of the gel. The cuvette was removed from the 
tank when electrophoresis was complete. The glass plates 
were separated, the stacking gel removed and the gel stained 
in order to visualise the proteins, using Coomassie Blue 
stain.
acid/water (5:2:13 by volume) containing 0.5% Coomassie blue 
G-250. The gel background was destained by immersing in 
progressive changes of propan-2-ol/acetic acid/water (1:1:8 
by volume) over a period of 48 hrs. The gel was stored in 
3% (v/v) glycerol at 4°C once the background had cleared.
Alongside the microsomal suspensions were run the 
following marker proteins:
Microsomal suspensions were diluted in buffer IV to
The gel was immersed overnight in propan-2-ol/acetic
Bovine serum albumen 68,000 - molecular weight 
in Daltons
Catalase
Hen egg albumen
Aldolase
Chymotrypsinogen A 
Cytochrome C
60,000
45.000
40.000
25.000 
12,500
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j) Binding Spectra Measurement
The addition of various substrates of. the mixed function 
oxidase system to aerobic liver microsomes causes two types of 
spectral change (Schenkman at al, 1967). Hexobarbital, a' 
type I substrate, which requires cytochrome P450 for its 
metabolism, is characterised by a trough at 420nm and an 
absorption peak at 385-390nm. Aniline is an example of a type 
II compound, requiring cytochrome P448 and is characterised by 
the appearance of an absorption peak at about 430nm and a trough 
at 390nm. The magnitude of the spectral change is known to 
be dependent on the concentration of substrate added as well 
as the concentration of microsomal protein used.
The method used to produce binding spectra was based 
on that of Schenkman e^t al (1967), adapted for use with guinea 
pig microsomes. Washed microsomes were prepared as previously 
described and were resuspended at a concentration of 2mg protein 
per ml in 50mM Tris-HCl buffer, pH 7.6. A 6ml aliquot of 
microsomal suspension was divided between two cuvettes and a 
base line was recorded, using a Varian Cary 219, dual beam 
spectrophotometer, which was automatically subtracted from the 
V- change in light absorbance caused by the addition of the 
substate, hexobarbital or aniline.
0 CSpectra were obtained at 25 C since at 37 C there is 
an increased turbity and the contents of the cuvettes were 
regularly mixed to avoid settling of the membrane particles 
in the suspension.
Small aliquots of either of the 500mM substrates were 
added to the sample cuvette with a Hamilton micro-syringe and 
an equal volume of buffer to the reference cell, up to a total 
of 20pl, representing a final concentration of 0~4mM.
By plotting the reciprocal of change in absorbance 
against the reciprocal of substrate concentration, it is possible 
to determine the spectral dissociation constant, Kg. For aniline, 
the absorbance is measured between 430 and 450nm and for 
hexobarbital between 422 and 450nm.
64
AA
A a
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^FIGURE IX.. Lineweayer - Burke plot for determinings Ks1.'1
where [Sj = substrate concentration 
A a = change in absorbance 
Kg = spectral dissociation constant
V METHODOLOGY FOR GENERAL LIVER COMPOSITION,
a) Total Phospholipid Determination
Total phospholipids were measured by an adaptation of 
the method of Naito (1975) in whole liver and in the microsomal 
fraction. For the whole liver, a 4% (w/v) homogenate was 
employed and for microsomes an 8% suspension (w/v). Following 
precipitation with TCA (10%) the liver samples were digested 
on a Kjeldahl mantle, using concentrated perchloric acid (0.5ml) 
with vanadium pentoxide as a catalyst. The samples were 
subsequently cooled and assayed for phosphate content using 
ammonium molybdate and l-amino-2-naphthol-4-sulphonic acid. 
Spectrophotometric measurements were made at 660nm against 
a blank containing water and 0.5ml of digestion mixture. A 
range of standards was' also prepared, containing 0-20pg/ml. 
inorganic phosphate, these too contained 0.5ml digestion mixture.
b) Determination of Individual Phospholipids
Estimation of individual phospholipids in 50% (w/v) 
microsomal suspensions was made by an adapted three stage 
process (Folch et al, 1957). Initially lipids were extracted 
then they were separated by thin layer chromatography (T.L.C.) 
and finally quantitation was achieved by determining the inor­
ganic phosphate content of the spots on the T.L.C. plates.
(i) Extraction
Reagents: Chloroform : methanol (2:1)
Pure Solvents Upper. Phase - chloroform:methanol
water
(3:48:47)
0.88% KC1 (w/v)
An aliquot of microsomal suspension (0.25ml), which had 
been previously stored at -40°C, was shaken in a stoppered tube 
for 10 mins. with 4.25ml chloroform : methanol (2:1). The 
resulting emulsion was filtered through a 7.0cm Whatman number 
1 filter paper, which had been moistened with solvent. The 
remaining contents of the tube were re-extracted with a further
6 6,
3ml of solvent and then filtered through the same filter 
paper to give a total volume of 7.5ml. To each tube was 
added 1.5ml 0.88% KC1 and after a 5min extraction the tubes 
were centrifuged. The upper phase was discarded and the 
lower phase was washed three times with small volumes of 
pure solvents upper phase, taking care not to disturb the 
lower phase. Any remaining upper phase was solubilised by 
the addition of a drop of methanol.
Finally the solvent was removed via a stream of
nitrogen at 30*0 and after redissolving the extracted lipid
■ ©
in 1ml. of chloroform, the samples were stored at -40 C.
(ii) Separation of Phospholipids
Reagents: Freshly prepared solvent system -
chloroform; methanol; glacial 
acetic acid water (65:25:8:4) 
iodine crystals
phospholipid markers (see below)
Onto a TLC plate was streaked 200]nl of the extracted 
lipid in chloroform, in duplicate, together with phospholipid 
markers. Each plate was run in a saturated TLC tank containing 
a lining of Whatman number 1 filter paper which had been 
equilibrated with 100ml of the freshly prepared solvent system.
The run was terminated after approximately If hours, by which time 
the solvent front had travelled 15cm from the origin. Spots were 
visualised by placing the plates in a further tank containing 
iodine crystals for 5-10 mins. (Skipski et al, 1962).
The spots were compared with phospholipid markers run on 
each plate as follows :
phosphatidyl-choline 
phosphat idyl-inositol 
phosphatidy1-serine 
phosphatidyl-ethanolamine 
L a-lysophosphatidyl-choline 
L a-phosphatidic acid 
sphingomyelin
Bovine liver III 
Soya bean III 
Bovine brain 
Bovine brain 
Egg yolk 
Egg lecithin 
Bovine brain
All the markers were obtained from Sigma and were stored in 
the dark at -40*C. Despite the deviation from the original 
method with respect to the concentrations of the components 
of the solvent system, it was not always possible to 
confidently separate phosphatidy1-choline and phosphatidyl- 
serine.
(iii) Quantification :
Quantification was carried out by scraping the spots 
into individual tubes and assaying for inorganic phosphate as 
described in section Va (Naito, 1975). Following perchloric 
acid digestion, the tubes were centrifuged to sediment the 
silica from the plates. Colour production was then determined 
ClVa) . '
The method of extraction and measurement was found 
to be 95% efficient.
c) Glucose-6-Phosphatase.
The activity of glucose-6-phosphatase was measured 
in a 2.5% (w/v) liver homogenate by the method of Nordlie and 
Arion (1966) and made use of the fact that this liver enzyme 
cleaves its substrate, glucose-6-phosphate, to produce glucose 
and inorganic phosphate. Following a 10 min. incubation of 
the liver fraction with substrate, the reaction was terminated 
by the addition of 10% TCA. The tubes were then centrifuged 
and phosphate, as an indirect measure of enzyme activity, 
measured in the supernatant (Va).,
d) Glucose-6-phosphate dehydrogenase
The activity of this enzyme was measured in 2.5% (w/v) 
10,000g fraction by an adaption of the method of Langdon (1966) 
at 340nm using quartz cuvettes. For each sample, a test and 
a reference cuvette were prepared. The reference cell contained 
only phosphate buffer, 0.1M, pH 7.4 and tissue, but the test 
cuvette had, in addition, NADP (2nmoles) and glucose-6-phosphate 
(3 nmoles). The cuvettes were incubated at 38°C for 5 mins in 
a constant temperature chamber of an SP-1800 spectrophotometer
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and then the rate of production of NADH was measured in the 
test cuvette, compared to the reference cell. To calculate 
the activity of the enzyme, an extinction coefficient for
NADH of 6.22 cm ^mM ^  was used.
.e) Lipid Peroxidation
The extent of lipid peroxidation in the 10,000g fraction
was measured by the thiobarbituric acid method (Tappel & Zalkin,
1959). The protein in a 1ml aliquot of 25% (w/v) 10,000g 
fraction was precipitated with 10% TCA and the malonaldehyde 
content of the supernatant determined using 0.67% thiobarbituric 
acid. Malonaldehyde is an end product of lipid peroxidation, which 
reacts with thiobarbituric acid to give a red colour, which is 
measured at 535mm. 1,1, 3,3,-tetramethoxypropane, which produces
malonaldehyde on hydrolysis, was used as standard for the reaction 
in the range 0-8 nmoles/ml.
f) Ascorbic Acid Determination
Ascorbic acid was measured in the plasma and tissues by 
the method of Denson and Bowers (1961). Plasma protein was 
precipitated with 5% TCA and the supernatant frozen at -40°C.
Guinea pig tissues, directly after removal from the animal, 
were placed in ice-cold 5% TCA such that the ratio 1:20 (w/v) 
was achieved. Samples were frozen as quickly as possible at 
-40eC. Prior to being assayed, samples were thawed and homogenised 
and then centrifuged at 2,000rpm for 10 mins. Supernatant was 
then used for the ascorbic acid determination. When it was 
required to measure the vitamin C content of subcellular liver 
fraction, the fractions were prepared as quidkly as possible 
at 4°C and aliquots were precipitated with 5% TCA and frozen 
at -40°C.
All assays were carried out within one week of freezing, 
and involved the reaction of samples with a reaction mixture 
containing 2,4-dinitrophenol hydrazine, thiourea and copper 
sulphate at 37°C. Standards in the range of 0-4pg/ml were 
employed and the samples were read at 520nm.
g) Histology
Pieces of tissue were fixed in 10% neutral buffered 
formalin over a period of several days. The buffered formalin 
contained 100ml 40% formaldehyde, 4.5g sodium dihydrogen 
orthophosphate and 6.5g anhydrous disodium hydrogen orthophosphate 
per litre in distilled water. Samples of tissue, 2-3mm in 
thickness, were then dehydrated in a Histokinette automatic 
tissue processor (British American Optical Company Ltd., Slough). 
This processed the samples for periods of 1 hour in increasing 
concentrations of ethanol, 70%, 85% and 95% respectively, 
followed by three 1 hour periods in 100% ethanol. Tissues 
were then cleared by two 1 hour treatments in toluene.
Impregnation with paraffin wax was achieved at 58 C, during which 
process care was taken in order that the tissue was orientated
such that the surface to be cut rested on the base of the mould.
\
Sections were cut from the blocks at a thickness of 7F 
using an American Optical Spencer 820 Rotary microtome. The 
sections were floated on tepid water to remove the creases and 
then transferred to microscope slides and dried.
Samples were dewaxed with xylene and then washed in 
decreasing concentrations of ethanol for periods of 1 min.,
100%, 70% and 50% respectively. Following a brief rinse in 
distilled water, the sections were stained with Ehrlich's acid 
haematoxylin (Lamb, London) and then counterstained in 1% 
aqueous eosin (Lamb, London). Finally, after dehydration with 
increasing concentrations of ethanol, the tissue was cleared 
with xylene and mounted in D.P.X. (B.D.H. Ltd.). Slides were 
examined at magnifications of x40, xlOO and x400 using a Vickers 
M15c microscope.
Haematoxylin has the property of reacting with and binding 
to acidic groups such as are found in nucleic acids. Such 
components of cells are referred to as 'basophilic'. In acid 
solution, haematoxylin is reddish coloured and when rendered 
alkaline it turns blue and becomes permanently fixed to the 
tissues. Eosin is used mainly as a background stain but con­
centrates. mainly in the cytoplasm and other non-nuclear components 
referred to as 'eosinophilic' or 'acidophilic'. This method is
a regressive staining method in which sections are over-stained 
and the stain selectively removed in acid alcohol. Sections may 
be examined under a low power microscope and returned to 
haematoxylin if not blue enough or to acid alcohol if not 
sufficiently differentiated.
h) Superoxide Dismutase
Superoxide dismutase activity was measured in the 10,000g 
fraction by a modification of two existing methods (McCord & 
Fridovich, 1969; Misra & Fridovich, 1972), which determines the 
inhibition of adrenochrome production from adrenalin following 
the addition of tissue fraction, and is unusual in the fact 
that it relies on the ability of an enzyme to inhibit an 
observable process. The action of xanthine on xanthine oxidase 
liberates superoxide radicals, which are capable of catalysing 
the oxidation of adrenaline to the coloured product, adrenochrome 
since adrenaline is a free radical scavenger. Addition of 
superoxide dismutase to the reaction mixture removes the 
superoxide anions, thus inhibiting the rate of formation of 
adrenochrome.
The assay mixture contained lOOpl xanthine in 1M sodium 
hydroxide giving a final concentration in 3ml of ImM, lOOpl 
xanthine oxidase in 2.3M ammonium sulphate giving a final 
concentration of lOOnM, lOOpl adrenaline in 1M HC1 giving a 
final concentration of 600pM, 2.7ml 0.05M sodium carbonate buffer 
pH 10.2. and tissue equivalent to l-2mg protein.
The reaction was carried out at room temperature in 1cm 
cells in a total volume of 3ml. The change in absorbance due 
to adrenochrome formation was monitored at 480nm using a SP1800 
spectrophotometer, attached to a chart recorder. The reaction 
was initiated by the addition of the adrenaline and in this 
way there was no lag in the rate of adrenochrome formation. The 
reaction rate.measured against blanks containing buffer, xanthine 
and xanthine oxidase, was found to be linear over a period of 
6-8 minutes. The amount of superoxide dismutase required to 
inhibit the rate of oxidation of adrenochrome by 50% was defined 
as one unit of activity. It was found that samples could be 
stored at -40°C and thawed as required.
The 'in vitro' determination of superoxide dismutase 
in hepatic cellular fractions including the 10,000g fraction, 
microsomes and cytosol of untreated guinea pigs was repeated 
with different concentrations of ascorbic acid, in the range 
0-10mM, in the reaction mixture. At each concentration of 
ascorbic acid, a blank containing no tissue was also measured.
VI METHODOLOGY FOR HAEM METABOLISM
a) Delta-amino-laevuiinic Acid Synthetase
This method is based on that of Ebert et^  al (1970), 
which was modified for use in the guinea pig by Rikans et: al 
(1977), and measures the production of labelled delta-amino- 
laevulinic acid following incubation with a labelled substrate, 
succinate.
An aliquot (1ml) of a 5% (w/v) whole liver homogenate
was added to 1ml of incubation mixture, containing 200mM
glycine, 150mM tris-HCl (pH 7.4), 20 mM EDTA, 0.4mM pyridoxal
14phosphate and lpCi ( C)-succinate (50mCi/mmol). Prior 
to addition both the liver homogenate and the incubation mixture 
had been separately pre-incubated. The combined reagents were 
incubated for 10 mins in soveril tubes and the reaction terminated 
by the addition of 0.25ml 50% TCA. The samples were then 
prepared for column chromatography by the method of Ebert et al 
(1970), for which were used 20cm columns, 1cm in diameter con­
taining a glass scintor and a 3cm bed of Dowex 50 resin, which 
had been previously converted to the sodium form by repeated 
heating with strong sodium hydroxide.
Following centrifugation the sample was added to the 
column in combination with 2 pmoles carrier delta-amino- 
laevulinic acid, and 50 pmoles carrier succinate. The columns 
were eluted with successive volumes of acetate buffer, pH 3.9; 
methanol-acetate buffer (2:1, v/v) and 0.01M HC1. The labelled 
delta-amino-laevulinic acid was finally eluted off in 5ml 
ammonium hydroxide (1M), the first 2ml being discarded, since 
it did not contain appreciable quantities of radioactivity.
Aliquots of eluate were added to scintillant, containing
toluene, metapol, PPO and dimethyl-POPOP and counted on a
Rack Beta counter in mini-vials for 5 mins. As a standard,
14samples containing O.OluCi ( C)~delta-amino-laevulinic acid
*‘14(42mGL/mmol) instead of ( C)— succinate were run through the 
same process, together with blanks containing id radioactivity.
Both radioisotopes were obtained from the Radiochemical 
Centre, Amersham. Initial experiments suggested that the
recovery was 85-90%; however, by running standards through 
the entire process, any losses of radioactivity should be 
common to all tubes. In addition, soveril tubes were found 
to be interchangeable with the flasks used in the quoted 
methods. This allowed easier handling of large numbers of 
samples, such that each determination could be carried out 
in triplicate.
b) Microsomal Haem Oxygenase
Haem oxygenase was assayed in the 10,000g fraction 
using an adaption of the method of Tenhunen jet _al (1970), 
which determines the rate of formation of the end-product 
of haem metabolism, bilirubin, at 468nm, using an extinction 
coefficient of 30mM ^cm \  The 10,000g fraction served as 
a source of the enzyme biliverdin reductase . The incubation 
mixture of 3ml contained approximately lOmg protein, 17pM 
hemin and phosphate buffer, 0.1M, pH 7.4. Following a five 
minute incubation at 37°C in a constant temperature cuvette, 
the reaction was initiated by the addition of NADPH (180jjM).
In the reference cell, NADPH was replaced by an equal volume 
of buffer.
c) Microsomal Haem
Total haem content was assayed by measuring the for­
mation of the pyridine haemochromagen in washed microsomes 
by the method of Schenkman et aA (1973). A sample of washed 
microsomial suspension containing 5-1 Cmg. protein was added to 
60% pyridine (2ml) and 1M sodium hydroxide (1ml). The volume 
was adjusted to 6ml and was divided between two cuvettes.
The test cuvette contents were reduced with dithionate and the 
difference in absorbance between the test and reference cells 
was determined by scanning between 550 and 660nm using a 
SP1800 spectrophotometer. The difference in absorbance 
between 557 and 575nm, using an extinction coefficient of 
32.4mM ^cm enabled calculation of the haem content. In a 
similar manner, the haem content of a 1% liver homogenate 
was determined. The protein content used was chosen such
that the assay could be performed at a sensitivity within 
the range 0.1-1.0
VII METHODOLOGY FOR COPPER, ZINC, IRON AND 
CERULOPLASMIN INTERACTIONS
a) Ceruloplasmin
Serum ceruloplasmin was measured by the method of 
Sunderman and Nomoto (1970) by determining its p-phenylenediamine 
oxidase activity, using phenylenediamine (PPD) dihydrochloride, 
8.92 mM, as substrate.
In general, the PPD-oxidase methods for the measurement 
of serum ceruloplasmin are more sensitive Ithan measurement of ' 
the absorbance change caused by decolouration of ceruloplasmin 
and are more precise than determination of ceruloplasmin by 
immunodiffusion or enzymatic oxidation of Fe(II), that is 
serum ferrioxidase activity (Sunderman & Nomoto, 1970).
At pH 5.4, ceruloplasmin catalyses the oxidation of PPD 
to yield a coloured product, which is believed to correspond 
either to Bandrowski's Base (Rice, 1962) or Wuerster’s Red 
(Henry, 1964). The rate of formation of this product is 
proportional to the concentration of serum ceruloplasmin if 
a correction is made for non-enzymatic oxidation of PPD. Hence, 
simultaneous assays were carried out with and without sodium 
azide, which inhibits the Aenzymatic oxidation of PPD, the 
difference between the results of the two assays was proportional 
to the ceruloplasmin concentration.
In addition the PPD oxidase reaction is subject to a 
lag phase, owing to oxidation of serum ascorbic acid (Aprison 
& Grosz, 1958; Osaki et_ al, 1964) and to avoid this potential 
source of error, timing of the reaction was delayed for 5 mins 
to allow for completion of the lag phase (Sunderman & Nomoto, 
1970).
Acetate buffer, 0.1M pH 5.45, was used since the PPD 
oxidase activity of rat ceruloplasmin has been reported to be 
markedly inhibited by phosphate buffer, although the effect on 
human serum was found to be only slight (Sunderman & Nomoto, 1970)
Aliquots of serum, 0.1ml, were diluted in twenty volumes 
of acetate buffer and pre-incubated at 37°C. Freshly prepared 
buffered PPD, 27.6mM was similarly equilibrated. For each
sample, there were four tubes; two blank and two reagent tubes.
PPD was added to each tube to give a final concentration of 
8.92mM. After 5 mins, 50jil of sodium azide, 1.5M was added 
to those tubes serving as blanks and the contents were 
thoroughly mixed. The water bath was covered with a sheet 
of silver foil and the tubes incubated for a further 30 mins, 
after which time sodium azide was added to the reagent tubes. 
After cooling to room temperature, the absorbance was measured 
in cuvettes of 1cm path length at 530nm.
Bandrowski’s Base was used as a standard in the range 
of 0-25 pg dye/ml (Rice, 1961), thus allowing the results to 
be expressed in pmoles Bandrowski’s Base formed per minute per 
litre serum under the specified conditions.
b) Haemoglobin
A 20pl aliquot of whole blood was added to Drabkins1 
reagent and, after mixing, the resultant red solution was 
allowed to stand for at least 4 mins and then the absorbance 
was measured at 540nm against a blank consisting of Drabkins’ 
reagent. The standard used was cyanomethaemoglobin, 57.2mg/100ml 
which corresponded to 11.5g Hb/lOOml blood.
c) Serum Copper and Zinc
Serum samples, 0.2mlwere diluted in the ratio of 1:5 
with water and aspirated into an atomic absorption spectrophoto­
meter (IL 353), which was attached to a chart recorder (Perkin 
Elmer 56). Absorbance was measured at 324.7nm in the case of 
copper and 214nm for zinc and was compared with standards in 
the range of 0-8 jiM. Standards were read after each eighth 
sample in order to check that no loss of sensitivity was 
occuring, perhaps through blockage of the probe. Blanks were 
also aspirated regularly to ensure that a steady baseline was 
achieved.
d) Serum Iron
Interference from non-visible haemolysis was eliminated 
by the removal of haemoglobin by protein precipitation. After 
centrifugation, the supernatant was decanted and aspirated
directly into the flame. The peak height of the samples was 
compared with those of a set of ferric chloride standards in 
the range of 0*-50pM. Base line drift was monitored by 
aspiration of a blank at regular intervals and standards 
were measured after every eighth sample to check that a loss 
in sensitivity did not occur.
The protein precipitating solution contained lOOg 
trichloroacetic acid, 30ml thioglycollic acid (mercaptoacetic 
acid) and 166ml concentrated hydrochloric acid per litre 
in double deionised water and it was stored in a brown bottle 
to ensure stability for at least two months. An aliquot,
0.5ml in size, was added to an equal volume of serum and after 
thorough mixing for 45 secs., the precipitated solution was 
allowed to stand for 5mins. prior to centrifugation in a bench 
centrifuge.
Sodium and potassium enhance iron absorption by repressing 
iron ionisation and hence this source of error was compensated 
for by adding a solution containing sodium and potassium in 
the ratio of 140:5 to the blanks and standards, such that each 
contained 2.5ml precipitating solution, 0-0.25ml 500pl stock 
ferric chloride standard and was diluted to a final volume of 
5ml with 140:5 sodium: potassium solution.
e) Tissue Copper, Zinc and Iron
Conical flasks of 50ml volume, were washed in 10% 
trichloroacetic acid, followed by distilled water and were then 
dried in an oven. Into each flask was placed 0.5g liver, 10ml 
concentrated nitric acid and 2ml concentrated perchloric acid, 
and the flasks were allowed to stand at room temperature 
overnight, by which time the samples had been solubilised.
The contents of the flasks were then digested, initially at 
a low heat, on a hot plate until a clear solution remained.
In all cases, this necessitated the addition of additional 
nitric acid to replace losses caused by evaporation. The clear 
solutions were then evaporated to dryness and cooled. The 
precipitates were redissolved in 5ml of 1% nitric acid ready 
for determination of trace metal levels with an atomic 
absorption spectrophotometer in a similar manner to that described
for serum elements.
Iron levels were determined in the neat extract, but 
for copper and zinc a further 1:10 dilution was found to be 
necessary. The standards used were the same as for serum 
determinations except for the fact that they were diluted 
in 1% nitric acid rather than water. In addition the protein 
precipitation step for iron determination proved to be 
unnecessary and consequently the protein precipitation solution 
Was omitted from the standards and additional 1% nitric 
acid added instead
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I * INTRODUCTION
Adverse effects have been reported when ascorbic 
acid is taken in gram quantities. Since the body pool of 
ascorbic acid has been reported to be 1.5g (Baker et al,1971b; 
Kallner et al, 1979) and an intake of lOOmg/day has been 
recommended to maintain this pool (Kallner et al, 1979), it 
could be suggested that gram quantities of the vitamin, 
when taken regularly, constitute a drug rather than a nutrient.
In general, polar and non-lipophilic compounds, like 
the water-soluble ascorbic acid, are readily eliminated from 
the body and as such are regarded as non-toxic. However, 
ascorbic acid can be excreted in various ways, one of which 
is as ascorbic acid sulphate (Baker et al, 1971a) and hence 
competition might occur for those small molecules., such as 
sulphate, required for conjugation with the functional groups 
of xenobiotics in order to facilitate excretion of such 
compounds. Furthermore, it should not be forgotten that the 
mere passage of a xenobiotic through the body's metabolic 
system involves competition for energy, building materials 
or binding sites with co-existing xenobiotics or endogenous 
molecules.
The drug metabolising system comprises at least four
different enzymes, namely cytochromes P450 and b_ and theiro
corresponding reductases, and is very versatile, being able 
to carry out oxygenations on a wide range of substrates. This 
is made possible by the presence of different forms of 
cytochrome P450 (Guengerich, 1979; Nebert, 1979; Thorgeirsson 
et al, 1979) and by alternative methods of oxygen transfer 
(Parke, 1977).
In the review by Guengeiidi (1979) the evidence for the 
multiplicity of cytochrome P450 is discussed. This includes 
spectral studies, SDS polyacrylamide gel electrophoresis, haem 
staining procedures based on the peroxidase activity of 
cytochrome P450, studies with purified fraction, immunochemical 
and immunohistochemical localisation experiments, the raising 
of antibodies to specific proteins and peptide mapping studies. 
The work described provides a strong case for the existance of
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multiple forms of cytochrome P450 and for the fact that these 
forms are different proteins and that different forms of 
cytochrome P450 are found in different animal species. The
variations in the ratio of these different forms of
/
cytochrome P450 may indeed influence the types of product
i
formed and also affect the risk of production of toxic or 
carcinogenic metabolites. In addition, the proportion of 
these multiple forms can be altered by inducers and inhibitors 
and in general terms phenobarbital produces induction of a 
haemoprotein with a characteristic Soret peak at 450nm and 
polycyclic hydrocarbons, such as 3-methylcholanthrene, a 
peak at 448nm. Parke (1980) suggests that cytochrome P448 
induction may be associated with toxic phenomena, although 
there is as yet no strong evidence to support this (FIGURE X)
There is a certain degree of variation in the quoted
figures for the number of forms of cytochrome P450 present
in the different animal species studied, basically due to
differences in methodology. However, under various conditions
adult rabbits can produce at least 8-10 different liver
\
microsomal cytochromes P450, rats 8-12 forms and mice a 
minimum of 5-8 forms (Guengerich, 1979).
In guinea pig microsomes, Rikans et a/1, (1978) have 
identified nine distinct polypeptide bands using SDS polyacryla*- 
mide gel electrophoresis, and induction studies lead the 
authors to suggest that at least eight of these bands, with 
molecular weights between 44,000 - 60,000 daltons, contain 
cytochrome P450, and that the changes observed in the relative 
staining of these bands may reflect changes in the quantities 
of the various forms of cytochrome P450. Indeed, using 
partially purified fractions of the haemoprotein, at least five 
polypeptide bands were found to be present in control guinea 
pig microsomes and were of molecular weight 44,000, 52,000,
55,000, 56,000 and 60,000 daltons. In phenobarbital pre­
treated animals (Rikans et al, 1978), an additional band of 
molecular weight 46,500 daltons was apparent, which was similar 
to that induced in the rat (Ryan et ad, 1975; Welton et'al, 1975), 
rabbit (Imai & Sato, 1974; Haugen & Coon, 1976) and mouse 
(Haugen et al, 1976). Administration of 3-methylcholanthrene
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,24h before killing the animals had no effect on the guinea 
pig polypeptide band pattern, although effects had been 
reported in other species. However, treatment for 7 days 
with, the polycyclic hydrocarbon did result in induction of 
four bands of molecular weight 44,000, 48,000, 57,000 and 
60,000 daltons (Rikans et aT, 1978).
Hence in addition to the different forms of 
cytochrome P450 isolated from different animals pretreated 
with various inducers, it has become increasingly evident 
that multiple forms exist in the liver microsomes of the 
same animal. Nebert (1979) suggested that in order to match 
the wide variety of substrates, hundreds of different forms 
of cytochrome P450 must exist. However, most authors 
(Guengerich, 1979) tend to suggest that a far smaller number 
exist which have overlapping specificities. Thus a difference 
in the proportion of these forms in a microsomal preparation 
could perhaps explain the species, strain, age, tissue and 
sex differences observed in drug metabolism (Lu, 1976).
The exact way in which oxygen is inserted into the 
substrate is unknown. Earlier, the involvement of superoxide 
anions was alluded to as was an oxygenated species generated 
by the cytochrome P450 system. This involvement can be 
extended to include participation of the actual anion in 
either the transfer of electrons or as the activated species 
during cytochrome P450 catalysed oxygenation (Strobel & Coon, 
1971; Coon et hi, 1973). Strobel and Coon (1971) observed 
that superoxide dismutase inhibited benzphetamine hydroxylation 
and demethylation ’in vitro’ and subsequently Coon et al (1973) 
* reported that superoxide is generated ^ y NADPH-dependent
cytochrome P450 reductase in the presence of NADPH and oxygen 
and that agents such as superoxide dismutase and Tiron, which 
are known to decompose the superoxide anion, inhibit cytochrome 
P450 catalysed drug hydroxylation. Under similar conditions, 
neither catalase nor heat-inactivated dismutase caused such an 
inhibition (Coon et a!L, 1973). On the basis of their results, 
these authors proposed a scheme showing the possible involve­
ment of superoxide dismutase in the mixed function oxidase
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,system, with the anion functioning as donor of either of 
the two electrons or as the activated oxygen species.
However, more recent work by these authors (Coon et al, 1977; 
White & Coon, 1980) has suggested that although superoxide 
dismutase may be a transient intermediate in the reaction, 
known stochiometry tends to dictate a role for peroxide 
anions in the reaction. This would also explain the ability 
of hydrogen peroxide to support hydroxylation in the absence 
of molecular oxygen and an external electron donor (Coon 
et al, 1977; O'Brien, 1978). In addition, these authors 
(Coon et al, 1977) suggest that the activated oxygen species 
is most likely to be an oxene moiety. This is in agreement 
with recently published reviews (O'Brien, 1978; White & Coon,
1980), who have rejected other oxygen species such as singlet 
oxygen and hydrogen peroxide. FigureXI shows a recent 
scheme for the mechanism of action of cytochrome P450 in
hydroxylation reactions (White & Coon, 1980) which includes
-  2-roles for superoxide (0 ), peroxy ions (0 ) and an oxene
3+ 2complex with iron (Fe-0 )
Glucuronyl- and sulphotransferase reactions are 
quantitatively the most important phase II reactions (Bock, 1977) 
and they attach a strongly polar group to a lipid soluble 
compound to aid excretion. Whilst the glucuronyltransferases 
are known to be membrane bound (Bock, 1977), the sulphotrans- 
ferases are located in the cytosol. All conjugations expend 
ATP to synthesise or activate the endogenous conjugating 
group, or more rarely to 'activate' the xenobiotic (Dutton,1978). 
In all.cases, xenobiotics and endogenous compounds routinely 
conjugated, such as bilirubin and steroids, will compete for 
the same substrates and in some cases conjugating enzymes 
(Dutton, 1978). In spite of difficulties which have arisen 
in the study of these transferases, it is known that both 
are ubiquitous as regard tissue and species (Dutton, 1975;
Dutton, 1978). Glucuronidation, catalysed by microsomal UDP- 
glucuronyltransferase, is probably the most significant 
phase II reaction, since many reactive species, including 
-OH, -GOOH, -NHg and -SH form glucuronides. Moreover, 
glucuronic acid is readily available from carbohydrates.
ROH RH
3+P450-Fe
ROH-P4 50-Fe 3+RH-P450-Fe
2+RH-P450-Fe3+R-P450-(Fe-OH)
RH-P450-Fe2+(0 )3+RH-P450-(Fe-O)
2H
RH-P450-Fe (0- )RH-P450-
e
FIGURE XI Proposed scheme for the mechanism of action
of cytochrome P450 in hydroxylation reactions, 
after White and Coon 1980.
RH represents a substrate and ROH the corresponding
product. 0 is the superoxide ion,
2— 3+
0^ is a peroxy ion; (Fe-0) is an oxene complex,
the proposed form of active oxygen.
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In general, glucuronidation is low at birth and genetic 
differences are becoming evident. Wilson (1972) reviewed 
racial variation, and there was suggestion of high and 
low glucuronidating strains in man. In addition it has 
been reported (Bock, 1977) that glucuronidation is an 
inducible process, and there is accumulating evidence in 
favour of multiple forms of glucuronyl-transferase, which 
are differently induced by phenobarbital and 3-methylcholan- 
threne, thus demonstrating a similar effect to that seen 
with the forms of cytochrome P450.
Similarly there is some evidence for multiple 
sulphotransferase species, although none of these have been 
systematically purified (Roy, 1971). A key reaction in the 
generation of the endogenous substrate of sulphotransferase,
PAPS (3’-phosphoadenosine-5-phosphosulphate), is the 
production of sulphate from cysteine. Sulphate is poorly 
absorbed from the gut and there is no large pool of this ion 
in the body. In addition cysteine is required for other 
metabolic pathways such as protein synthesis and formation 
of glutathione and taurine. Therefore, the generation of 
’active sulphate’ (PAPS) from cysteine is more likely to be 
depleted 'in vivo’ than the formation of UDP- glucuronic 
acid, generated from carbohydrates. Hence the proportion 
of sulphate ester to glucuronide may well fall with increasing 
dose of xenobiotic with those compounds that can be metabolised 
by either process. Indeed, this has been reported with 
concomitant administration of ascorbic acid and salicylamide 
(Houston & Levy, 1975).
Despite the importance of the role of the drug 
metabolising enzymes as a defence system, it should not be 
forgotten that these enzymes are merely a part of a more 
important intracellular system, the endoplasmic reticulum, 
which is concerned with many processes of intermediary metabolism, 
Including omega-oxidation and desaturation of fatty acids, the 
synthesis of cholesterol, bile acids, steroid hormones, prosta­
glandins, proteins and especially the synthesis of glycoproteins, 
which play a vital role in many biological processes, such as
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cell division cellular adhesion, immune surveillance and 
intercellular communication (Parke 1980). The involvement 
of cholesterol is of interest since ascorbic acid is known 
to be involved in the synthesis of cholesterol at the 
7- a-hydroxylation stage (Bjorkhem & Kallner, 1976). Overload 
or damage to this system may, in consequence, lead to 
adverse effects on the metabolism of lipids and cholesterol, 
on hormonal regulation, protein synthesis and on the rate 
of growth,
Finally, the ability to metabolise drugs is known to be
dependent on various factors, including age, sex, species .and
diet. Hence groups that are likely to be at risk can be
*
identified. The importance of diet has already been discussed 
but age is also a very important factor. With regard to 
the development of the drug metabolising enzymes, young 
animals, being exposed to a different environment from the 
adult, bave a different drug metabolising ability. The de­
velopmental pattern of the mixed function oxidases has been 
reviewed (Neims et a!L, 1976) and it is apparent that the ability 
to metabolise drugs via the mixed function oxidases is virtually 
absent in foetal and neonatal non-primate animals, although 
near term, the activities of enzymes begin to appear. Guinea 
pigs, born relatively mature, achieve adult values a few days 
after birth, but other species only after weeks or months.
Often, post-natal activities surge to values two to three fold 
those found in mature animals.
The primate foetus is exceptional in being able to 
oxidise many xenobiotics. As the foetal liver to body weight 
ratio is over twice that of the adult, hepatic drug oxidation 
could be as important in the foetus as in the adult. During the 
third trimester, the primate hepatic monooxygenase system 
and its components'increase, Qften reaching adult 
values during this period. In contrast to phase I metabolism, 
conjugation reactions are usually very scarce in early foetal 
life, developing mainly after birth. Indeed, they often appear 
earlier extrahepatically than in the liver. No outstanding 
difference between primates and non-primates is as yet evident, 
but man appears to be relatively less well equipped for
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.glucuronidation and better able to sulphate, acetylate 
or glutathione-conjugate than other animal species (Neims 
et al, 1976). On the basis of this information, it could be 
suggested that young children may be at an increased risk 
if exposed to large doses of ascorbic acid. Another group 
at risk is the elderly, whose ability to metabolise drugs 
is reputedly diminished, possibly due to chemical changes 
in the lipid milieu of the membranes, resulting in poorer 
transport of electrons (Hawcroft & Martin, 1974). In addition, 
such people are often on a multi-drug regimen, and hence 
competition for substrates and enzymes might occur.
Consequently, young guinea pigs, weighing approxi­
mately 250g, were chosen for studies of the effect of large 
doses of ascorbic acid on the components of the mixed function 
oxidase system, for although these animals are born relatively 
mature with respect to their ability to metabolise drugs, they 
might be considered to be at more risk than adults due to their 
rapid growth rate at this age.
II EX PE L
a) Measurement of Phase' I Metabolising Enzymes
Guinea pigs were prepared as described in Chapter 
2. Each animal in the test group received 300mg/day ascorbic 
acid, given as two equal portions, approximately 6 hours 
apart. An exception to this occured on the first day of each 
study, which was a Sunday, when each animal in the test 
group received a single oral dose containing 300mg ascorbic 
acid in 20% sucrose. In all cases, the control group received 
an equal volume of 20% sucrose solution. Animals were killed 
between 8.30 am. and 9.30 am. on the Thursday morning, following 
4 days treatment with the vitamin.
Cytochromes P450 and b and cytochrome c reductaseo
were measured in aliquots of frozen microsomes whilst the 
extent of oxygenation of various substrates was measured in 
fresh tissue, biphenyl-4-hydroxylation in the 10,000g fraction 
and ethoxyresorufin-O-deethylation and ethylmorphine-N- 
demethylation in the microsomal fraction.
b) Measurement of Glucurbnyltransferase Activity
Glucuronyltransferase activity was determined, as a 
measure of phase II metabolism, in animals treated for 4 days
with 300mg ascorbic acid, using 1-naphthol as substate . A
third group of animals was introduced, receiving 300mg/day 
ascorbic acid together with a lOmg supplement of cysteine.
c) Effect of various doses of ascorbic acid on 
Phase I metabolism.
In order to determine whether effects seen on hepatic 
drug metabolism were specific to a certain dose level of 
ascorbic acid, guinea pigs were given 50, 100, 200 or 300mg 
doses, as two equal portions as described previously. A
control group was also included and concentrations of
cytochromes P450 and b were compared.
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d) Effect of extended treatment with ascorbic 
acid oil Phase I metabolism.
Similarly, to determine whether effects seen after
4 days of treatment were not purely transient, to be shortly
followed by adaptation, guinea pigs were treated with 300mg/day
orally for a period of 28 days. Unlike previous experiments,
animals were caged in groups of six, instead of individually,
there being six control and six test animals. The guinea
pigs were initially matched for weight and previous rate of
weight gain. Both groups of animals received hay once a week
to supplement ascorbic acid intake and so prevent the control
group becoming sub-clinically scorbutic. Unfortunately, after
about one week, one of the test animals had to be killed, as
it was apparently suffering from a prolapse. The microsomal
concentrations of cytochromes P450 and br were determined
5
as a measure of the effect of ascorbic acid treatment.
e) Species variation
To investigate whether the effects seen with large 
doses of ascorbic acid were specific to a species unable to 
synthesise the vitamin, the experiment was repeated using 
190-200g rats. However, since this animal can synthesise 
the vitamin as required, it was decided that a larger dose 
than that used with the guinea pig was necessary to overwhelm 
the body pool of ascorbic acid. Hence each animal received 
either lOOmg ascorbic acid per 0.5ml buffered saline or 0.5ml 
buffered saline intra-peritoneally, twice daily over the usual 
4 day period. Apart from this variation in dosing procedure, 
the animals were treated in exactly the same way as described 
for guinea pigs. The haemoproteins, cytochrome c reductase, 
biphenyl-4-hydroxylation and ethylmorphine-N-demethylation 
were measured in the livers of these animals.
f) Induction with Phenobarbital
As discussed previously, phenobarbital is known to 
stimulate the terminal mixed function oxidase, cytochrome P450 
and hence the effects of large doses of ascorbic acid, 300mg/
day, were studied when given in combination with phenobarbital.
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Guinea pigs were prepared in the standard way and in addition 
received 50mg/kg phenobarbital intraperitoneally for the 
first three days and 75mg/kg for the final day of ascorbic 
acid dosing. The activities of the microsomal haemoproteins, 
cytochrome c reductase and biphenyl-4-hydroxylase were then 
determined as previously described.
g) Hexobarbital sleeping time
The ’in vivo' metabolism of a drug, hexobarbital, 
was studied in 20 guinea pigs, half of which had received 
300mg/day ascorbic acid in the standard manner. Following 
4 days of treatment with the vitamin, each animal was given 
an intraperitoneal injection containing 55mg/kg body weight 
hexobarbital, which resulted in sleep after a few minutes.
When the animals were able to roll onto their feet for the 
third time, it was concluded that sleeping had ceased.
h) TIn vitro'’ experiments
It could be suggested that as ascorbic acid is a 
powerful reducing agent, any effects seen are due to a chemical 
effect on ’in vivo’ metabolism. Consequently, aliquots of 
control microsomes were incubated at 37°C with varying 
concentrations of ascorbic acid, 0-300}ig/g liver, and cytochrome 
P450 concentration was determined at 0, 10, 20.and 30 minutes. 
The concentrations of the vitamin were chosen to be in the 
range 0 .1-10 fold that found in the cytosolic fraction of 
livers from animals treated with 300}ig/day ascorbic acid for 
4 days.
In addition, control microsomes were incubated
together with NADPH (200]iM), EDTA (ImM) and either zero or
30|ig/g ascorbic acid at 37°C for 0,10, 20 or 30 minutes.
This experiment was designed to find whether the addition of
NADPH could promote any effect of ascorbic acid.
Finally, cytochrome P450 was measured in both control 
and test microsomes,- with the variation that no carbon monoxide 
was added to either cell. The aim of the experiment was to 
ensure that no carbon monoxide, produced during the breakdown
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of cytochrome P450, was being formed 'in vitro1. The 
absence of an absorbance peak at 450nm would infer that 
carbon monoxide formation had not occurred. This was an 
important determination since previous production of 
carbon monoxide would automatically decrease the amount 
of haemoprotein available to bind with the exogenous 
carbon monoxide bubbled through the test cuvette during 
the P450 assay, leading to a false indication of decreased 
cytochrome P450 activity.
separate individual proteins within a defined molecular 
weight range. The method described in Chapter 2 was used, 
together with washed microsomes from guinea pigs which 
had previously been treated with 300mg/day ascorbic acid 
for 4 days, to separate proteins within the molecular 
weight range 12,500 - 150,000 daltons. A control group 
of animals was also included and in order to increase the 
quantities of haemoprotein present and the chance of 
identifying any changes occurring, the animals were 
selectively treated with the inducers phenobarbital and 
ft-naphthoflavone. Phenobarbital induces cytochrome P450 
and f^-naphthof lavone induces cytochrome P448. Both compounds 
were given intraperitoneally, the former in saline, 50mg/ml, 
and the latter in corn oil, 37.5mg/ml. Ascorbic acid was 
given orally in the standard manner.
i) Gel elec t rophor e s i s
Polyacrylamide gel electrophoresis can be used to
ASCORBIC ACID GROUP CONTROL
CONTROL) ■ 300mg/d ascorbic acid, 
no inducer
no ascorbic acid 
no inducer
PHENOBARBITAL 300mg/d ascorbic acid 
50mg/kg inducer
300mg/d ascorbic acid 
8Qmg/kg inducer
no ascorbic acid 
50mg/kg inducer
3-NAPHTHOFLAVONE no ascorbic acid 
80mg/kg inducer
TABLE 5 Dose regimen for guinea pigs, used to determine the effects
of ascorbic acid on the microsomal proteins in the molecular 
weight range 12,500 - 150,000 daltons.
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j) Binding spectra
To investigate whether the binding of type I and 
type II substrates to cytochrome P450 were affected by large 
doses of ascorbic acid, washed microsomes from guinea pigs 
treated for 4 days with 300mg/day ascorbic acid, in the 
standard manner, were used to produce binding spectra, as 
previously described, by the addition of increasing aliquots 
of aniline or hexobarbital to the test cuvette and an equal 
volume of buffer to the reference cell. The spectra produced 
by the binding of these substrates were then drawn on an 
accompanying chart recorder. The stock aniline substrate,
500mM, was made up in buffer and the pH brought back to 
5 - 6  with sodium hydroxide, 1M. The 500mM hexobarbital 
stock solution was made by dissolving the solid in 1ml of 
6M NaOH and tben further diluting this to 5ml with buffer.
Any undissolved solid was solubilised by gentle warming at 37°C.
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Ill RESULTS
Treatment of guinea pigs with 300mg/day ascorbic
acid over a period of 4 days had no significant effect on
either body weight gain or liver weight (Table 6:). In
addition, no change in food intake between the two groups
of pair-fed animals occurred. However, administration
of the vitamin decreased the specific activity of the two
microsomal haemoproteins, cytochromes P450 and b_, and5
also that of biphenyl-4-hydroxylase (Table 7 ). However, 
the activities of ethylmorphine-N-demethylase and ethoxyreso- 
rufin-O-deethylase and the activity of cytochrome c reductase 
remained unaffected. There was no effect of the vitamin 
on the concentration of microsomal protein.
The activity of 1-naphthol-glucuronyltransferase 
fell to 60% of control values in the presence of ascorbic 
acid. This loss of activity was partially restored when 
lOmg/day cysteine was added to the dose of ascorbic acid 
received by the test group of guinea pigs (Table 8 ).
The dose response relationships of ascorbic acid
with respect to microsomal haemoprotein concentrations are
shown in Figures XII &XIII. A daily dose of 50mg ascorbic
acid resulted in a statistically significant (p<0.05)
increase in specific activity of both cytochromes P450 and
b . This effect was maintained with a dose of lOOmg/day o
in the case of cytochrome b_ but cytochrome P450 concentrationso
returned to control levels with this amount of the vitamin.
A dose of 200mg/day resulted in both haemoproteins falling
below control concentrations and this depression in activity
was further exacerbated by 300mg/day (p <0.001). Hence there
appears to be a variation in sensitivity between the two
cytochromes, with enhancement of cytochrome b_ activity being5
sensitive to dose levels of up to lOOmg, which is in itself 
to be considered a very large dose to a 250-300g guinea pig, 
whose daily requirement to prevent scurvy is in the region 
of l-2mg/day, which is equivalent to a liver content of 
5mg/100g (Chatterjee, 1967).
TABLE 6:
EFFECT OF THE ADMINISTRATION OF ASCORBIC ACID (150mg b.d.) FOR 
4 DAYS ON LIVER AND BODY WEIGHTS OF GUINEA PIGS.
CONTROL TEST SIGNIFICANCE
Initial Body weight (g) 289 + 9
Final body weight (g) 318 + 6
Body weight gain (g) 2 8 + 3
Liver weight (g) 15.9 + 0.7
Liver weight x 100 4.9 + 0.2
Final body weight
291 + 6 
319 + 5 
30 + 3 
15.4 + 0.6 
4.8 + 0.1
n.s, 
n.s, 
n.s, 
n.s, 
n.s
Results expressed as mean + SEM for 48 animals and level 
of significance measured by a paired Student’s t-test.
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TABLE 8:
EFFECT OF THE ADMINISTRATION OF ASCORBIC ACID (150mg b.d.) FOR 
4 DAYS ON HEPATIC 1-NAPHTHOL-GLUCURONYLTRANSFERASE ACTIVITY 
BOTH IN THE PRESENCE AND ABSENCE OF CYSTEINE (lOmg/day).
1-naphthol-glucuronyltransferase 
(mnol/min/mg protein)
*
: NUMBER MEAN + SEM MEAN + SEM % SIGNIFICANCE
Control 12 89.0 + 10.2 100%
Ascorbic Acid 12 51.5 + 6.6 59.6 + 5.1% P:< o .o o i
Ascorbic Acid 8 72.2 + 7.4 88.1 + 9.9% p< 0.01
plus cysteine
Results expressed as mean + SEM and level of significance 
measured by a paired Student's t-test.
* Test value expressed as a percentage of paired 
control value.
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ON 
CONCENTRATIONS
EFFECT OF ADMINISTRATION OF DIFFERENT DAILY DOSES OF ASCORBIC 
ACID (0-300mg/d) OVER A PERIOD OF 4 DAYS ON THE MICROSOMAL 
CYTOCHROME P450 CONTENT OF GUINEA PIG LIVER.
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It should be noted that following 28 days treatment
with 300mg/day ascorbic acid, the effect seen with cytochrome
P450 and b_ was not so great as that seen with shorter 
5
dosing periods (Table 10), hence it could be mooted that a 
certain degree of adaptation had occurred and this will be 
discussed later. In addition, there is a small but highly 
significant increase of 9% in the protein content of the 
livers when expressed per gram of tissue. Changes were also 
seen in the body weight gain and final liver weight (Tablell), 
with the ascorbic acid treated group gaining 19% more weight 
over the 28 day period than the controls and showing a 
highly significant 70% increase in liver weight. It was 
also noted that 3 of the 5 test animals had extremely lipaemic 
blood, as evidenced by the formation of a fatty clot when the 
samples were centrifuged for serum.
The components of the drug metabolising system in 
the liver of the rat appear to be relatively unaffected by 
the administration of large doses of ascorbic acid intra- 
peritoneally, 300mg/day. No strong trends were evident 
(Tablel2), however, it should be stressed that there were 
only 4 animals in each group and these animals were dosed 
intraperitoneally, rather than orally, in order to increase 
the quantity of ascorbic acid reaching the tissues.
Phenobarbital is known to induce the haemoprotein, 
cytochrome P450 and the administration of this drug, together 
with 300mg/day ascorbic acid to guinea pigs, removed the 
effects seen in the presence of the vitamin alone. It should 
be noted that cytochrome concentrations are 2-3 fold.((Table 13) 
higher than normal, this being evidence of the occurrence 
of induction with phenobarbital. It was observed, with interest, 
that following intraperitoneal injection of the barbiturate, 
prior to becoming dozy, the animals appeared to have an 
increased appetite and thirst.
Although ascorbic acid reduced the activity of the 
mixed function oxidases, there was no effect on the 'in vivo1 
action of the barbiturate, hexobarbital, such as extended 
sleeping time. The animals in the control group slept for a
EFFECT OF TREATMENT OF GUINEA PIGS WITH ASCORBIC ACID (150mgtfd) 
OVER A PERIOD OF 28 DAYS ON HEPATIC MICROSOMAL CYTOCHROMES 
P450 AND b_
CONTROL TEST
(6 animials) (5 animals)
SIGNIFICANCE
Cytochrome P450
(nmol/mg protein)
Cytochrome
(nmol/mg protein)
Microsomal protein 
(mg/g liver)
0.79 + 0.05 0.73 - 0.02 (92%) n.s.
0.46 + 0.04 0.39 + 0.05 (85%) n.s.
21.40 + 0.43 23.26 + 0.72 (f09%) p<0.05
Results expressed as mean -+ sem and significance measured 
by an un-paired Students , t-test. Figures in brackets 
represent the test values as a % of the control values.
TABLE 11:
EFFECT OF ADMINISTRATION OF ASCORBIC ACID (150mg b.d.) FOR 28 DAYS 
ON LIVER WEIGHT AND BODY WEIGHT GAIN IN THE GUINEA PIG.
CONTROL TEST SIGNIFICANCE
(6 animals) (5 animals)
Initial body weight (g) 268 + 9 264 + 9 (98%) n .s.
Final body weight (g> 438 11 464 + 21 (106%) n.s.
Body weight gain (g) 169 + 7 201 + 16 (119%). n.s.
Liver weight (g) 17.1 + 0.4 20.9 + 1.5 (117%) p <0.05
Liver weight x 100 4.0 + 0.1 4.5 + 0.2 (113%) p <0.05
Final body weight
Results expressed as mean + sem and level of significance 
determined by an un-paired Student’s t-test. Figures in 
brackets represent the test values expressed as a % of 
control values.
TABLE 12:
EFFECT OF THE ADMINISTRATION OF ASCORBIC ACID <150mg b.d.) ON BODY 
AND LIVER WEIGHT AND SOME HEPATIC DRUG METABOLISING ENZYMES OF THE RAT.
CONTROL TEST SIGNIFICANCE
Initial body weight (g) 193 + 12 192 + 6 n.s.
Final body weight (g) 229 + 11 222 + 7 n.s.
Body weight gain (g) 36 + 2 30 + 3 n.s.
Liver weight (g) 10.8 + 0.3 9.3 + 0.5 0.05
Liver weight x 100 4.7 0.3 4.2 + 0.1 n.s.
Final body weight
ENZYME ACTIVITY
Biphenyl-4-hydroxylase 0.12 + 0.02 0.06 + 0.01 n.s.
(pnol/min/g liver)
Ethylmorphine-N-demethyLase 4 J05 + 0.06 4.13 + 0.08 n.s.
(nmol/min/mg protein)
Cytochrome P450 0.84 + 0.03 0.74 + 0.06 n. s.
(nmol/mg/protein)
Cytochrome bg 0.48 0.02 0.49 + 0.03 n.s.
(nmol/mg ’protein)
Cytochrome c reductase 63.7 + 2.5 65.3 + 0.03 n.s.
(nmol/min/mg protein)
Results expressed as mean + sem of 4 animals and level 
of significance determined by a paired Student's t-test.
TABLE 13
THE EFFECT OF CONCOMITANT ADMINISTRATION OF ASCORBIC ACID (150mg b.d.) 
AND PHENOBARBITAL C50mg/kg) FOR 4 DAYS ON THE PHASE I HEPATIC DRUG 
METABOLISING ENZYMES OF THE GUINEA PIG.
CONTROL ■ TEST SIGNIFICANCE
Biphenyl-4-hyroxylase 0.31+0.10 0.40+0.13 n.s.
Cpmol/min/g liver)
Cytochrome P450 2.06+0.13 1.81+0.12 n.s.
(nmol/mg protein) “ ""
Cytochrome bg 0.81+0.04 0.76+0.03 n.s.
(nmol/mg protein)
Cytochrome C Reductase 83.98 + 10.6 108.01 +18.1 n.s.
Results are expressed as the mean + sem of 5 animals 
and the level of significance determined by a paired 
Student’s t-test.
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mean period of 54.9 + 3.5 mins and the test group animals 
for 50.3 + 3.7 mins.
The ’in vitro’ incubation of microsomes from untreated 
animals with varying concentrations of ascorbic acid showed . 
no change in cytochrome P450 concentration with change in 
ascorbic acid content, suggesting that the effects seen 
’in vivo’ are not due to a purely chemical action of the 
vitamin, it being a powerful reducing, agent and antioxidant.
The further addition of NADPH,( 20OpM) and EDTA (ImM) to the 
incubation mixture, similarly, did not result in a decrease 
in cytochrome P450 specific activity, which may have arisen 
through lipid peroxidation for example. In addition, there 
was no evidence of ’in vitro’ carbon monoxide formation, 
it being produced during breakdown of the cytochrome, since 
there was no absorbance at 450nm in the absence of exogenous 
carbon monoxide (TABLE 14)\
Examination of a gel produced by polyacrylamide 
gel electrophoresis (Figure XHIi)suggests that in the presence 
of the cytochrome P450-inducing agent, phenobarbital, there 
was a decrease in at least one of the polypeptide bands in 
the molecular weight range of 45,000 - 60,000 daltons, of 
approximate molecular weight 52,000 daltons. Such evidence 
further supports the idea that ascorbic acid has an effect 
on at least one species of cytochrome P450.
Reciprocal plots for both hexobarbital and aniline
binding to cytochrome P450 suggest that the vitamin has
no effect on substrate binding, since K remains unaffecteds
by ascorbic acid pretreatment of the animals. However, it
can be seen from Figures XIV & XV chat two different K valuess
might exist for each substrate, depending on whether the 
substrate concentration is greater or less than 1.6mM. Such 
an effect has been previously reported by Sehenkman (1S70) 
and might be considered to be due to an increased capacity 
for binding, facilitated by the presence of higher concen­
trations of substrate or to a solvent effect. Thus the affinity 
for the substrate and the capacity to accept it are perhaps
affected, such that a high K represents a low affinity high
s
TABLE 14:
(a) EFFECT OF ’IN VITRO' INCUBATION OF CONTROL MICROSOMES WITH 
VARYING CONCENTRATIONS OF ASCORBIC ACID (0-300pg/g liver) 
ON CYTOCHROME P450 CONTENT.
CYTOCHROME P450 (nmol/mg protein)
ASCORBIC ACID
ADDED Cpg/g liver) 0 10 20 30 (minutes)
0 1.25 1.18 1.21 1.23
3 1.17 1.08 1.06 1.18
30 1.24 1.14 1.14 1.21
300 1.25 1.14 1.17 1.09
(b) EFFECT OF 'IN VITRO’ INCUBATION OF CONTROL MICROSOMES WITH
AND WITHOUT ASCORBIC ACID ON CYTOCHROME P450 CONTENT IN THE
PRESENCE OF NADPH (200pM) AND EDTA (lmM) .
CYTOCHROME P450 (nmol/mg protein)
ASCORBIC ACID 
ADDED Cpg/g liver) 0 10 20 30 (minutes)
0 1.32 1.10 1.06 1.04
30 1.41 1.15 1.11 1.13
* ratio 1.07 1.05 1.05 1.09
* the ratio presented is that of the microsomes treated 
with 30pg/g ascorbic acid to the control microsomes.
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capacity and a lower K a high affinity coupled with as
low capacity.
The Lineweaver-Burke plot is not the only way in which
enzyme kinetics can be studied. Two. other types of plot are
the Woolf plot and the Hoftsee plot (Figure XVI). By plotting
the data on these axes (Figures XVII - XX) the case for two
different K values for each substrate is less clear in the s
case of hexobarbital. However, there is confirmation that although
may change, the K value for control and test groups max s
of animals remains the same.
IV DISCUSSION
Many previous studies, for example Degkwitz and 
Kim (1973); Rikans et al_ (1978); Zannoni (1977) and Omaye 
and Turnbull (1980) have demonstrated an effect of ascorbic 
acid deficiency on the hepatic drug metabolising enzymes in 
guinea pigs. The present study has shown that large oral 
doses of the vitamin have effects which are similar, in some 
respects, to those previously reported in ascorbic acid 
deficient animals. In such animals, cytochromes P450 and b^ 
concentration and the rates at which various substrates are 
oxygenated are decreased (Leber et al, 1969;Degkwitz & Kim 1973; 
Zannoni jet' a!L, 1972) with a specific effect on hydroxylating 
reactions (Kato et al, 1969).
These earlier results, taken together with those 
determined in the present study, suggest a biphasic action 
of the vitamin, with both very large and inadequate doses of 
ascorbic acid having an inhibitory effect. Further evidence 
for such an effect on cytochrome P450 is provided by polyacry­
lamide gel electrophoresis, in which a decreased intensity 
of a polypeptide band of molecular weight 52,000 daltons was 
apparent in microsomes from animals receiving 300mg/day ascorbic 
acid, together with the P450 inducer, phenobarbital. Little 
can be concluded from the data from animals dosed with the P448 
inducer, p-naphthoflavone as both control and test animals 
ceased to grow well and generally appeared ill during the 
dosing period.
Rikans et aT (1978) have reported that microsomes 
from ascorbic acid deficient guinea pigs consistently demon­
strated a decrease in three polypeptide bands of molecular 
weight 44,00, 52,000 and 57,000 daltons. Importantly, these 
differences were maintained in partially purified fractions 
from normal and ascorbic acid deficient animals. It should 
be noted that phenobarbital does not only induce cytochrome 
P450 but several other proteins may be similarly affected. 
Consequently, it cannot be conclusively stated that any 
variation in band intensity is specifically due to a change 
in cytochrome P450, since the staining technique used is
general one for proteins. However, such changes can be 
used in association with other evidence in support of an 
effect on the haemoprotein. Finally, it is of interest 
that the two bands decreased in intensity in ascorbic 
acid deficiency (Rikans et al, 1978) are two of the four 
bands that can be induced by 3-methylcholanthrene, a P448 
inducer.
Consequently, not only do the results presented 
here suggest a biphasic effect of the vitamin, they are also 
in keeping with a selective action of ascorbic acid on 
a specific form of cytochrome P450. This selectivity is 
consistent with the overall effect of ascorbic acid 
deficiency on this important haemoprotein, the concentration 
of which, never decreases below 40 - 60% control values, 
even in extreme deficiency states (Zannoni & Lynch, 1973; i
Degkwitz et al, 1975; Kuenzig et al, 1977). Such an effect 
would occur if there were several forms of cytochrome P450 
which, are unaffected by ascorbic acid. That ascorbic acid 
deficiency or excess may selectively affect certain forms 
of cytochrome P450 is important, especially in the light of 
the findings that ascorbic acid deficiency can exert both 
substrate specific and organ specific effects on the activity 
of cytochrome P450 in guinea pigs (Sikic et al, 1976;
Kuenzig et al, 1977) . These studies support the view that 
variations in the forms of cytochrome P450 present can account 
for variations seen between tissues, species, sexes and age 
groups. It would be interesting to correlate the effects of 
both ascorbic acid deficiency and large doses of the vitamin 
with the specific forms of cytochrome P450 present in different 
tissues.
A recent report (Holloway & Rivers, 1981) describes 
investigations into the influence of chronic ascorbic acid 
deficiency and excessive consumption of the vitamin on the 
hepatic microsomal cytochromes, bile acid metabolism, liver 
and plasma cholesterol concentrations and biliary lipid composition 
Dietary extremes of ascorbic acid were found to cause similar 
alterations in these parameters, again indicating a biphasic 
effect of the vitamin. The data demonstrated an extreme
$usceptibility of cholesterol 7-^-hydroxylase activity to 
alteration by dietary extremes of ascorbic acid, which far 
exceeded that of either cytochrome P450 or b^ _. The work of 
these authors is not directly comparable with the present 
study since in the latter divided oral doses were used, 
whereas Holloway and Rivers (1981) used deficient diets 
supplemented with ascorbic acid. Nevertheless, the top 
dose level of ascorbic acid, 20g/kg diet, is equivalent 
to approximately 5OOmg/day/animal and so is far in excess 
of the American National Research Council recommendation 
of 200mg/kg diet (1978),which is roughly 5mg/day/animal, 
and is also of a similar order to that used in the present 
study, 300mg/day.
Experiments with a range of dose levels of ascorbic
acid suggested that cytochrome P450 activity is enhanced by a
dose of 50mg/day, however a daily dose of lOOmg ascorbic
acid caused a return to control values and larger doses led
to a progressive decline in specific activity. A similar
effect was seen with cytochrome b_, however in this case
5
the increase in activity was sustained with lOOmg/day but 
daily dosing with 200mg/day caused a progressive decrease in 
specific activity as with cytochrome P450. Consequently, 
not only is there a similar effect with very high and deficient 
quantities of the vitamin, but there is also a dose response 
effect when the required daily intake of the vitamin is 
exceeded.
In the light of these results, those of Sato and 
Zannoni (1974) showing enhanced cytochrome P450 activity at 
a dose level of 75mg/day can be explained. Indeed, other 
data from these workers (Rikans et_ al, 1978) suggests that 
a correlation exists between hepatic cytochrone P450 and 
ascorbic acid concentration in the 15,000g supernatant 
fraction (Figure XXI). Animals were fed a chow diet plus 
Irag/ml ascorbate in drinking water for 20 days and were 
grouped according to liver ascorbic acid concentration and 
then compared with groups receiving either an unsupplemented 
chow diet or an ascorbic acid deficient diet. Although 
cytochrome P450 concentration rose with liver ascorbic acid,
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FI GURE XXICORRELATION' OF HEPATIC CYTOCHROME P450 
AND ASCORBIC ACID CONCENTRATION.
The open bar represents the deficient group 
and the dotted bar the unsupplemented chow 
diet group, (after Rikans enb al, 1978).
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the group with the highest ascorbic acid concentration, i.e.
2-3.0 ]imol/100mg protein, in fact had a lower cytochrome P450 
concentration than the preceeding group. Using the fact that 
1 pmol. ascorbic acid per lOOmg protein is equivalent to 
19mg/100g weight liver (Rikans et_ al, 1978), it can be calculated 
that, as will be seen in Chapter 4, the group receiving the 
unsupplemented chow diet had an ascorbic acid concentration 
similar to that found in the control group of animals used 
in the present study. However, the top group, with liver 
ascorbic acid concentrations in the range 2-3 pmol/lOOmg protein 
in fact exceeded the liver ascorbic acid concentrations found 
in guinea pigs fed 300mg/day as two oral doses in the present 
study. Hence it is not suprising in the light of the results 
of Holloway and Rivers (1981) and the data presented in this 
thesis that there was a decrease in the cytochrome P450 
activity in this group of animals. In addition, using trained 
monkeys it has been reported that smaller amounts of ascorbate 
were required to maintain similar blood ascorbate levels when 
the vitamin was incorporated into the diet rather than being 
giyen as a single oral dose (Tillotson & O'Connor, 1980). This 
could explain the fact that higher liver ascorbic acid con­
centrations were attained in the studies of Rikans et al (1978).
Induction of cytochrome P450 by phenobarbital removes
the effect of ascorbic acid on phase I metabolism, again
suggesting that the action of the vitamin is mediated through
the terminal oxidase, cytochrome P450. In addition, substrate
binding effects are not the mode of action of the vitamin, since
’in vitro’ studies of the binding of both the type I substrate,
hexobarbital, and the type II substrate, aniline, could determine
no effect on the spectral dissociation constant, K and although
— s
AA was slightly lowered in the ascorbic acid treated animals, max
this can be explained by the fact that experiments have shown 
that the specific activity of cytochrome P450 is decreased in 
animals treated with 300mg/day ascorbic acid for a period of 
four days.
Furthermore, effects of the vitamin may be restricted 
to those species unable to synthesise ascorbic acid, since 
rats were relatively unaffected despite a large dose of
ascorbic acid given intraperitoneally to remove the effect of 
losses incurred during passage through the gastrointestinal 
tract.
It could be argued that, since ascorbic acid is 
known to be a powerful reducing agent and an antioxidant, 
effects seen are due to such actions provoked by the mere 
presence of the vitamin in the tissues in which the drug 
metabolising enzymes are measured. However, ’in vitro’ 
studies with microsomes from untreated guinea pigs incubated 
with a range of concentrations of ascorbic acid tend to 
discount this idea, since no change in specific activity 
of cytochrome P450 was seen, even with concentrations of 
the vitamin ten times those found in the cytosolic liver I 
fractions from guinea pigs treated with 300mg/day ascorbic 
acid for 4 days. In addition, effects seen were not due to 
'in vitro' carbon monoxide production, via breakdown of the 
haemoprotein, since without addition of exogenous carbon 
monoxide there was no evidence of a Soret peak at 450nm.
Following treatment of guinea pigs with 300mg/day 
ascorbic acid for 28 days, the differences between the specific . 
activities and concentrations of both cytochromes P450 and b,_ 
in control and test animals were no longer statistically 
significant. This could suggest an adaptive response, however, 
In this respect it is of interest to note that control values 
for the haemoproteins were lower than those previously found.
In addition, measurement of liver ascorbic acid content 
revealed values higher than usual. One explanation for this 
can be provided by the fact that hay was given to both groups 
of animals once weekly to avoid the risk of scurvy in the 
control group, again reflecting the results of the study of 
Tillotson and O ’Connor (1980), such that the effect of large 
doses of ascorbic acid on the haemoprotein was masked.
Unlike during the 4 day treatment period, extended; 
dosing resulted in an increase in body weight gain and liver 
weight, together with an increase in liver microsomal protein 
content of the test group, and 3 of the 5 test animals had 
very fatty serum. Liver hypertrophy and increase in protein 
content can be indicative of induction of the drug metabolising
pnzymes and this phenomenon will be discussed later.
So far all discussion has related to phase I 
metabolism of drugs. However, evidence has already been 
reyiewed suggesting that phase II metabolism can be affected 
by large doses of ascorbic acid due to competition for 
sulphate CHouston & Levy, 1975). Few studies have investigated 
the effect of ascorbic acid deficiency on phase II metabolism, 
hence it cannot be determined whether a biphasic effect also 
exists for conjugation reactions. However, it is of 
interest that in the present study, the addition of cysteine, 
an important sulphur-containing amino acid, partially 
alleyiated the fall seen in 1-naphthol-glucuronyltransferase 
activity.
As discussed previously, the two major pathways 
for phase II conjugation reactions are glucuronidation and 
sulphation (Bock, 1977), the latter of which is thought to 
be limited by sulphate availability (Levy & Matsuzawa, 1967). 
Indeed, Houston and Levy (1976a) have proposed that the 
availability of sulphate, rather than activation of PAPS 
C31-phosphoadenosine-5’-phosphosulphate) or the subsequent 
transfer of activated sulphate to the acceptor molecule, is 
the rate-limiting step in phenolic sulphate formation. The 
limited availability of sulphate in the body causes the 
sulphate conjugation process to be easily saturated and 
subject to competitive inhibition.
The interrelationships between ascorbic acid and 
the sulphate pool (Baker jet al, 1971a; Basu, 1977) have 
already been discussed and can be used to suggest that in 
the presence of large quantities of ascorbic acid, sulphation 
is saturated, such that exogenous and endogenous compounds 
are forced to seek an alternative route of excretion, which 
could be glucuronidation, resulting in a decreased availability 
of enzyme sites as evidenced by the decrease in 1-naphthol- 
glucuronyltransf erase activity presented here.
In fact, various reports can be used to illustrate 
this point. Levy and Matsuzawa (1967) demonstrated that the 
phenolic compound, salicylamide, was eliminated mainly as
Its glucuronide and sulphate and that the fraction of the dose
excreted as the sulphate decreased with increasing dose, but 
that the situation could be restored to normal by the con­
comitant administration of cysteine. This again suggests a 
saturable process with respect to sulphation. In addition, 
a further study (Levy & Yamada, 1971) showed that two 
phenolic compounds, acetaminophen and salicylamide, competed 
for sulphation, with a larger proportion of each being 
excreted as the glucuronide than when a single drug was given 
alone. The study also suggested that competition for the 
formation of the glucuronides occurs, since more of the free 
drug was excreted when the drugs were given together. Co­
administration of cysteine again prevented these effects.
Ascorbic acid has also been shown to modify drug conjugation 
In the rat, which also metabolises ascorbic acid to ascorbic 
acid sulphate and has a limited capacity for sulphation 
CBuch et hi, 1967) and it has been found that the route of 
administration is extremely, important (Houston & Levyj 1976b) 
such that, when comparing intravenous with oral dosing, the 
oral administration of the two compounds, ascorbic acid and 
salicylamide, caused a profound decrease in the sulphation 
of salicylamide and salicylamide clearance from the body.
WHereas intravenous treatment with the vitamin had little 
effect. These observations are consistent with the view that 
the pronounced effects are due to a high concentration of the 
two compounds In the intestinal wall and in the liver. Indeed, 
salicylamide is known to be extensively metabolised during the 
’first pass’ in both man and other animal species (Barr, 1969), 
suggesting th.at at least some conjugation occurs in the intestinal 
wall. It has also been reported that the intestine is a major 
site for ascorbic acid sulphate formation in the rat (Hornig 
et' al, 1973), further supporting the hypothesis that competition 
can occur at this site.
Ascorbic acid also modifies the conjugation of 
acetaminophen CHouston & Leyy, 1976a). However, unlike 
salicylamide, this antipyretic is not subject to a pronounced 
’first pass’ effect (Levy, 1971) and hence the effect seen is 
systemic rather than occurring, at least in part, in the gut wall. 
Nevertheless, it is not unreasonable to expect similar
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interactions between large doses of ascorbic acid and 
steroids and other endogenous and exogenous compounds, where 
conjugation with sulphate is mediated by different 
sulphokinases. However, of particular concern is an inter­
action between ascorbic acid and drugs subject to pronounced 
’first pass’ conjugation, such as isoproterenol (Houston &
Levy, 1975), since competition for sulphate conjugation at 
tbe level of the intestinal mucosa could increase the systemic 
availability of such drugs and thereby enhance the pharmo- 
cological effect. The oral dose of isoproterenol is about 
one thousand times larger than an equivalent intravenous 
dose to cater for its extensive deactivation via sulphation 
in the gut wall. Hence concomitantly administered large 
doses of ascorbic acid could result in catastrophic effects 
to asthma sufferers taking such a drug. Indeed, it has 
been shown that the effect of oral isoproterenol is potentiated 
by large doses of ascorbic acid (Houston eb al, 1976).
Finally, the effect of large doses of ascorbic acid
on antipyrine and warfarin disposition in man has been 
investigated (Feetman et al, 1975; Wilson et al; 1976; Houston 
1977) but with these drugs there is an element of disagreement 
about the results. Antipyrine, in man, undergoes oxidative 
metabolism to an extent of 95%. The total body clearance of 
tbe drug is low and consequently it is not affected by changes 
In hepatic blood flow and therefore might directly reflect 
changes in the drug metabolising enzymes (Brodie & Axelrod, 1950; 
Eichelbaum eb al, 1976). Work by Wilson et al,(1976) with 
antipyrine suggested an interesting dose relationship, in which 
doses of the vitamin below 1 .2g/day caused an increase in total 
body clearance, in agreement with the work of Houston (1977), 
but amounts above this level resulted in a retention of the 
drug within the body. Such an effect perhaps illustrates the
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found in the present study, since antipyrine is largely metabolised 
by oxidation. Studies by Feetman eb al (1975) with warfarin 
failed to demonstrate an effect of large doses of ascorbic acid.
As previously mentioned, the data presented here 
could be considered to infer induction ofthe drug metabol­
ising enzymes, which is a natural response to xenobiotic 
overload, causing substrate saturation of the enzyme active 
sites, and is generally preceded by a period of inhibition 
CParke, 1975). Furthermore, it might be suggested that the 
effect seen following 4 days of treatment with ascorbic 
acid represents this period of inhibition, hence it is 
important to discuss types of induction at more length.
Depending of the type of xenobiotic involved, 
induction can promote either cytochrome P450 or cytochrome 
P448 activity (Table 15). The induction of hepatic 
microsomal enzymes by phenobarbital has been shown conclun 
sively to stimulate an increase in the smooth endoplasmic 
reticulum, synthesis of enzyme proteins, including cytochrome 
P450, phospholipids and haem, DNA-dependant RNA synthetase 
and the synthesis of specific m-RNA’s as evidenced by the 
inhibition of their induction by Actinomycin D and a-amantin 
(Lindell et al, 1975; Parke, 1975).
Increased protein synthesis also appears to occur 
in the induction of the mixed function oxidases following 
treatment of animals with the carcinogenic polycyclic 
hydrocarbons and, as with, phenobarbital, microsomal ribonuclease 
is inhibited. However, there is generally an absence of 
marked hypertrophy, no significant increase in phospholipid 
synthesis, an increase in cytochrome P448 at the expense 
of P450 and a change in substrate specificity (Parke, 1975).
Despite the similarity of the results presented
here to some aspects of induction, there are several disf
crepancies. For instance, cytochrome c reductase is generally 
increased in phenobarbital induction and hence might be 
expected to be affected during the preceeding period of 
inhibition. However,the present study yielded no evidence 
of this and, as will be seen later, neither was there any 
effect on microsomal phospholipid content or N-demethylation 
reactions. In addition, ascorbic acid does not resemble in 
any way the type of compound generally assumed to effect
induction. Inducers are usually lipid soluble compounds,
PHENOBARBITAL POLYCYCLIC HYDROCARBON
Liver enlargement 
Enzyme components
Protein synthesis
Phospholipid
synthesis
Substrate binding
Substrate
metabolism
TABLE
marked hepatic hyper­
trophy .
cytochrome P450 in­
creased; NADPH cytochrome 
C reductase increased.
increased; inhibition 
of microsomal 
ribonuclease.
maiked increase in 
microsomal phospho­
lipid; increased 
latency of IJDPGA - 
transferase.
no marked hypertrophy
cytochrome P450 replaced 
by P448; no marked in­
crease in reductase
delayed increase; 
inhibition of microsomal 
ribonuclease.
no marked increase; 
UDPGA-transferase is 
expressed.
increased type I and 
type II
increased ethyl -morphine- 
N-deme thy 1 as e, 4-hy droxy- 
lation of biphenyl and 
hydroxylation of hexo 
barbital
generally increased 
type II.
increased hydroxylation 
of benzpyrene, 2-hydroxy- 
lation of biphenyl and 
de-ethylation of 
ethylmorphine.
15: Comparison of effects of phenobarbital and
polycyclic hydrocarbon inducers .
(Adapted from Parke, 1975).
.whereas ascorbic acid is a water soluble vitamin, and they 
axe generally metabolised very slowly such that they are in 
contact with the enzyme site for a prolonged period of time. 
Consequently, it is unlikely that the effects seen are due 
to an inductive action of the vitamin and it is more likely 
that they are due to a direct or indirect interaction with 
the terminal oxygenase, cytochrome P450. The mechanism 
causing increased liver weight and body weight gain in the 
animals treated for 28 days remains obscure.
Different types of inducers have been reported to 
affect haem metabolism itself in a variety of ways (Ioannides 
& Parke, 1976) and since it is possible that ascorbic acid 
exerts its effect via the formation of the haemoproteins, 
it is important to discuss this further.
The 1 de novo1 synthesis of liver mixed function 
oxidases requires the synthesis of protein, haem, and ' 
phospholipid. Most drugs which induce the microsomal 
enzymes, like phenobarbital, increase the hepatic concentration 
of cytochrome P450 without any marked stimulation of haem 
synthesis or induction of delta-aminolaevulinic acid synthetase 
presumably because the haem pool provides an adequate reserve 
(loannidee & Parke. 4976). Inducers of this type probably 
exert a feed-back regulation via the synthesis of the apoenzyme 
moiety only. However, other classes of enzyme inducer, such as 
allobarbital and safrole, which contain an allyl group, and 
chlorinated hydrocarbons and pesticides all increase the 
synthesis of cytochrome P450 and also result in the increased
breakdown of this cytochrome and haem and consequently exert
A
a feed-back effect on haem and porphyrin synthesis and induce 
delta-aminolaevulinic acid synthesis (Figure XXII), Yet other 
compounds, such as the drug sedormid (allylisopropylacetylurea), 
DDC (3,5-diethoxycarbonyl-l,4-dihydroxycollidine) and AIA 
Callylisopropylacetamide) increase the breakdown of haem 
and cytochrome P450 synthesis, resulting in a significant 
induction of delta-aminolaevulinic acid synthetase (Parke, 1978)
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As mentioned previously, the endoplasmic reticulum 
is not only inyolved in drug metabolism and so a general 
effect on the organelle might be expected to affect enzymes 
like glucose-6-phosphatase, whereas lack of an effect on 
such enzymes might be indicative of a localised effect on 
the mixed function oxidases, or indeed a specific effect 
on one aspect of phase I metabolism such as cytochrome P450 
itself. Therefore it was decided to investigate various 
aspects of general liver metabolism, such as glucose-6- 
phosphstase, glucose-6-phosphate dehydrogenase, lipid peroxi­
dation, phospholipid synthesis and histology, in order to 
reveal whether the effect of ascorbic acid was aimed at 
general liver metabolism, specifically at the endoplasmic 
reticulum or at a specific component of the mixed function 
oxidase system. If the latter proved to be the case, it 
would then be necessary to investigate the synthesis and 
degradation of this specific target in relation to large 
doses of ascorbic acid.
FIGURE XXII Possible role of chemical stimulation
 __ of porphyrin, haem and cytochrome P450
synthesis. (Parke, 1978).
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I INTRODUCTION
As previously stated, the endoplasmic reticulum 
is not only involved in the detoxification of drugs, but 
has many other diverse functions. Hence it was important 
to determine, by measuring other constituents of this 
organelle, whether the effects seen on the mixed function 
oxidase system were due to a direct or indirect effect of 
ascorbic acid on the endoplasmic reticulum, or indeed on 
the general cellular function. It wqs also possible that 
the vitamin had an effect which was specific to the mixed 
function oxidase system. Figure XXIII indicates the complexity 
of some of the microsomal endoplasmic reticulum’s functions.
The endoplasmic reticulum contains a large proportion 
of the liver cell’s phospholipid and protein and responds 
dramatically to changes in physiological state, such as 
starvation and exposure to xenobiotics (Depierre & Dallner, 
1975).
Phospholipids are ubiquitous and essential components 
of membranes and are found almost exclusively in membraneous 
structures of the cell and, in general, most mammalian tissues 
contain quantitatively the same phospholipids, although species 
and organ differences can be demonstrated (McMurray, 1973).
The lipids of the smooth endoplasmic reticulum are composed 
mainly of phospholipids, of which approximately 55% is 
phosphatidylcholine,20-25% phosphatidylethanolamine, 5-10% 
phosphatidylserine, 5-10% phosphatidylinositol and 4-7% 
sphingomyelin (Colbeau et al, 1971; Davison & Wills, 1974).
The fatty acid composition varies with the type of phospholipid 
but between 40-50% of the total fatty acids are unsaturated 
(Colbeau et al, 1971; Davison & Wills, 1974).
It has been firmly established that phospholipids 
in membranes, and the lipoproteins of tissue fluids, are in 
a constant state of metabolic flux, with the rates of synthesis 
and degradation often varying with the physiological activity 
of the organism (Thompson, 1973).
MIXED FUNCTION OXIDATION AND RELATED REDOX REACTIONS OCCURRING 
IN LIVER MICROSOMES. ---  ------ --
R-OH3+ 3+
Cyt.P-450
_ 2
3+ 34-
Lipid
Peroxidation
2+
Heme
OxygenaseCO
2+
Co
Cyt. c
NADPHCN
Desaturase
Stearyl CoA Oleyl CoA >N-0> N-
FIGURE Cytochrome P-450 is depicted by the oxidation state of the
XXI11 iron of the haemoprotein (Fe3+? etc), R = the substrate for
cytochrome P-450, Fp^ is NADPH-cytochrome P450 reductase, Fp 
is NADH-cytochrome bs reductase,, Fp is amine N-oxygenase,^ 
and b5 is cytochrome bg. 3
(from Estabrook, 1978).
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Phosphatidylcholine, otherwise known as lecithin, 
is the principle phosphate containing lipid in most animal 
tissues (Thompson, 1973) and is also a key factor in facili­
tating the transfer of electrons from NADPH-cytochrome P450 
reductase to cytochrome P450 (Lui, 1976) . Several studies 
have suggested that phospholipids may also be required for 
the binding of type I substrates to cytochrome P450 (Chaplin 
and; Mannering 1970; Leibman & Estabrobk, 1971). However,
Vore et al (1974) have shown that the removal of 80-90% 
of phospholipid actually increases the magnitude of type I 
binding per nanomole of cytochrome P450. Thus it seems 
unlikely that phospholipid is absolutely required for the 
binding of substrates to cytochrome P450, however, phospholipids 
may enhance the binding of substrates, as suggested by 
Guengerich and Coon (1975). Hence it is likely that phos­
pholipid plays a predominantly physical role rather than a 
chemical one.
Phosphatidylcholine contains a cytidine nucleotide 
and is formed from choline, although it can also be derived 
via methylation of phosphatidylethanolamine (Figure XXIV). 
Similarly, phosphatidylethanolamine is synthesised from 
ethanolamine, although it can' also be formed via decarboxylation 
of phosphatidylserine. Phosphatidylinositol synthesis is 
different since it involves a microsomal enzyme, and phospha- 
tidylserine is not synthesised in animal systems but instead 
is formed by an exchange process in which pre-existing phos­
pholipid, principally phosphatidylethanolamine, exchanges its 
nitrogenous base with free serine (Thompson, 1973).
phosphatidylethanolamine * L-serine ~— w phosphatidylserine + ethanolamine
Consequently, these interconversions give the cell 
the potential to change the cellular distribution with no net 
change in phospholipid concentration. Hence a compound 
capable of interfering with these interconversions could, for 
instance, prevent adequate production of phosphatidylcholine 
for mixed function oxidase activity. Furthermore, not only
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do phospholipids exist and function in the endoplasmic 
reticulum, it has been suggested (McMurray, 1973) that the 
terminal steps for at least phosphatidylcholine and 
phosphatidylethanolamine formation occur in the endoplasmic 
reticulum, with the mitochrondria and cytosol having roles 
to play in the earlier phases. In addition, phosphatidyl- 
serine production is probably predominantly in the microsomes. 
Some of the phospholipid turnover is involved in the special 
functions of the liver, such as response to drug administration, 
starvation and liver regeneration, and in response to recovery 
from metabolic or peroxidative damage. Export of phospholipid 
also occurs (Coleman, 1973).
It is well known that the endoplasmic reticulum 
responds to phenobarbital and other inducers by increasing 
its volume and surface area, together with a substantial 
increase in the specific activity of the cytochrome P450- 
linked drug metabolising system (Depierre and Dallner, 1975). 
Cytochrome P450 is enclosed in a phospholipid halo which is 
more rigid than the bulk of the microsomal lipids (Stier, 1976) 
and it was estimated (Stier and Sackman, 1973) that less than 
20% of the microsomal phospholipids are located in this halo, 
which may affect the diffusion of lipid soluble compounds to 
and from the cytochrome P450 molecule.
Hence it can be seen that the phospholipids of the 
cell have many important functions and many of these functions 
could be said to be involved with the metabolism of xenobiotics, 
especially in the case of phosphatidylcholine. However, in •: 
spite of this importance, quantitative analysis of phospha­
tidylcholine in normal and ascorbic acid deficient guinea pigs 
indicated that ascorbic acid deficient microsomes showed only 
an 18% decrease in concentration of the phospholipid compared 
with controls (Sato and Za.nnoni, 1976). In addition, these 
authors found no significanct differences in the chromatographic 
migration of either phosphatidylcholine or its precurssor, 
phosphatidylethanolamine in normal or ascorbic acid deficient 
guinea pigs.
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+ PhosphatidylethanolaminePhosphatidylserine
SAM
SAHSAH
Phospha tid^l-N, N ' - 
dimethylethanolamine
SAM
■. Phosphatidyl-N-methylethanolamine
SAM
SAH
Posphatidylcholine
FIGURE ZKXIY
A schematic representation of the interconversion 
of phospholipids by the exchange of nitrogenous 
bases Carter Thompson,1973)
SAM S-adenosylmethionine
SAH S-adenosylhomocysteine
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Recently, it hasbeen possible to demonstrate that 
lipid peroxidation may occur 'in vivo' (Wendel et al, 1978).
Several consequences may result from peroxidation, which 
include loss of membrane structure and activity of fhecforane 
bound enzymes (Wills, 1971) and release of toxic aldehydes 
and a variety of other breakdown products which cause enzyme 
inhibition (Bendetti et jlL, 1979). Lipid peroxidation 
usually begins with the abstraction of a hydrogen atom from 
an unsaturated fatty acid, resulting in the formation of 
conjugated dienes. Attack by molecular oxygen produces 
a lipid peroxy radical, which can either abstract a hydrogen 
atom from an adjacent lipid to from a hydroperoxide, or form 
a lipid endoperoxide. The formation of the latter in unsaturated 
fatty acids containing at least three - uninterrupted methylene 
double bonds can lead to the formation of malonaldehyde as a 
breakdown product (Buege & Aust, 1977). Differences between 
species have been shown in the ability to produce malonaldehyde, 
with production being most extensive in the rat, followed by 
the guinea pig and then the rabbit (Kamataki and Kitagawa, 1974).
Ascorbic acid has been implicated as a catalyst for 
lipid peroxidation, especially when in conjunction with certain 
transition metals (Wills, 1965; Schaefer et_ al, 1975). Induction 
of lipid peroxidation with ferrous ions in isolated microsomes 
caused an immediate sharp decline in ethylmorphine-N-demethylase 
activity (Kamataki and Kitagawa, 1973) and pre-incubation 
of the microsomes with ascorbic acid or a NADPH generating 
system reduced aminopyrine, ethylmorphine and codeine demethylases 
CKitada eL al, 1974).
Lipid peroxidation can be defined as the oxidative 
deterioration of polyunsaturated lipids, which leads to the 
formation of free radical intermediates, which can provoke 
autocatalysis. Lipid peroxidation 'in vivo' has been said to 
be of basic importance in ageing, in some phases of atherosclerosis, 
in some forms of liver injury and in oxygen toxicity (Plaa and 
Witschi, 1976). With regard to the metabolism of xenobiotics, 
evidence suggests that breakdown of cytochrome P450 can result 
from lipid peroxidation and this breakdown can be prevented
1?2
by chelating agents and free radical trapping agents (Plaa 
and Fitschi, 1976). However, UDP-glycuronyl-transferase is 
activated by moderate lipid peroxidation and returns to normal 
or is deactivated, if peroxidation becomes excessive.
Similarly, glucose-6-phosphatase activity may be lowered
by peroxidative change (Plaa and Witschi, 1976; Bentley et_ al,
1979).
In addition, the cytochrome reductases play an 
essential role in the peroxidation of microsomal lipids 
(Pederson et 'al, 1973) and the finding that ’in vitro' 
microsomal lipid peroxidation can be inhibited by superoxide 
dismutase (Pederson et al, 1973; Zimmerman et_ al, 1973) 
suggests that the superoxide anion and possibly singlet oxygen 
may be instrumental in microsomal lipid peroxidation.
Recent studies (Svingen et al, 1978) indicated
that the mechanism of NADPH-cytochrome P450 reductase catalysed 
2+and ADP-Fe catalysed lipid peroxidation parallel that of 
xanthine oxidase in that initiation occurs through a superoxide 
dismutase-sensitive reaction and that singlet oxygen is present 
during propagation of lipid peroxidation (FIGURE XXV). However, 
Sharma (1979) reported that ascorbic acid and iron-induced lipid 
peroxidation in brain mitochondria was not inhibited by super­
oxide dismutase, catalase or 1,3-diphenylisobenzofluran, trappers 
of superoxide anions, hydrogen peroxide and singlet oxygen 
respectively, and hence suggests that non-enzymatic lipid perox­
idation follows a different set of initial events as compared 
to enzymatically-induced lipid peroxidation.
It is known that lipid peroxidation is detrimental 
to drug metabolism and antioxidants which inhibit peroxidation, 
such as N,N’-diphenylenediamine, protect drug enzyme activities 
(Carpenter, 1972). Hence the possibility exists that ascorbic 
acid, through its properly as an antioxidant, could be functioning 
by inhibiting lipid peroxidation. However, conversely ascorbic 
acid has been reported to catalyse lipid peroxidation (Fills,
2965; Schaefer et al, 1975), especially when in the presence of 
transition metals such as copper and ferrous ions.
Xanthine ADP-Fe
3+
Xanthine 
Oxidase
i >
Urate
NADPH-cytochrome 
P450 reductase
2
NADP+SOD
2+3+
(ADP-Fe -0 (ADP-Fe
SOD
3+
2+
ADP= Fe
LOOH
INITIATION
PROPAGATION
LH
LO LOOH
DPF (2,5-diphenylfuran 
oxidised by *0 )Propagation 
of lipid 
pero:xi da t ion
End Products
FIGURE XXV Summary of the reactions involved in the peroxidation
of liposomes promoted by xanthine oxidase and NADPH-cytochrome 
P450 reductase (after Svingen et_ al, 1978).
LOOH lipid hydroperoxides
'0 singlet oxygen
0 • superoxide anion
Work with ascorbic acid deficient guinea pigs (Sato 
and Zannoni, 1976) showed that lack of the vitamin did not
promote an increase in the end-products of lipid peroxidation__
and hence the fall in drug metabolising ability seen in ascorbic 
acid deficiency could not be attributed to lipid peroxidation.
In fact peroxidation was higher in control animals than in 15 
day ascorbic acid deficient guinea pigs. Since lipid peroxi­
dation may be initiated by generation of peroxide free-radicals 
of cytochrome P450 (Sato & Zannoni, 1976), the higher quantity 
of cytochrome P450 in control animals could explain this higher 
rate of lipid peroxidation (O’Brien & Rahimtula, 1975).
Glucose-6-phophatase is found throughout the endo­
plasmic reticulum, located on the luminal surface, and is an 
important enzyme that not only hydrolyses glucose-6-phosphate 
but can also synthesise this compound from glucose and inorganic 
pyrophosphate, carbamyl phosphate or other high energy phosphates, 
under appropriate conditions (Nordlie, 1974). Hence due to its 
important role and widespread nature, this enzyme can be used 
as a marker for damage to the endoplasmic reticulum. In addition, 
the activity of the enzyme is associated with phospholipids since, 
in general, phospholipases inhibit and low levels of detergent 
activate glucose-6-phospatase activity (Nordlie, 1974). In 
addition, lipid peroxidation 'in vitro' leads to a marked decrease 
in glucose-6-phosphatase activity (Wills, 1971), which can be 
partially protected against by the substrate glucose-6-phosphate. 
Wills suggests that this loss in activity is not due to the 
formation of breakdown products from peroxidation, but to a loss 
of membrane structure, which is essential for enzyme activity.
In addition, other demethylation and oxidation reactions are 
inhibited by lipid peroxidation/ He further suggests that lipid 
-peroxidation, by controlling membrane intergrity, may exert a 
regulatory effect on the oxidative metabolism and carbohydrate 
metabolism of the endoplasmic reticulum in vivo.
Glucose—6—phosphate deiiyi'Ogenase is a cytosolic enzyme 
involved in the pentose phosphate pathway in the conversion of 
glucose-6-phosphate to 6-phosphoglucono-S-lactone, and requires 
NADP as electron acceptor for the production of NADPH. Since 
this enzyme is cytosolic, any variation in its activity cannot
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be, for instance, directly related to an effect on t h e ---
endoplasmic reticulum and so is a measure of general damage 
to the hepatocyte, whereas glucose-6-phosphatase is a measure 
of an effect on the endoplasmic reticulum, being located in 
that organelle.
Sato and Zannoni (1976) presented evidence that a 
quantitative relationship of ascorbic acid and cytochrome P450 
exists in normal and ascorbic acid deficient liver and adrenal 
microsomes, of the order of 2:1. Indeed, such a ratio was 
consistently found in those organs known to metabolise drugs.
This ratio was maintained on storage, upon dialysis and in 
other species, such as the mouse. There was a slow loss of the 
vitamin from microsomal preparations during dialysis, up to 4 
days being required, and the authors suggested that this could 
be evidence for the vitamin being bound to some microsomal 
component. Furthermore, the ratio of ascorbic acid to cytochrome 
P450 remained relatively constant through partial purification 
of guinea pig microsomes isolated from normal and ascorbic 
acid deficient animals. Interestingly, other tissues with low 
drug metabolising ability, such as brain, spleen and heart did 
not sbow a consistent relationship between the two components.
The possible involvement?of superoxide anions in the 
cytochrome P450 cycle have already been discussed in Chapter 3.
In addition, an association between ascorbic acid and superoxide 
dismutase has also been alluded to (Nishikimi, 1975; Halliwell & 
Foyer, 1976). Evidence exists that ascorbate may be important 
in protection against superoxide anions generated ’in vivo’.
The following was predicted by Halliwell and Foyer (1976):-
Ascorbate 2H* + 20„  ► 2H_0_ + DHAA2 2 2
Consequently, since it appears that ascorbic acid can 
augment superoxide dismutase activity by scavenging superoxide 
anions, and such anions may be involved in Phase I drug 
metabolism (Coon et_ al, 1963; White & Coon, 1980), it seemed 
important to investigate the effects of the administration of 
large doses of ascorbic acid to guinea pigs on the ability of 
the liver to scavenge toxic superoxide anions.
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In summary, therefore, in order to investigate the 
mechanistic action of ascorbic acid, it was necessary to 
investigate the extent of its influence on the hepatocytes 
of guinea pigs receiving large doses of the vitamin. Hence 
for an overall picture, histology was used, together with 
determination of glucose-6-phosphate dehydrogenase, a cytosolic 
enzyme. In addition, the concentration of total and individual 
phospholipids was determined, since these are not only important 
structural components of membranes but are also thouglt to have 
an important part to play in the metabolism of drugs. To 
investigate effects on the endoplasmic reticulum itself, 
glucose-6-phosphatase activity was determined, since this is 
an enzyme located in the endoplasmic reticulum, which is not 
directly involved in the metabolism of drugs. Finally, lipid 
peroxidation was estimated since this process is known to be 
deleterious to drug metabolic processes.
Failure to detect any effect of large doses of ascorbic 
acid on these components might indicate that the effect of the 
vitamin Is a specific one, perhaps involving only the drug 
metabolising system.
In addition to these investigations, the relationship 
of ascorbic acid to cytochrome P450 was studied since a 
quantitative molar ratio has been reported.
One other avenue to be investigateliwas the relationship 
of ascorbic acid and superoxide anions, an important one 
because these anions are thought to be associated with the 
oxidative metabolism of xenobiotics and ascorbic acid has been 
reported to be a scavenger of the toxic superoxide anions.
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„II METHODOLOGY
a) Liver Constituents not Directly Involved in 
Drug Hetabolism.
Guinea pigs were prepared in the pre-described manner, 
receiving ascorbic acid (150mg b.d.) for 4 days and subcellular 
liver fractions were prepared and constituents measured as 
described in Chapter 2. The enzyme of the endoplasmic reticulum 
glucose-6-phosphatase, was measured in the total homogenate 
and cytosolic glucose-6-phosphate dehydrogenase was measured 
in the 10,000g fraction. The extent of lipid peroxidation was 
measured by determining the amount of malonaldehyde present, 
it being a break-down product of ’in vivo’ lipid peroxidation.
Total liver and microsomal phospholipids were also 
determined, as were the concentrations of individual phospho­
lipids in the microsomal pellet by a thin layer chromatography 
procedure.
Finally histological staining procedures were used 
on slices of liver to look for evidence of cellular damage, 
which might occur if a generalised attack on the hepatocyte 
was incurred by treatment with large doses of ascorbic acid.
b) Ascorbic Acid Determination
Ascorbic acid concentration was estimated in a variety 
of guinea pig organs in order to determine whether certain 
regions of the body are target organs for ascorbic acid deposition 
Furthermore, an additional group of animals was included, which 
received 150mg b.d. ascorbic acid, together with a daily cysteine 
supplement of lOmg.
In order to study the location of the vitamin within 
the hepatocyte, the ascorbic acid content of various subcellular 
fractions was measured, together with plasma concentrations.
Finally, using animals treated for 28 days with 150mg b.d 
ascorbic acid, the vitamin content of the same subcellular 
fractions was measured, again in conjunction with plasma.
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  c) Superoxide Dismutase Determination  __  ___
The effect of ascorbic acid on :superoxide dismutase 
was measured as described in Chapter 2. ’In vitro’ studies 
were performed in tandem with 'in vivo’ studies with guinea 
pigs, using a range of concentrations of ascorbic acid. For 
these studies, three different cellular fractions were used 
from untreated guinea pigs; the 10,000g fraction, microsomal 
fraction and the microsomal supernatant. At each concentration 
of ascorbic acid, a blank containing no tissues was included.
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I I I R E S U L T S  _____________________
Table 16 shows that large doses of ascorbic acid, of the 
order of 300mg/day, had no effect on the concentration of either 
the cytosolic enzyme, glucose-6-phosphate dehydrogenase, or the 
endoplasmic reticulum enzyme, glucose-6-phosphatase. Lipid 
peroxidation, as measured by malonaldehyde concentration, remained 
"unchanged, as did the concentrations of both total liver and 
■microsomal phospholipids. However, there was a significant.decrease 
in both phosphatidylcholine and its precursor, phosphatidylethan- 
olamine. There was no evidence of histological damage in the 
liver sections studied.
Despite the adoption of various solvent systems, the 
satisfactory separation of the phospholipids, phosphatidylcholine 
and phosphatidylserine, by thin layer chromatography, was not 
achieved and so the concentrations of the two phospholipids are 
presented together (Table 17). Phosphatidylserine represents 
only a small proportion of the total microsomal phospholipid 
content compared with phosphatidylcholine, the major phospholipid.
Although the total microsomal phospholipid concentration 
was unchanged by ascorbic acid, both phosphatidylcholine and its 
precursor, phosphatidylethanolamine, were significantly decreased. 
The ratio of the concentration of phosphatidylcholine to that 
of phosphatidylethanolamine fell, but the difference was not 
statistically significant. In fact the other phospholipid 
measured, phosphatidylinositol, also showed a decrease in 
concentration, which again was not statistically significant.
Table 18 shows that the concentration of ascorbic acid 
in all the tissues studied was increased by administration of 
large doses of the vitamin over a period of 4 days. The high 
levels of the vitamin in parts of the gastrointestinal tract 
of the ascorbic acid treated animals can probably be explained 
by the fact that absorption of the vitamin was still continuing 
despite the fact that the last dose of ascorbic acid was given 
approximately 12 hours before the animals were killed. The 
high levels found in the kidney may similarly reflect the fact 
that increased amounts of the vitamin are excreted when large 
doses are administered. The addition of lOmg cysteine to the
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TABLE 16 EFFECT OF ADMINISTRATION OF ASCORBIC ACID (150mg b.d.) 
FOR 4 DAYS ON HEPATIC CONSTITUENTS NOT DIRECTLY 
INVOLVED IN THE METABOLISM OF DRUGS..
No. CONTROL TEST
Glucose-6-phosphatase 8 58.8 + 3l8 64^ 4.. +6.1
C|ig phosphate/ mg protein) —  (111 + 9%)
Glucose-6-phosphate 8 1124 + 0107 1.47 _+ 0.13
dehydrogenase (119 + 9%)
(nmol/min/mg protein)
Lipid peroxidation 6 51.9 4-2.6 50.9 +^5.0
Cpmol. iaIonaldehyde/
4 .  protein) <101 ±  13»
Total phospholipids 12 13.9 + 1.9 13.2 j+ 1.2
(pg phosphate/rag protein) (102 _+ 9%)
^Microsomal Phospholipids 12 22.5 + 2.2 21.1 _+ 1.6
Cpg phosphate/mg protein) ( 99 4- 7%)
Results are expressed as mean + SEM. Figures in 
brackets represent the test group value expressed 
as a percentage of the control value. The level of 
significance was measured by a paired Student’s 
t^ -test.
SIGNIFICANCE 
N.S .
N.S.
N.S.
N.S.
»■
N.S.
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TABLE 17 EFFECT OF THE ADMINISTRATION OF ASCORBIC ACID (15Qmg b.d.) 
ON THE CONCENTRATION OF INDIVIDUAL PHOSPHOLIPIDS AS 
DETERMINED BY THIN LAYER CHROMATOGRAPHY-.
Jjg phosph ate /m g  protein
CONTROL TEST SIGNIFICANCE
Phosphatidylinositol
Phosphatidylcholine & 
Phosphatidylserine
6.01 + 0.61 
12.4 + 1.1
4.98 + 0.44 N.S.
9.27 + 0.65 p < 0.01
Phosphatidylethanolamine 8.30 +0.79 6.76 + 0.48 p < 0.05
Phosphatidylcholine & 
Phosphatidylserine
Phosphatidylethanolamine
1.53 + 0.06 1.37 + 0.07 N.S.
Results expressed as mean + SEM for 20 observations. 
Level of significance measured by a paired Student’s 
tr-test.
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FIGURE XXVI Photographs of histological slides produced from 
slices of liver from control and ascorbic acid 
treated guinea pigs, receiving 300mg/day over a 
period of four days.
i) Control guinea pig
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ii) Ascorbic acid treated guinea pig.
Slides show the central vein and periportal areas and were viewed with a
magnification of :x 100 (i.e. zx 10 objective and x 10 eyepiece). A 
haematoxylin and eosin preparation was used.
TABLE 18. ASCORBIC ACID CONTENT OF VARIOUS GUINEA PIG ORGANS
  FOLLOWING TREATMENT FOR 4 DAYS WITH EITHER ASCORBIC
ACID (150mg. b.d.) OR ASCORBIC ACID TOGETHER WITH- 
A lOmg SUPPLEMENT OF CYSTEINE.
m9 j lOOg t i s s u e
CON TRO L ASCORBIC ACID A A -f- C Y S T E IN E
Liyer 
Ki dney 
Heart
Large intestine 
Small intestine 
Stomach 
Pancreas 
Adrenals
6.88 + 0.52 (16)
5.03 + 0.32 ( 8)
4.04+0.48 (8)
6.01 + 0.59 (8)
6.13 + 0.93 ( 8)
5.72+0.79 ( 8)
5.10 ± 0.71 ( 8)
31.4 + 3.5 ( 8)
** 20.10 + 1.58 (16)
** 14.88 + 0.78 ( 4)
** 9.16 + 0.93 ( 8)
** 12.80 + 1 . 1 4  (8) 
*** 23.65 + 1.26 ( 8)
*** 14.53+ 1.00 ( 8)
*** 8 . 8 1 + 0 . 7 4  ( 8)
**111.8 + 14.7 (4)
**20.91 + 1.45 (12) 
**17.15 + 1.02 ( 4)
* 8.68 +0.89 ( 4)
* 8.55 + 1.17 ( 4) 
**22.49 +2.17 ( 4)
***12.20 +0.81 ( 4) 
*** 7.46 + 0.16 ( 4) 
*119.9 +318 (4)
Results are expressed as a mean ■+ SEM. Figures in 
brackets represent the number of animals in each grotip, 
Leyel of significance was measured by a paired 
Student's t-test.
* p < 0.05
.** p < 0.01
.*** p < 0.001
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daily dose of ascorbic acid had no effect on the distribution 
of ascorbic acid within the body.
Table 19 shows the distribution of ascorbic acid 
within the hepatocyte following treatment of the guinea pigs 
with the vitamin (150mg b.d.) for periods of both 4 and 28 
days. Following 4 days treatment, the ascorbic acid concen­
tration in the plasma and liver were statistically significantly 
increased. The microsomal supernatant concentration of the 
vitamin was similarly increased but this effect was not 
extended to the microsomal fraction. Similar effects were 
seen following a 28 day treatment period. However, it should 
be noted that ascorbic acid concentrations were markedly higher 
in the 28 day treated control group than in the 4 day treated 
control group. An explanation for this will be offered later.
It was also noteworthy: that liver weights were increased in 
tbe ascorbic acid treated animals compared with controls after 
28 days, an effect not apparent after 4 days treatment with 
the vitamin.
Shown in Table 20 is the effect of large doses of 
ascorbic acid on superoxide dismutase activity in 12 guinea 
pigs. An apparent increase in activity of the enzyme was seen 
in the test group showing a mean rise in activity of 21%.
This effect was continued in ’in vitro' studies with both the 
10,Q00g fraction and the microsomal supernatant, using varying 
concentrations of ascorbic acid (Figure XXVII).. However, no 
change was seen in the activity of the enzyme in the microsomal 
fraction.
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TABLE 20
Control
Test
THE EFFECT OF ADMINISTRATION OF ASCORBIC ACID (150mg b.d.) 
ON ’IN VIVO’ SUPEROXIDE DISMUTASE ACTIVITY FOLLOWING 4 DAYS 
TREATMENT OF GUINEA PIGS.
(units SOD/g liver)
ACTIVITY OF SUPEROXIDE TEST GROUP VALUE EXPRESSED
DISMUTASE AS A PERCENTAGE OF CONTROL
204.0 + -11.8 100
240.5 * 1.6.4 120.60 + 9.55
Hesults expressed asnean + SEM for 1.2 observations. 
Results were significant by a Wilcoxon signed rank 
test.
One unit of superoxide dismutase activity is defined 
as that amount of superoxide dismutase required to 
inhibit the rate of oxidation of adrenalin by 50% 
"under the defined conditions.
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FIGURE XXVII THE * IN VITRO' EFFECT OF DIFFERENT DOSES OF
ASCORBIC ACID, ADDED TO UNTREATED LIVER FRACTIONS, 
ON THE ACTIVITY OF SUPEROXIDE DISMUTASE IN THE 
GUINEA PIG.
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Each, point on the graph is the mean ol three determinations.
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IV DISCUSSION ----  --------
Results presented in this chapter provide indirect 
evidence that the effects of large doses of ascorbic acid 
are chiefly directed towards the mixed function oxidase 
system. Liver histology remained unchanged as did the activity 
of the cytosolic enzyme, glucose-6-phosphate dehydrogenase.
The endoplasmic reticulum enzyme, glucose-6-phosphatase 
remained unaltered, reflecting the fact that the effects seen 
on the drug metabolising enzymes were not due to a generalised 
effect on the endoplasmic reticulum.
Lipid peroxidation, measured by a relatively 
insensitive method, was not affected by large doses of ascorbic 
acid. This result was slightly surprising since ascorbic acid 
has been reported to induce lipid peroxidation especially when 
in the presence of ferrous ions (Wills, 1969). However, 
studies with rats (Jayanthi Bai et a!L, 1979) given 150mg/100g 
ascorbic acid orally or lOOmg/lOOg intraperitoneally, showed 
depression of ’in vitro’ lipid peroxidation in liver, brain, 
kidney and spleen homogenates, and the catalytic efficiencies 
for the peroxidation of linoleic acid were similarly depressed. 
These results could reflect the antioxidant nature of ascorbic 
acid.
Lipid peroxidation is one of the ways in which 
cytochrome P450 can be broken down 'in vivo’ (De Matteiii, 1978a). 
The pathway can be stimulated by starvation and ferrous ions 
(De Matteis, 1978a). The degradation of the haem molecule 
occurs via cleavage of the tetrapyifole ring at one of the 
inethylene bridges and can be accompanied by an increase in 
the rate limiting enzyme in haem biosynthesis, delta-amino 
laevulinic acid synthetase, without any significant increase 
in liver porphyrin concentration, a finding which is compatible 
with an increased rate of liver haem synthesis (De Matteis & 
Sparks, 1973).
The processes of lipid peroxidation and drug metabolism 
appear to be inversely related, such that an increased rate 
of lipid peroxidation will result in a decrease in drug 
metabolising activity (Wills, 1969; Kamataki & Kitagawa, 1973;,
Kitada et al, 1974) and vice versa.
Recent findings suggest that cytochrome P450 may be 
involved in both the decomposition of lipid peroxides (Hrycay 
& O ’Brien, 1971) and also in the generation of lipid peroxides 
from organic peroxides (Radkte & Coon, 1974). Both these 
reactions are of a peroxidative nature and are accompanied 
by a substantial destruction of haem. Hrycay and O ’Brien 
(1971) have proposed a mechanism for the peroxidative 
breakdown of lipid peroxides in which the first step is the 
oxidation by the lipid peroxide of the thiol ligand of the 
haem of cytochrome P450 to produce the high spin form of 
cytochrome P420, a very powerful peroxidase. The latter 
can then decompose the lipid peroxide, producing free-radical 
intermediates, which are then responsible for the destruction 
of haem.
Therefore, non-haem iron appears to be the main site 
of initiation of lipid peroxidation, whereas cytochrome P450 
may be involved, following its conversion to cytochrome P420, 
in the breakdown of both lipid peroxides and haem and also 
possibly in the diffusion of the peroxidative damage through 
the generation of new lipid peroxides. Protective agents, 
like reduced glutathione (GSH) may act by preventing conversion 
of P450 to P420 and also by inactivating and destroying 
peroxides and free-radical species involved in the oxidative 
damage to components of the membrane, the latter effect occuring 
mostly in conjunction with the selenium containing enzyme, 
glutathione peroxidase (Little & O'Brien, 1968; Rotruck et_ al, 
1973). Anything causing a decrease in GSH might result in an 
increase in lipid peroxidative damage. Ascorbic acid may have 
a similar protective effect to GSH since it, too, is a reducing 
agent.
A limited controlled amount of lipid peroxidation may 
have a physiological role to play in the liver cell 'in vivo’.
A number of studies (Kadlubar et al, 1973; Rahimtula & O ’Brien, 
1975; Hrycay et iiQ, 1975; Ellin & Orrenius, 1975) have shown 
that cytochrome P450 can utilise certain organic hydroperoxides 
for the hydroxylation of several drugs, steroids and fatty 
acids, all of which are normally metabolised by the mixed
function oxidase system. In addition, lipid peroxidation 
may have a role in the normal turnover of the membranes of 
the endoplasmic reticulum, and Hrycay & O ’Brien (1971) have 
suggested that degradation of cytochrome P450 during lipid 
peroxidation may account for the high rate of turnover of this 
haemoprotein observed in the liver under normal conditions 
(Levin & Kuntzman, 1969).
For the reasons presented above, it might be 
expected that ascorbic acid would have an effect on the extent 
of lipid peroxidation. However, the results presented here, 
achieved by using malonaldehyde determination, which is known 
to be relatively insensitive, tend to indicate that large 
doses of.ascorbic acid have no net effect on lipid peroxidation.
Phospholipids are intimately involved in drug 
metabolism and despite the fact that total liver and total 
microsomal phospholipid concentrations remained unchanged 
when measured individually, phosphatidylcholine, its precursor 
phosphatidylethanolamine and also phosphatidyl inositol showed 
highly significant decreases in concentration. Since 
phosphatidylcholine is required for cytochrome P450 function, 
the decrease seen in phosphatidylcholine concentration may be 
instrumental in the lowering of the specific activity of the 
haemoprotein in ascorbic acid treated animals. Sato and 
Zannoni (1976) similarly reported an 18% fall in phosphatidyl­
choline concentration in ascorbic acid deficient guinea pigs. 
However, since it is known that interconversion of phospholipids 
can occur without net synthesis (Thompson, 1973), the decrease 
in phosphatidylcholine might simply represent a decreased 
requirement for the phospholipid due to the decrease in 
specific actiyity of cytochrome P450. Alternatively, ascorbic 
acid might exert an effect on drug metabolism by affecting the 
relative proportion of the phospholipids in the lipid halo 
surrounding cytochrome P450. Such an effect could alter the 
ability of the phospholipid to act as an electron transport agent.
Glucuronyltransferase can be deactivated by lipid 
peroxidation as can glucose-6-phosphatase activity (Plaa &
Witschi, 1976; Bentley et a!L, 1979) due to the changes caused
by lipid peroxidation to the membrane structure. Glucuronyl­
transferase requires a competent membrane for its function and
therefore any change in microsomal phospholipid content could 
reduce its activity. This fact, together with the fact that 
glucose-6-phosphatase activity was unchanged (Chapter 3), 
suggests that lipid peroxidation was not the cause of the 
decrease in phase II metabolism and was more likely the result 
of a change in the composition of the microsomal membranes.
Studies on the distribution within the hepatocytes of 
ascorbic acid in guinea pigs receiving large doses of the 
vitamin reyealed that although total liver and cytosolic 
ascorbic acid concentration can be increased, there is 
little change in the microsomal content of ascorbic acid, 
indicating that the subcellular fraction is more-or-less 
saturated under normal conditions.
Sato and Zannoni (1976) predicted a 2:1 ratio of 
ascorbic acid to cytochrome P450 in tissues of the guinea pig 
involved in the metabolism of drugs. Furthermore,* the ascorbic 
acid seemed to be bound to some component of cytochrome P450 
since the ascorbic acid remained in association with the 
haemoprotein even after partial purification (Sato & Zannoni, 
1976). This ratio does not appear to hold with large doses 
of ascorbic acid. Nevertheless ascorbic acid can still 
share an important association with cytochrome P450. Evidence 
for an association with the ferrous ion of cytochrome P450 
was obtained with the use of metal chelators with a high affinity 
for ferrous iron such as a ,a’-dipyridyl and o-phenanthroline. 
These chelators caused a decrease in the cytochrome P450 
carbon monoxide spectrum and also interacted with the cytochrome 
to give an absorption spectrum at 450nm, thus allowing a more 
direct study of ascorbic acid and the catalytic metal site of 
the haem protein (Sato & Zannoni, 1976). Importantly, ascorbic 
acid preyented the formation of the cytochrome P450-a,ct’- 
dipyridyl spectrum, Structually, similar chelators with low 
affinities for ferrous ions did not cause a decrease in the 
P45O-earhon monoxide ligand spectrum. Furthermore, although 
the cytochrome P450- cl, c l ' -dipyridyl spectrum could be observed 
within 6 hours, maximum absorbance required treatment with 
chelators for 80 hours in normal microsomes and 36 hours in 
microsomes from ascorbic acid deficient guinea pigs. The authors
(Sato & Zannoni, 1976) provide one possible explanation for 
this discrepancy , in that the site of a, a1-dipyridyl ligand 
formation to cytochrome P450 is protected by ascorbic acid.
The maximum inhibition of the cytochrome P450- 
carbon monoxide spectrum with a, a’-dipyridyl was of the order 
of 55%, suggesting that about half of cytochrome P450 may be 
accessible to this metal chelator which is in keeping with the h 
theory that more than one type of cytochrome P450 exists 
(Haugen' et al, 1975; Ryan et slL, 1975).
These studies suggest that there is an interaction 
between ascorbic acid and cytochrome P450 involving the haem 
iron.
Some of the data obtained with guinea pigs receiving 
300mgyday for 28 days was at variance with that found with 4 
day treated animals, as discussed in Chapter 3. Ascorbic acid 
concentrations were found to be higher in control animals than 
would have been expected on the basis of previous experiments 
and this can only be attributed to the fact that both groups 
of animals received hay throughout the experiment as an ascorbic 
acid source supplementary to the diet. Tillotson and O ’Connor 
(1980) reported that, in monkeys, serum ascorbic acid concentration 
could be maintained on a far lower dose of the vitamin if it 
was given in the diet rather than as a single oral dose.
Th.e activity of the enzyme superoxide dismutase appears 
to be enhanced in the presence of ascorbic acid. However, a 
more realistic interpretation of the data is that ascorbic acid 
is augmenting the effect of superoxide dismutase, as has been 
previously reported (Nishikimi 1975; Halliwell & Foyer, 1976), 
since during ’in vitro’ studies, the addition of ascorbic acid 
to a blank cuvette, containing no tissue, still resulted in a 
decrease in the .-oxidation of adrenaline to adrenochrome, indicating 
that,in the absence of endogenous superoxide dismutase, super­
oxide anions had been removed from the incubation mixture. The 
implications of these results are difficult to assess because 
superoxide dismutase is such an ubiquitous enzyme. Nevertheless, 
it could be suggested that since a critical balance exists 
whereby toxic superoxide anions are removed by superoxide
dismutase whilst sufficient remain to act as substrate for 
a variety of reactions, tissues which have relatively high 
concentrations of ascorbic acid such as adrenals, liver, 
pancreas and kidney, may be subjected to localised deficiency 
of superoxide anions due to over zealous scavenging of these 
toxic oxygen species. In addition, superoxide anions have 
been implicated as one of the oxygen species involved in the 
cytochrome P450 cycle (Coon et; al, 1973; White & Coon, 1980) 
either at the level of electron transfer or indeed as a 
precurssor of the activated oxygen form, which is believed 
to be an oxene compound (White & Coon, 1980; O ’Brien, 1978).
It Is, therefore, conceivable that ascorbic acid in excess 
amounts might reduce valuable superoxide anions, thus removing 
theix capacity to operate in the oxidation of endogenous 
compounds and xenobiotics via the mixed function oxidase 
system.
Thus, the effects of large doses of ascorbic acid 
seem to be chiefly directed towards the mixed function oxidase 
system, whether it be via lipid peroxidation, effects on the 
concentration of Individual phospholipids or a direct interaction, 
perhaps with the ferrous ion of the haem of cytochrome P450.
It therefore seemed important to study the effects of ascorbic 
acid on the synthesis and breakdown of cytochrome P450 and 
also to look more closely at the interrelationship of ascorbic 
acid and iron.
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I INTRODUCTION
 From the data presented in earlier chapters, it
appeared possible that the effect of ascorbic acid, whether 
in deficiency or in excess of the recommended intake, has 
'.it£L. principle effect of the terminal oxygenase of the 
mixed function oxidase system, cytochrome P450. This chapter 
describes further studies on the synthesis and degradation 
of this haemoprotein.
Virtually all cells in higher animals are capable 
of haem synthesis, either continually throughout life or 
at some stage of their development. The haem thus made serves 
as a prosthetic gibup in a variety of proteins (Bonkowsky et al, 
1979) concerned with:
the carriage and transfer of oxygen 
within and among cells eg. haemoglobin 
and myoglobin.
the protection of cells against toxic 
oxidising species eg. catalase and 
peroxidase.
the orderly and efficient transfer of
electrons with attendant synthesis of
A.T.P. eg. mitochondrial cytochromes.
microsomal metabolism of fatty acids,
steroids and xenobiotics eg. microsomal
cytochrome P450 and b_.5
"Whereas most prosthetic groups of proteins are derived 
from dietary sources, the haem moiety is synthesised entirely 
in the animal. Quantitatively, developing Erythrocytes account 
for most of the haem produced by higher animals, but the liver 
is a second major locus of haem synthesis. Furthermore, the 
rate of haem synthesis is highly inducible in both the bone 
marrow and in the liver (Bonkowsky et' al, 1979). Figure XXVIII 
shows the pathways of the biosynthesis and catabolism of haem. 
SuccinyiCoA is condensed with glycine to from delta-amino 
laevulinic acid. This reaction is catalysed by the mitochondrial 
enzyme delta-amino laevulinic acid synthetase, which is a 
pyridoxal phosphate requiring enzyme. Delta-amino laevulinic 
acid leaves the mitochondrion and, in the cytoplasm, two 
molecules of delta-amino laevulinic acid are condensed to form
(i)
(ii)
(iii)
(iv)
porphobilinogen, the monopyrrole precursor of porphyrins.
This reaction is catalysed by delta-amino-laevulinic acid ■—  
dehydratase. The intermediates formed from porphobilinogen, 
which can give rise to protoporphyrin are not themselves 
porphyrins but hexahydroporphyrins or porphyrinogens. The 
next step requires two enzymes acting in concert to condense 
four molecules of porphobilinogen into one uroporphyrinogen III.
The precise mechanism of this complicated reaction is not yet 
clear. Side-chain decarboxylation then occurs, forming copro-03
porphyrin/III, which enter the mitochondrion, where the 
proprionate side-chains of rings A and B are oxidatively 
decarboxylated to vinyl groups; the product being protoprophy- 
rinogen IX. Protoporphyrinogen is converted to protoporphyrin 
by an oxygen-dependent protoporphyrinogen oxidase. Although 
ferrous ions can be inserted into protoporphyrin non-enzymatically 
at appreciable rates (Kassner & Walchak, 1973), the insertion 
i& catalysed by ferrochelatase. The enzyme will also utilise 
cobalt and zinc ions and perhaps other divalent cations instead 
of ferrous ions as the metal substrate.
In the liver, most of the haem produced is incorporated 
into hepatic haemoproteins, of which cytochrome P450 quantitatively 
is the most important (Bonkowsky eV al, 1979). Hepatic haem 
can be catabolised in several ways. The major route normally 
involves the microsomal enzyme, haem oxygenase, which requires 
molecular oxygen and NADPH-cytochrome P450 reductase for activity 
(Tenhunen et_ al, 1968; Tenhunen el: al, 1969). The final products 
of the reaction are iron, carbon monoxide, the carbon being 
derived exclusively from the a-methylene bridge of haem, and 
biliverdin-IX. Haem oxygenase can be induced by haem (Tenhunen 
et' al, 1970) and various other substances, such as cobalt (Maines 
& Kappas, 1975b; De Matteis, 1976; Maines & Kappas, 1976).
In mammals, biliverdin IX is reduced to bilirubin IX 
by a cytoplasmic enzyme biliverdin reductase, which can use 
either NADPH or NADP as cofactor. Most of the biliverdin formed 
is then conjugated, chiefly with glucuronide.
Another pathway for hepatic haem degradation is lipid 
peroxidation (Figure XXVIII). This pathway again utilises NADPH 
and molecular oxygen and produces carbon monoxide and compounds
FIGURE XXVIII PATHWAYS FOR HEPATIC CYTOCHROME P450 SYNTHESIS
AND DEGRADATION (after Omaye and Turnbull, 1979b)
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known as ’green pigments'. The pathway can be stimulated by 
ferrous ions and starvation (De Matteis, 1978a) Ascorbic 
acid, especially when in combination with ferrous ions, 
has also been reported to stimulate lipid peroxidation (Wills,
1969).
A major site for control of hepatic haem biosynthesis 
is at the level of delta-amino laevulinic acid formation 
CTait, 1968). However, if the activity of delta-amino laevulinic 
acid synthetase is markedly increased, then other enzymes in 
the pathway may become rate-limiting, and accumulation of inter­
mediates may occur proximal to these (Bonkowsky et al, 1979).
It has been suggested that the haem synthetic pathway 
is under negative feedback end-product control and there exists 
a ’regulatory’ or ’repressor’ haem pool which tightly controls 
delta-amino laevulinic acid synthetase activity (Tait, 1978). 
Furthermore, this pool can be envisioned as exchangeable with 
haem in the liver cell’s numerous haemoproteins (Bonkowsky et 
al, 1979). Experimental evidence for the existance of a 
regulatory pool has been provided by studies with a number of 
potent prophyrinogenic compounds (Bonkowsky et al, 1979), such 
as A1A Callylisopropylacetamide), DDC (3,5-diethoxycarbamyl-l,
4—dihydrocollidine) and griseofulvin.
It has recently been proposed that iron itself rather 
than the iron-porphyrin chelate, is the.proximate physiological 
regulator of haem metabolism (Maines & Kappas, 1977a). Much 
of the evidence offered in support of this idea has been obtained• 
from studies, primarily carried out on rats, on the effects 
of divalent cobalt on haem metabolism. Certain other divalent 
metallic ions, Zn, Ni, Cu, Pt, Cd, Hg, Pb and Mn have also been 
used together with ferrous and ferric ions, albeit less extensively 
(Maines & Kappas, 1976, 1977b). Maines and Kappas (1976) suggest 
that the effects of cobalt and other non-ferrous metals seen 
on haem synthesis are due to the same pathway as for iron.
The mechanism underlying the increase in microsomal 
haem oxygenase activity seen i& response to metals and haem 
itself, is not understood. Some consider it due to induction 
by haem in a regulatory pool derived from increased degradation 
of cytochrome P450 (Bissell & Hammaker, 1976) or from newly
synthesised haem normally destined for cytochrome P450 
(Guzelian & Bissell, 1976), whereas others belive that 
metals directly (Maines & Kappas, 1977a) or through 
metalloporphyrins (De Matteis 8s Gibbs, 1976) induce synthesis 
of haem oxygenase.
Iron is the physiological metal substrate for the 
final enzyme of the haem biosynthetic pathway and an adequate 
supply of iron is necessary for normal haem synthesis, such 
that in anaemia due to iron lack, erythrocyte protoporphyrin 
levels are decreased as expected (Bonkowsky et al. 1979).
However, despite extensive studies, there is no evidence 
that hepatic ferrochelatase activity is decreased in animals 
deficient in iron. Similarly, cytochrome P450 concentrations 
were not affected by lack of iron (Catz_et .al, 1970; Becking, 1972).
This difference in sensitivity of bone marrow and 
liver to iron deficiency probably relates to the fact that the 
liver’s iron requirement is considerably less than that of 
the bone marrow. Also hepatocytes recycle their iron efficiently 
sihce their haemoproteins never leave the cell, whereas 
erythrocytes are constantly leaving the bone marrow, eventually 
to be destroyed largely at distant sites of reticuloendothelial 
activity.
In contrast, iron excess does affect hepatic haem
metabolism. In both human subjects (Bonkowsky & Pomeroy, 1977)
and rats receiving an iron-overload (Ibrahim et al_, 1977),
delta-amino laevulinic acid synthetase activity was positively
correlated with hepatic iron concentration.1. Furthermore, repeated
administration of iron dextran to rats, rather than a single
oral dose, exacerbated the decrease seen in the concentrations
of cytochromes P450 and b and haem (Bonkowsky et al, 1979).o
Figure XXIX shows the possible sites at which iron 
may influence hepatic haem metabolism (Bonkowsky .et .al, 1979) . 
Regardless of whether hepatic iron excess stimulates haem catabolism 
by increasing lipid peroxidation or increasing the activity of 
microsomal haem oxygenase, the net effect on hepatic haem 
homeostasis and delta-amino laevulinic acid synthetase would 
be similar. The effects on haem degradation, however, are 
different from those due to iron inhibitors of haem synthesis.
Iron is not the only metal capable of causing loss 
of liver cytochrome P450 when administered in excess ’in vivo’.
A similar effect has been reported after the administration 
of cobalt chloride (Tephly & Hibbeln, 1971), lead nitrate 
(Scoppa et al, 1973) and also salts of the following metals: 
manganese, nickel, copper, zinc and mercury (Maines and 
Kappas, 1975a), cadmium (Hadley et al, 1974) and methyl- 
mercury (Lucier et ad, 1973) . These metals possibly work 
by inhibiting haem synthesis and stimulating the breakdown 
of cytochrome P450.
Recent studies have been performed which deal with 
the possible mechanism of inhibition of ferrochelatse by 
cobalt chloride. Cobalt does not compete with iron for 
ferrochelatase under normal circumstances, but in the presence 
of either ascorbic acid or reduced glutathione, cobalt is an 
effective inhibitor of ferrochelatase activity. However, 
the addition of cupric ions ’in vitro’ reversed this inhibition 
(Wagner & Tephly, . 1975). Since copper can regulate the 
Michaelis constant of iron with ferrochelatase in the presence 
of reduced glutathione (Wagner et al,1976), this effect was ^ 
interpreted as an allosteric regulation of the enzyme in the 
presence of copper. The inhibition of ferrochelatase by lead 
is also reversed by copper ions ’in vitro' (Wagner & Tephly, 1975)
These finding suggest a possible role for copper in haem 
biosynthesis 'in vivo', especially as it is known that copper 
deficiency can alter normal erythropoiesis (Lee et al, 1968;
Vilter et' al, 1974). Ascorbic acid is also able to regulate 
iron utilisation by ferrochelatase as shown by Goldberg and 
colleagues (Goldberg, 1959;Lochhead & Goldberg, 1959; 1961) who 
suggest a possible role for ascorbic acid and sulphydryl compounds 
such as GSH, in the physiological regulation of haem.
In the light of these early reports linking ascorbic 
acid, copper and iron, it is of interest that a recent report 
makes a similar link (Omaye & Turnbull, 1980) and includes 
ceruloplasmin, the copper carrying protein which is also a 
ferroxidase (Figure XXX). The hypothesis is based on the findings 
that pharmacological doses of ascorbic acid, result in two- to 
three- fold decreases in serum copper and the copper-containing
FIGURE XXIX THE POSSIBLE EFFECTS OF IRON ON HEPATIC HAEM METABOLISM 
(after Bonkowsky e>t al, 1979) .
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protein, ceruloplasmin (Milne & Omaye, 1979), and that 
ceruloplasmin and liver copper were elevated in ascorbic 
acid deficient animals. Serum and hepatic iron levels were 
also found to be related directly to ascorbic acid intake.
The scheme (Figure XXX), suggests that the decreased levels 
of cytochrome P450 found in ascorbic- acid deficiency may be 
mediated by an increase in ceruloplasmin level. The increase 
in ceruloplasmin may shift the equilibrium of the hepatic 
iron pool from the ferrous to the ferric state, in which iron 
is unavailable for incorporation into haem (Hill & Starcher,
rlt'lnS.
1965; Van Campen, 1972; Frieden & Osaki, 1974;A& Omaye, 1979).
At this point it is perhaps relevant to briefly 
review the interrelationships of ascorbic acid and iron.
The metabolism of these two nutrients seems to be intimately 
connected. The total amount of iron in a 70kg man is about 
4.5g, of which 2.6g is present in haemoglobin, 0.4g in myoglobin 
and a small but vital fraction i's present in mitochondrial and 
microsomal cytochromes. A substantial portion, 0.5g is present 
as non-haem storage iron as ferritin or haemosiderin (Nimeh & 
Bishop, 1980). Ferritin differs from haemosiderin in being 
soluble, diffuse and mobile (Bothwell et aJ, 1979).
The usual diet contains 10-15mg/day iron of which 
about 10% is absorbed. Dietary iron can be of two types, haem- 
iron or of non-haem origin. Absorption of non-haem iron is less 
efficient than haem iron but can be enhanced by ascorbic acid 
and other nutrients, such as amino acids, especially cysteine 
(Torres et al, 1981) and sugars. Ascorbic acid is a particularly 
effective promotor of non-haem iron absorption because it is 
not only a powerful reducing agent and mononeric ligand o(r iron, 
but it also binds iron in equimolar concentrations (Bothwell 
et al, 1979). Iron seems to share a carrier mechanism with some 
other transition metalS and competitive inhibition can occur 
CBothweir et al, 1979; Solomons & Jacob, 1981).
After uptake by the mucosal cell, in the ferrous form, 
iron is either bound to an intracellular protein resembling 
transferrin or is incorporated into ferritin in the epithelial 
cell. The major factor regulating iron absorption under normal 
circumstances is the iron requirement of the body. Iron is
FIGURE XXX POSSIBLE INTERACTIONS OF ASCORBIC ACID, COPPER
AND IRON METABOLISM. (after Omaye & Turnbull, 1980).
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transported in the plasma bound to transferrin, in the ferric
9
form. It has been suggested (Evans & Abraham, 1973; Bothwell 
et al, 1979) that the conversion of ferrous iron to the ferric 
form involves the copper-carrying protein, ceruloplasmin, because 
copper deficient swine showed decreased absorption of iron and 
the impairment was found to be at the level of transfer of iron 
to the plasma (Lee et a!L, 1968). The situation could be 
alleviated by copper, but ceruloplasmin had a more rapid action 
(Lee et al, 1968; Ragan et al, 1969). The effect of hypocerulo- 
plasminaemia was not evident until ceruloplasmin levels had 
fallen to 1% of normal in swine (Roeser et al, 1970).
Transferrin readily circulates in the intestinal spaces 
and exchanges iron with all cells of the body. Normally, most 
of the iron is delivered to developing erythrocytes. However, 
excess iron is stored as ferritin or haemosiderin, found 
chiefly in the bone marrow, liver and spleen. Again, iron 
as ferritin is in the ferric form and it is believed that for 
the transfer from transferrin to ferritin, it is necessary that 
the iron be converted to the ferrous form. It is possible
that ascorbic acid has a part to play here (Mazur et al, 1960)
and it is evident that ascorbic acid is involved in the release 
of iron from ferritin (Mazur et al, 1955; Crichton et al, 1980).
A recent report is in agreement with this hypothesis (Bienfait 
& Yan den Briel, 1980) and adds that the reaction is strongly 
stimulated by copper:'ions ’in vitro’. Further evidence that 
ascorbic acid is important as an intermediate in iron metabolism 
is its ability to promote the availability of storage iron for 
chelation by desferrioxamine (Wapnick et al, 1969) and to 
increase serum iron levels in subjects with iron overload. 
(Wapnick et al, 1970) . Lynch et aT, (1967) have suggested that 
iron overload may result in an accelerated catabolism of ascorbic 
acid and thus contribute to the scorbutic state found in many 
siderotic Bantu. If ascorbic acid status is affected by the 
magnitude of iron turnover in the body, then iron deficient 
subjects, in whom ascorbic acid utilisation for this purpose 
would be decreased to a minimal level, might be expected to 
show higher levels of ascorbic acid in the tissues. Indeed, a
study by Jacobs et al (1971) reported such an event. In
addition, ascorbic acid deficiency in guinea pigs caused serum
ferritin to fall and blocked the rise in serum ferritin 
observed in response to acute iron loading in control animals ^ - 
(Roeser et a!L, 1980). A single oral dose of ascorbic acid 
(75mg/kg) resulted in a significant-rise in serum ferritin.
The final stage in the transfer of iron from ferritin 
to transferrin is the oxidation of ferrous ions to the ferric 
form. Ceruloplasmin is again thought to be involved here 
(Bothwell et al, 1979). In copper deficiency, iron accumulates 
in storage sites and this can be corrected by the administration 
of copper. However, ceruloplasmin acts more rapidly, suggesting 
that this is the active agent rather than copper (Roeser et^  al,
197Q: Williams et al. 1974; Ragan et alT 1969). In scorbutic 
guinea pigs, a greater proportion of the hepatic and splenic 
non-haem iron is insoluble and. this situation can be rectified 
by ascorbic acid administration (Bothwell et al. 1979), suggesting 
that ascorbic acid may be involved in the solubilisation of 
iron stores. The sudden rise in the plasma iron concentration 
when ascorbic acid deficient human subjects were given ascorbic 
acid is consistent with a similar situation existing in man 
(Wapnick et_ al, 1970).
At virtually every known step in iron metabolism, 
including storage, transport, biosynthesis and degradation, 
ferrous to ferric ion cycles appear to play a most significant 
role. It appears that ascorbic acid and ceruloplasmin have 
opposing roles in iron metabolism, ascorbic acid as a ferroreductase 
and ceruloplasmin as a ferroxidase.
Ceruloplasmin is a copper containing glycoprotein of 
plasma, made in the liver. Although not considered a transport 
protein in the manner of transferrin, it does account for 85-90% 
of the copper in plasma, the remainder being bound to albumen 
(Hsieh & Frieden, 1976). It has been suggested that ceruloplasmin 
may be the major antioxidant in serum (Dormandy, 1978) based 
on its ability to inhibit autoxidation of lipids induced by 
ascorbic acid or inorganic iron (Al-Timimi & Dormandy, 1977).
In the adult human, ceruloplasmin oxidase activity 
does not vary appreciably under normal conditions. However, 
the glycoprotein concentration is decreased during infancy and 
Wilson's disease and is increased in pregnancy, after acute
infection and myocardial infarction and with cancer (Linder 
et al, 1979) . It has also been reported to be increased in 
smokers (Davidoff et al, 1978). A number of hormones, notably 
oestrogen, may be involved in the control of ceruloplasmin levels 
in different physiological states and regulatory effects of 
copper have also been reported (Linder et aT, 1979). In rats 
Pribyl and Schreiber (1977) reported that oestrogens caused 
an increase in ceruloplasmin, which could be potentiated by 
ascorbic acid (5Qmg/day) although the vitamin had no effect 
alone.
The involvement of both ascorbic acid and ceruloplasmin 
in the mobilisation and transfer of iron is interesting since 
both are known to be capable of scavenging superoxide anions 
(Nishikimi, 1975; Halliwell & Foyer, 1976; Goldstein et al, 1979). 
Lovstad (1981) reported that ceruloplasmin, via its ferroxidase 
activity, is able to prevent ferrous ion-induced peroxidation, 
which results in haemolysis. Copper deficiency in a human 
subject has been reported to have resulted in a decrease in 
superoxide dismutase and erythrocytic copper together with 
dramatic decreases in both plasma copper and ceruloplasmin 
(Gkahata et‘ al, 1980). The superoxide dismutase found in red 
blood cells contains copper and zinc and accounts for 60% of 
the red blood cell’s copper. A similar effect has also been 
reported in copper deficient rats and pigs (Williams eit aT, 1975; 
Paynter et aJ, 1979).
There are, in addition, reports of interrelationships 
between ascorbic acid and copper. High levels of ascorbic acid 
depress copper absorption (Van Campen & Gross, 1968) and wholebody 
studies suggest that this is achieved predominantly by a decrease 
in absorption. Evans eb a]L (1970) demonstrated that ascorbic 
acid decreased the binding of copper by metallothionein, a 
mediator in copper absorption, from both intestinal and hepatic 
origin, and thereby inhibited the formation of mercaptides. In 
addition, dietary ascorbic acid has been reported to reduce 
the uptake of radio-labelled copper by the liver, regardless of 
whether the isotope was given orally or intraperitoneally (Hill 
& Starcher, 1965).
Many trace elements are known to interfere with copper
absorption (Dayies, 1972), such as zinc, leading to an 
imbalance in the copper/zinc ratio (Van Campen, 1969).
However, the effect abscorbic acid has of exacerbating 
existing deficiency seems to be restricted to copper deficiency 
since zinc and iron deficiencies were not similarly affected 
CHill & Starcher, 1965).
It was decided to follow studies of the effects of 
large doses of ascorbic acid on synthesis and degradation of 
hepatic haem, by an investigation into the effects of large 
doses of ascorbic acid on the related trace elements, iron and 
copper, in order to try to find a mechanism of action of the 
vitamin. Iron and copper were chosen since ascorbic acid 
seems to be very closely linked with these two transition metals
II METHODOLOGY
a) Haem Synthesis and Degradation
Animals were prepared as previously described, receiving 
15Qmg b.d. ascorbic acid for 4 days. Delta-amino laevulinic 
acid synthetase and microsomal haem oxygenase were determined, 
as described in Chapter 2, in the total liver homogenate and 
10,00Qg fraction respectively. In addition, the haem content 
of the total liver and of the washed microsomal fraction was 
also determined, together with protein concentration of the 
various fractions used. In order to investigate a dose response 
relationship with respect to haem, the pigment concentration was 
determined in both the whole liver homogenate and in the washed 
microsomal fraction of guinea pigs given various doses of ascorbic 
acid (0-30Qmg /day).
b) Ceruloplasmin and Haemoglobin
The two carrier proteins were determined, haemoglobin 
in whole blood and ceruloplasmin in serum, by the methods 
described in Chapter 2. Determinations were carried out in 
animals treated for both 4 day and 28 day periods with 300mg/day 
ascorbic acid. In addition, measurements were made in groups 
of animals which had received various doses of ascorbic acid 
over a period of 4 days (0-300mg/day).
c) Serum and Liver Trace Elements
Copper, iron and zinc concentrations were measured in 
the serum and liver of animals treated with a range of doses 
of ascorbic acid over a period of 4 days. In addition, the 
trace elements were also determined in animals which had received 
3Q0mg/day for 28 days. The methods used are described in 
Chapter 2.
Ill RESULTS
The mean activity of delta-amino laevulinic acid
synthetase rose to 219% of the control values (p<0.01),
whereas microsomal haem oxygenase fell to 55% of the control
value (p<0.01) (TABLE 21). Microsomal haem concentrations
mirrored the effects seen with the haemoproteins, cytochrome
P450 and b_ as reported in Chapter 3 ( p < 0.001) but total 5
liver haem concentrations remained unchanged during the 4 
day dosing period.
When a range of dose levels of ascorbic acid was used
CTARLE 22), the fall in microsomal haem did not start to
occur until 200mg/day and was only slight at this level, as 
was seen with the concentrations of the haemoproteins in 
Chapter 3.
Treatment of guinea pigs with 300mg/day ascorbic 
acid for 4 days resulted in a statistically significant increase 
in haemoglobin of 14%, whereas ceruloplasmin concentration 
was decreased by 19% (TABLE 23). Neither of these effects 
were apparent following a 28 day treatment period with 300mg/ 
day ascorbic acid. When a range of doses of ascorbic acid 
were used (TABLE 24), no effect on either carrier protein was 
seen with less than 300mg/day of the vitamin.
TABLE 25 and 26 show the changes in copper, iron and
zinc concentration in both serum and liver samples from animals 
treated with 300mg/day ascorbic acid for 4 day and 28 day 
periods. These changes were all insignificant, although trends 
were apparent. Therefore, no real significance can be attached 
to these results. However, it should be remembered that only 
small groups of animals were used.
When guinea pigs were given smaller doses of ascorbic 
acid, 50mg/day and lOOmg/day, there was again no significant 
change in either the serum or liver concentrations of copper, 
iron or zinc.
TABLE 21 EFFECT OF THE ADMINISTRATION OF ASCORBIC ACID
(300mg/day) FOR 4 DAYS ON HEPATIC HAEM METABOLISM 
IN THE GUINEA PIG.
C O N T R O L  T E S T
Delta-amino laeyulinic 8 1.26 + 0.12 2.70 + 0.43 p<0.01
£9jid synthetase (218 7  28%)
(pmol/mg protein)
Microsomal haem 8 64.9 j+10*3 32.7 +_ 6.9 p<0.01
Oxygenase (55 + 12%)
(pmol/mg protein
Microsomal haem 10 1.13 _+ 0.08 0.62 0.07 p< 0.001
(nmol/mg protein) (58 + 8%)
Total haem 6 1.70 _+ 0.12 1.6 _+ 0.09 n.s.
(nmol/mg protein)
Results are expressed as mean + SEM. Figures in brackets 
represent the test group expressed as a percentage of the 
control group. The statistical significance was determined 
by a paired Student’s T-test.
TABLE 22
CONTROL 
50mg / day 
lOOmg/ day 
200mg/ day 
300mg/ day
EFFECT OF ADMINISTRATION OF DIFFERENT DOSES OF ASCORBIC 
ACID ON THE HAEM CONCENTRATION IN DIFFERENT LIVER FRACTIONS 
OF THE GUINEA PIG.
n. mol.4/ mg>PROTEIN 
NO. TOTAL HOMOGENATE WASHED MICROSOMES
8 1.93+0.24 1.19+0.06
4 1.25+0.21 1.32+0.09
8 1.61+0.19 1.22+0.02
4 1.76+0.05 0.96+0.02
6 1.60 + 0.18 0.62 + 0.07 ***
Results expressed as mean _+ SEM. Statistical 
significance was determined by a paired Student's 
T- tes t.
p <  0.001 when test group is compared with control.
TABLE 23 EFFECT OF ADMINISTRATION OF ASCORBIC ACID (300mg/day) 
ON HAEMOGLOBIN AND CERULOPLASMIN CONCENTRATION 
IN GUINEA PIGS.'
CONTROL TEST SIGNIFICANCE
HAEMOGLOBIN - 4 days 12.9 + 0.4 14.5 + 0.2 (114 + 5%) p<0.05
Cg/lOOml)
HAEMOGLOBIN - 28 days 13.2 + 0.4 12.8 + 0.6 ( 98 + 6%) n.s.
Cg/lOOml)
CERULOPLASMIN - 4 days 50.6 + 7.8 37.1 + 4.1 (81,2 + 14%) n.s.
Cpmol/min/I)
CERULOPLASMIN- 28 days 39.5 + 1.9 41.3 + 2.9 (102 + 8%) n.s.
Cpmol/min/l 
Bandrowski*s Base)
Results expressed as nean ± SEM. Results in brackets 
represent the test value expressed as a percentage of 
the control value. Level of significance determined by 
means of paired Student’s T-test in the case of the 4 
day treated animals and by an impaired test for the 28 
day groups. All groups contained 6 animals with the 
exception of the 28 day test group which had only 5 
animals.
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TABLE 24
CONTROL
5Gmg/day
lOOtmg/day
3QGmg/day
EFFECT OF ADMINISTRATION OF A RANGE OF DOSES OF 
ASCORBIC ACID OVER A PERIOD OF 4 DAYS ON 
HAEMOGLOBIN AND CERULOPLASMIN CONCENTRATION IN 
GUINEA PIGS.
NO.
g/lOOml
HAEMOGLOBIN
pmol/min/1 Bandrowski’s Base 
CERULOPLASMIN
12.7 + 0.5
11.8 + 1.0 
11.9 + 1.6 
14.5 + 0.5 *
48.0 +6.1
45.1 + 3.8 
44.8 + 4.2
37.1 + 4.1
Results are expressed as mean _+ SEM. The 
statistical significance was determined by 
a paired Student’s T-test.
* p <0.05
TABLE 25 EFFECT OF ADMINISTRATION OF ASCORBIC ACID (300mg/day)
FOR 4 DAYS ON SERUM AND LIVER CONCENTRATIONS OF
COPPER, ZINC AND IRON.
SERUM
Copper CpM) 
Zinc CjiM)
Cn_/Zn
Iron CpM)
Fe/Cn
LIVER
Copper Cpnol/g) 
Zinc Cpmol/g)
Cu/Zn
Iron (pnol/g)
Fe/Cu
CONTROL
69.9 + 8.4
84.64 + 6.70
0.87+ 0.16
89.7 +10.0
1.33 + 0.15
236.8 + 70.9
JL31.4 + 48.6
1.31+ 0.10
417.9 + 45.8
3.20 + 1.67
TEST
57.3 + 7.5
110.2 + 8.6 
0.56 + 0.11
90.8 + 13.0
1.72 + 0.31
358.1 + 70.2
302.9 + 69.1
1.25 + 0.11
418.6 + 60.3
1.78 + 0.66
Results expressed as mean + SEM. Determination 
of statistical significance by a paired Student's 
t-test failed to reveal any statistical significance 
between test and control groups. Each group 
contained 6 animals.
TABLE 26 EFFECT OF ADMINISTRATION OF ASCORBIC ACID (300mg/day)
FOR 28 DAYS ON SERUM AND LIVER CONCENTRATIONS OF
COPPER, ZINC AND IRON.
SERUM
Copper (pM) 
Zinc (pM)
Cu/Zn
Iron CpM)
Te/Cu
CONTROL
45.3 + 2.3
82.6 + 2.5
0.55 + 0.03
74.4 + 5.9
1.69 + 0.19
TEST
44.5 + 5.3
76.2 + 4.0
0.58 + 0.05
85.5 + 5.1
2.06 + 0.32
LIVER
Copper
Zinc
Cu/Zn
Iron
Fe/Cu
(|im:pl/g)
(pmol/g)
(pmol/g)
405.3 + 56.4
444.3 +55.5
0.92 + 0.67
337.9 + 26.1
0.96 + 0.21
445.9 + 57.0
452.6 + 28.9
0.98 + 0.10
396.3 +20.8
0.94 + 0.14
Results expressed as mean ■¥ SEM. The use of an 
unpaired Student’s t-test failed to reveal any 
statistical significance between control and test 
groups. The control group contained 6 animals and 
the test group 5 animals.
TABLE 27 EFFECTS OF THE ADMINISTRATION OF A RANGE OF DOSES
OF ASCORBIC ACID FOR 4 DAYS ON SERUM AND LIVER
CONCENTRATIONS OF COPPER, ZINC AND IRON IN GUINEA PIGS.
SERUM
C O N T R A  L
c?)
50 mg jday
O J
PO mg j
C«)
clay
Copper C^M) 48.4 + 10.9 44.7 + 5.6 42.6 + 2.9
Zinc CpM) 89.3 ■* 14.8 92.9 + 11.1 96.4 + 4.9
Cu/Zn 0.92 -+ 0.39 0.50 + 0.09 0.44 + 0.01
Iron C*lM) 80.5 ± 14.9 77.02 + 11.3 105.4 + 22.0
Fe/Cu 1.42 ± 0.36 1.65 + 0.50 2.54 + 0.44
LIVER
Copper Cpnol/g) 462.0 + 123.8 547.9 + 100.1 318.7 + 79.8
Zinc (^ imol/g) 273.9 + 70.0 411.4 + 27.4 300.0 + 47.8
Cu/Zn 1.57 + 0.24 1.32 + 0.19 1.28 + 0.13
Iron Cpmol/g) 374.2 + 71.2 314.0 + 59.3 487.5 + 121.9
Fe/Cu 1.71 + 1.41 0.64 + 0.16 1.38 + 0.39
Results expressed as mean + SEM, The use of a
paired Student’s t-test failed to reveal any
statistically significant difference.
IV DISCUSSION
The administration of large doses of ascorbic acid 
to guinea pigs resulted in induction of the rate limiting 
haem synthetic enzyme, delta-amino laevulinic acid synthetase, 
with a corresponding decrease in the degradatory enzyme, 
microsomal haem oxygenase. These results, coupled with a 43% 
decrease in microsomal haem, suggest an attempt on behalf of 
the liver to conserve haem.
The decrease in microsomal haem concentration mirrors 
the effect, reported in Chapter 3, on microsomal cytochromes:P450 
and b^. Similarly, the first signs of a decrease were seen 
at dose levels of about 200mg/day for both microsomal haem 
and the two cytochromes. Total liver haem concentration-; 
remained unchanged, suggesting that there may have been a slight 
increase in non-microsomal haem since microsomal haem had 
fallen in concentration. It is possible that some of the other 
haemoproteins of the liver, such as catalase, peroxidase or 
the respiratory haemoproteins, had been increased at the 
expense of the microsomal haemoproteins, although it should be 
remembered that microsomal haem is a relatively small proportion 
of the total haem.
Hence ascorbic acid seems to exert either a direct or 
indirect effect following the formation of delta-amino laevulinic 
acid but prior to the formation of a complete cytochrome P450 
molecule. Examination of Figure XXVIII suggests that, presuming 
that the formation of the haem precursor, protoporphyrin IX 
occurred normally, ascorbic acid could exert an effect on the 
incorporation of iron by ferrochelatase, the formation of the 
cytochrome P450 apoprotein or the ability of the apoprotein to 
combine with haem to form a complete cytochrome P450 molecule.
In deficient guinea pigs, Omaye and Turnbull (1979b;
1980) reported the absence of an effect of ascorbic acid on haem 
synthesis and degradation following studies with radioactive 
labels. They proposed that apoprotein synthesis or the in­
corporation of this with haem was the more likely site of action 
of the vitamin. Similarly, Rikans e_t ad (1977) were unable to 
demonstrate an effect on haem synthesis in ascorbic acid deficient 
guinea pigs. However, Walsch and De^witz (1980a) reported
that microsomal haem oxygenase was increased two-fold after 
14 days deprivation and decreased by 20% below control levels 
after 21 days deprivation of ascorbic acid in the guinea pig.
These authors discussed the association of this change in 
activity of the enzyme with the enhanced degradation of a 
part of the cytochrome P450 haem also seen at this particular 
stage of ascorbic acid deficiency (Walsch & Deg&vitz, 1980b).
In addition, the authors suggest that the altered catalytic 
properties of haem oxygenase might be brought about by modif­
ications in the surrounding microsomal membrane. This hypothesis 
is strengthened by the results of Schulze et a!L (1970), who 
reported a reduction in the phospholipid content of microsomes 
in ascorbic acid deficient guinea pigs. Such a hypothesis could 
equally be applied to the situation seen with ascorbic acid 
treated guinea pigs, especially as decreases in the concentrations 
of phospholipid components of microsomal membranes occurs 
(Chapter 4). In addition, lipid appears to be involved in the 
incorporation of metal into haem (Yoshikawa & Yoneyama^ 1964; 
Manzonowski et ad, 1966), although its role is not clear. 
Phosphatidic acid was found to stimulate haem synthesis but 
phosphatidylcholine and phosphatidylethanolamine had no effect.
Returning to the effect of large doses of ascorbic acid 
on haem synthesis, Sato and Zannoni (1976) presented evidence 
for an association of ascorbic acid with the ferrous ion of 
cytochrome P450 on the basis of studies with metal chelators 
wbich had a high affinity for ferrous ions. Alternatively, 
as mentioned earlier, ascorbic acid could affect the formation 
or molecular structure of the apoprotein moiety of cytochrome 
P450, possibly causing an accumulation of unbound haem. A 
negative feedback response is known to be exerted by either haem 
(De Matteis, 1978a), the metal chelated within it (Maines &
Kappas, 1978) or indeed free iron (Maines & Kappas, 1977a) and 
so an accumulation of haem is contraindicated since delta-amino 
laevulinic acid has been shown to be induced. However, proto- 
phorphyrin IX has not been shown to exert such an effect on the 
enzyme pathway and hence it is conceivable that this intermediate 
could accumulate and result in the effects seen. Nevertheless, 
gel electrophoretic studies (Chapter 3) and work by Rikans et al 
(1978) suggest that both large doses and deficiency of ascorbic
.^cid result in alternations in the proportions of the various 
polypeptides associated with the multiple species of cytochrome 
P450.
It is also possible that haem is being used extensively 
elsewhere in the liver cell, as previously mentioned, such as 
for an increased requirement in catalase. There is no pattern 
immediately evident relating levels of cytochrome P450 to levels 
of catalase (Sweeney, 1976) . Both cytochrcme P450 and catalase 
are decreased following treatment with AIA and related drugs 
containing an allyl group and also by cobalt, but this effect 
is by no means consistent when other groups of xenobiotics, known 
to influence cytochrome P450 activity, are considered. Catalase 
and cytochrome P450 are both thought to be synthesised outside 
the mitochondrion, probably on the 'endoplasmic reticulum, and 
it has been suggested (Sweeney, 1976) that either provision of 
catalase and cytochrome P450 apoproteins is differentially 
regulated with synthesis of the latter having priority over 
the former or competition for haem reflects different affinities 
of the two haemoprotein apoproteins for their common prosthetic 
group.
Haem is not exported, to the red blood cells for 
example, and hence the raised haemoglobin levels can not be 
used as an explanation for this rise. The synthesis of 
haemoglobin in the precursor of the erythrocyte, the normoblast, 
takes approximately 6 days and studies with radiolabelled iron 
(Bothwell et al, 1979) showed that although it was incorporated 
into the haemoglobin within a few minutes, very little entered 
the circulation in the first two days in normal humans and from 
then on, it was released in an exponential fashion with a half 
life of 3.5 days. A similar statistically significant increase 
in haemoglobin has been reported in guinea pigs treated with 
150mg/day ascorbic acid for 7 days (Basu et al, 1979) and in 
guinea pigs treated with 200mg/day for 8 weeks (Veen Baigent et 
al, 1975),and in school boys (Loh et al, 1971), although a 
corresponding group of girls showed.no such effect.
In the studies with guinea pigs, (Veen-Baigent et al, 1975;
Basu ejt al, 1979) haematocrit values were similarly 
significantly increased, and Basu et al, 1979 also reported a 
non-significant increase in total and unsaturated iron
binding capacity in association with elevated plasma iron 
concentration. The improved haematological status of the 
guinea pigs could have been attributed to haemoconcentration 
rather than an effect on iron metabolism (Basu et^  al, 1979).
Ceruloplasmin levels fell despite the fact that Evans
and Abraham (1973) reported that changes in ceruloplasmin and
haemoglobin paralleled one another in copper deprivation and
repletion, with low copper levels resulting in low ceruloplasmin,
high tissue iron and low haemoglobin concentrations. This fall
in activity, however, corresponds with that predicted by Milne
and Omaye (1979), although it is not nearly so great. Serum
and hepatic iron levels, hepatic microsomal cytochrome P450
and b , and blood haem factors all appeared to be directly o
related to ascorbic acid intake in both guinea pigs and 
monkeys (Milne & Qmaye, 1979), whilst hepatic copper, plasma 
copper and ceruloplasmin were inversely related to ascorbic 
acid status.
Following 28 days treatment with the vitamin, these 
changes in haemoglobin and ceruloplasmin had been lost and the 
use of different dose levels suggested that a dose of 300mg/day 
was required for any effect to be seen.
Veen-Baigent 'et al (1975) reported a significant 
decrease in serum copper in response to ascorbic acid. However, 
in the present study, following 4 days treatment with ascorbic 
acid, a non—significant decrease in serum copper was seen, which 
corresponded with the decrease seen in the carrier protein, 
ceruloplasmin. In addition, the mean liver copper concentration 
was slightly increased possibly suggesting deposition of the 
metal in this organ. Zinc concentration, which can often be 
inversely related to copper (Strain et a!L, 1972; 1975), showed 
an increase in both serum and liver, suggesting an increase 
in availability. However, care should be taken in interpreting 
these results since changes were not statistically significant. 
Large doses of ascorbic acid have been reported to decrease 
absorption of copper in chicks (Van Campen & Gross, 1968) and 
since copper and zinc can compete for absorption (Bothwell et 
al, 1979; Solomons & Jacob, 1981), this might allow increased 
absorption of zinc at the expense of copper, resulting in the 
increase in tissue level seen. In several disease states, which
/have an accompanying ascorbic acid deficiency, including 
malignancy and haematological disorders (Strain et al, 1972;
1975) there is a significant decrease in the serum copper/ 
zinc ratio. It is not yet known whether a correlation actually 
exists between this ratio and ascorbic acid status.
After 28 days treatment with 300mg/day ascorbic acid, 
a different pattern was seen to that after 4 days treatment, 
perhaps indicating adaptation. Serum copper concentration 
was no longer decreased although tissue copper was still 
slightly increased. Changes in zinc concentration were seen, 
suggesting that any effect of ascorbic acid on the availability 
of zinc had been modified or lost. However, mean concentrations 
of iron in both serum and liver of treated animals were 
enhanced, perhaps reflecting the role of ascorbic acid of 
increasing intestinal absorption of iron and its distribution 
throughout the body (Bonkowsky et_ al, 1979). It should be 
remembered that small groups of animals were used and this fact 
might go some way to explaining the non-significance of the 
results. When comparing groups of animals, which had received 
different dose levels of the vitamin, there seemed to be no 
strong trends.
The idea cannot be excluded that large doses of 
ascorbic acid, via an effect on absorption, for example, or 
on distribution of trace metals, may exert an indirect effect 
on haem metabolism. A recent report (Drummond & Kappas, 1980) 
adds more metals to the list of those already known to modify 
hepatic haem metabolism (Maines & Kappas, 1977a). It is known 
that metal ion induction of haem oxygenase in the liver can be 
greatly altered by cysteine, reduced glutathione and diethyl- 
maleate (Maines & Kappas, 1976; 1977c), which presumably 
influence the availability of free metal ions to interact at reg­
ulatory sites for haem oxygenase (Maines & Kappas, 1976).
The possibility that metal ions may themselves affect the 
induction of microsomal haem oxygenase has been actively 
explored (Drummond & Kappas, 1979) since metal ion interactions 
in various biological systems are well known..
It is of interest that Drummond and Kappas (1980) 
reported that some trace elements eg. zinc and manganese,
/exhibit some tissue specificity as well as metal-ion-inducer 
specificities in blocking haem oxygenase synthesis and this 
may reflect differential tissue distribution patterns of 
inducer and blocking metal ions, differences in binding 
affinities or in cellular concentrations of chemical sub­
stituents which complex these ions eg. cysteine and GSH.
Zinc, in excess, is known to induce metallothionein 
formation in the liver of male rats (Webb, 1972; Cherian 
& Goyer, 1978). Thus metallothionein formation may also 
influence the extent of haem oxygenase induction and the 
associated perturbations of haem metabolism that can be 
elicited by certain metal ions.
Another factor which should be considered is that 
cobalt is known to be a substrate for ferrochelatase (Labbe & 
Hubbard, 1961) and the formation of a cobalt-porphyrin, 
lacking the activity of its ferrous counterpart, might well 
■result in induction of delta-amino laevulinic acid synthetase 
and the other effects seen. Indeed, cobalt chloride adminis­
tration is well known to produce a transient decrease in 
hepatic delta-amino laevulinic acid synthetase activity, this 
being followed by a substantial rebound induction of the enzyme 
(Maines & Kappas, 1975b; De Matteis & Gibbs, 1976).
It can be concluded that although the mechanism of 
action of large doses of ascorbic acid on hepatic mixed function 
oxidase activity and associated haem synthesis has not been 
characterised, evidence suggests that interactions of trace 
elements may indeed be involved. To elucidate this situation, 
detailed studies of the concentrations of a wide range of trace 
elements in a range of organs would be required, using ascorbic 
acid treated and control animals. In addition, determination 
of ferrochelatase activity may prove worthwhile since if an 
involvement with trace elements exists, it is likely that the 
interaction is occurring at this level.
Alternative investigations could involve further study 
of apoprotein synthesis and its incorporation with haem, an 
avenue still under investigation, with respect to ascorbic acid 
deficiency, in other laboratories. In addition, determination 
of peroxisomal catalase concentration may be advantageous,
^specially as this enzyme might be expected to be enhanced 
in activity in situations where cytochrome P450 was being 
broken down to its components either via lipid peroxidation, 
or possibly, and more importantly, through its ability to 
produce hydroperoxides and hence oxygenate substrates in 
the absence of the normal cofactors (Hrycay & O ’Brien, 1971), 
an activity which is reported to result in its own destruction 
Finally, although studies failed to reveal any effect of . 
large doses of ascorbic acid on lipid peroxidation, such 
studies should perhaps be extended with more sensitive 
methods for the detection of lipid peroxidation, since an 
augmentation of basal lipid peroxidation by ascorbic acid 
could account for the results seen with large doses of the 
vitamin.
F I N A L D I S C U S S  I O N
Many arguments have been advanced in favour of the 
use of large doses of ascorbic acid, both prophylactically 
and therapeutically. These are based on the results of various 
studies, which suggest that humans and animals who undergo 
biochemical stress or body malfunctions are characterised by 
reduced ascorbic acid levels in plasma and leucocytes (Rinehart 
et al, 1936; Kakar et al, 1974; 1975; Wilson, 1975). On 
recovery from the stress or following ascorbic acid supplement­
ation, concentrations of the vitamin returned to that considered 
to be normal. Further evidence for an increased requirement 
of the vitamin under conditions of stress has been derived from 
the presence of high concentrations of ascorbic acid in several 
tissues concerned with response to biochemical stress, such as 
the adrenals, pancreas and leucocytes. In addition, animals 
known to synthesise their own ascorbic acid, such as the rat, 
have been reported to increase their synthesis ten-fold in 
response to certain drugs (Conney et al, 1961; Boyd & Taylor, 1969).
On the basis of these arguments, various authors, 
including Pauling (1970) and Stone (1972), have concluded that 
since man cannot synthesise ascorbic acid, during periods of 
stress the vitamin should be consumed in therapeutic quantities.
Although there is a wide variation throughout the world 
in the Recommended Daily Intake of ascorbic acid, in general 
this intake is based upon protection against scurvy (Dickerson, 
1979). Doubt has been cast on the ability of these quantities 
of ascorbic acid to protect against diseases.and conditions 
in which low plasma ascorbic acid concentrations are found 
(Pauling, 1970; Stone, 1972) and consequently Pauling (1970) 
suggested doses of l-9g per day, depending on the individual 
concerned. Nevertheless, recent work by Kallner et al (1979) 
has indicated that body pools can be saturated with an intake 
of lOOmgyday in adults. This dose should be increased for 
smokers (Pelletier, 1975) and women on the contraceptive pill 
(Rivers, 1975) since it is known that components of cigarette 
smoke and oestrogens increase the requirement for the vitamin.
.This work was carried out using healthy volunteers 
(Kallner et al, 1979) and so perhaps it could be considered 
that individuals' subjected to a situation where plasma and 
tissue concentrations of the vitamin are decreased eg. cancer 
(Basu et al, 1974) and the common cold (Wilson, 1975), may 
require additional ascorbic acid to maintain tissue stores. 
However, on the basis of the studies of Kallner et al (1979) 
it is difficult to see the advantage of regularly taking gram 
doses of the vitamin, since any ascorbic acid absorbed beyond 
the requirement for metabolism and saturation of the tissue^ 
is simply excreted unchanged or is metabolised through the 
body’s detoxification mechanisms and as such is no longer 
acting as a vitamin but as a drug. Metabolism of the excess 
ascorbic acid bythessmechanisms uses valuable cofactors, 
such as NADPH, and transport mechanisms, and indeed it would 
appear from the work of Houston and Levy (1975) that the 
vitamin can evoke competition for valuable sulphate, which is 
used in the phase II conjugation of drugs and is derived 
from dietary sources (principally sulphur-containing amino 
acids) and so limited in its availability.
The major part of the work described in this thesis 
has been concerned with the investigation of the hitherto almost 
totally neglected effects of large doses of ascorbic acid on 
hepatic drug metabolism.
The information on the absorption of large doses 
of ascorbic acid in man is limited. Whereas, the absorption 
of single oral doses of up to 180mg was between 71% of the 
dose (Kuebler & Gehler, 1970) and 80-90% of the dose (Kallner 
et' al, 1977), the absorption of single oral doses decreased 
to 50% after 1.5g and 16% after 12g (Kuebler & Gehler, 1970). 
From this data, using equations of saturable kinetics, it was 
concluded (Mayersohn, 1972) that the absorptive mechanism of 
ascorbic acid in man is a non-passive, saturable process.
Recent data (Hornig et al, 1980) suggests that the absorptive 
capacity of the intestine is reached with a single oral ilntake 
of 3g, since plasma ascorbic acid concentration was only 
slightly increased by larger doses. Extrapolation from these 
results suggested, under the conditions of the experiment, that
the maximum amount of ascorbic acid that could be absorbed 
over a 24hr. period was 1160mg. However, about 75% of the 
radioactive tracer dose used in the experiment could not be 
accounted for. It is unfortunate that labelled carbon 
dioxide was not measured, since this is not usually a pathway 
for excretion in man. The authors offered microbial destruction 
to gaseous products in the gut or interactions with nitrite 
as possible explanations. Hence it is possible that when 
large doses of ascorbic acid are ingested, additional excretory 
pathways come into play, such as expiration as carbon dioxide, 
a major excretory pathway in the guinea pig.
In tbe present series of experiments, 300mg/day as 
two equal doses, was given to guinea pigs, with a mean body 
weight of about 330g. The recommended intake of ascorbic acid 
for guinea pigs is 20-50mg/kg and a control chow diet contains 
about 40mg_/day. A dose of 300mg/day was chosen following 
extrapolation from the high doses recommended by some authors 
(Pauling, 1970) for man, taking into account the fact that 
the absorptive capacity is different and, in the guinea pig, 
the half-life of ascorbic acid is about 4 days compared with 
about 16 days in man (Norkus & Rosso, 1975). On the basis 
of this, 300mg to a 330g guinea pig is equivalent to about 
4.5gyday to a 70kg man. Hence, the effects of ascorbic acid 
on hepatic drug metabolism are in some ways representative 
of a situation that might occur in man.
It should not be forgotten that many drugs disturb 
ascorbic acid metabolism, resulting in an increased requirement 
for the vitamin. Among these are asprin, oestrogen, barbiturates, 
paraldehyde, the hydantoins, laminopyrine, antipyrine, ether and 
a wide variety of carcinogenic compounds found as atmospheric 
pollutants or as components of cigarette smoke (Krumdiek & 
Butterworth, 1974).
The results presented in this thesis, together with 
those of Holloway and Rivers (1981) indicate that large doses 
of ascorbic acid can no longer be considered totally inoccuous 
in the guinea pig, an animal species unable to synthesise the 
vitamin. It would appear that both excess and deficiency of
ascorbic acid affects the mixed function oxidase system (FigureXXXI) 
resulting in a decreased capacity to metabolise both exogenous 
and endogenous compounds such as steroids.
The inhibitory effect on the enzymes of the mixed 
function oxidase system was not extended to a generalised effect 
on either the liver cell or the endoplasmic reticulum, but 
it was characterised by altered haem synthesis, suggesting that 
cytochrome P450 formation or activity might be the target.
This hypothesis is reinforced by evidence that the polypeptide 
pattern of cytocbrome P450 apoprotein was Altered in pheno- 
barbital treated animals, receiving ascorbic acid and that 
hydroxylation of type I substrates, eg. biphenyl, by cytochrome 
P45Q was decreased, whereas type II substrates requiring oxygen­
ation by the modified P450, cytochrome P448, remained unchanged.
Since only some of the polypeptides were altered 
in deficiency CRikans et_ al, 1978) and excess, this adds 
weight to the argument that multiple forms of cytochrome P450 
exist (Guengerich, 1979). Ascorbic acid perhaps specifically 
affects some species of the cytochrome, leaving others unaffected 
and hence the 40-60% decrease seen in the cytochrome P450 
concentration of ascorbic acid deficient guinea pigs (Zannoni & 
Lynch, 1973;Degkwitz et 'al, 1975) and the decreases of 21% 
seen in ascorbic acid treated animals, are perhaps more severe 
than they appear at first sight, since some species of the 
haemoprotein may be virtually lost whilst others remain 
relatively unaffected. Ascorbic acid also appears to have 
substrate and organ specific effects (Sikic eh 'al, 1976; Kuenzig 
et al, 1977), which could explain the differences in response 
to various drugs seen between different species, the different 
sexes and different age groups.
In addition, the phospholipid required for cytochrome
P450 activity, phosphatidylcholine,and its precursor, phosphati-
dylethanolamine were significantly decreased in ascorbic acid
treated animals, as was the activity of the electron donor,
cytochrome b_. Stier C1976) proposed that a lipid halo exists 5
around the cytochrome P450 molecule (Figure XXXII) which accounts 
for about 20% of the microsomal phospholipids. If disruption
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of the lipid components were to occur here, the diffusion 
of lipid soluble compounds to and from the cytochrome could 
be severely affected. The lipid composition of membranes is 
also very important with respect to the activity of enzymes 
bound to the membrane, such as glucuronyl transferase and 
glucose-6-phosphatase. The decrease in activity of the former 
could be explained by such an effect of ascorbic acid on the 
phospholipid components of the endoplasmic reticulum. In 
addition to supplying phosphatidylcholine as a basic membrane 
structure, recent studies have shown that the conversion of 
phosphatidylethanolamine to phosphatidylcholine by methylation 
is important in some very special functions. These include 
release of histamine by rat basophils (Crews et aT, 1980), 
lectin-induced lymphocyte mitogenesis (Crews et al, 1979) 
and changes in membrane fluidity (Hirata & Axelrod, 1978).
These reports are of special interest since ascorbic acid
is also known to be involved in at least some of- these functions
,C
(Lewin, 1976; Chaterjee et al, 1975). It is, for instance, 
thought to potentiate the activity of adrenalin on adenylcyclase- 
induced cyclic-AMP production and reduce interfacial tension, 
together with a possible regulatory action of histamine secretion.
Of particular significance is the biphasic effect
of ascorbic acid, by which it is capable of exerting similar
effects on the mixed function oxidase system regardless of
whether it is present in the diet in deficient quantities or
in excess. The effects seen appear to obey a dose response
relationship, whereby cytochromes P450 and b_ and microsomal
5
haem concentrations all show their first signs of decrease
in concentration at a dose level of 200mg/day, which in all
cases, becomes highly significant at a dose level of 300mg/day.
It is also interesting that at a dose level of 50mg/day, both
cytochrome P450 and cytochrome b were increased in specific
5
activity, reflecting the results published earlier with doses
of 85mg/day (Sato & Zannoni, 1974).
7
The recently published work of Holloway and Rivers 
(1981), using both deficient and ascorbic acid supplemented 
guinea pigs, suggests a marked susceptibility of 7- a-hydroxylase 
to dietary extremes of the vitamin. Other workers (Bjorkhem &
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FIGURE XXXII.
Schematic representation of the incorporation of the 
hydroxylating enzyme system, cytochrome P450-cytochrome 
P450 reductase, embedded within the lipid matrix of 
the microsomal .membrane. The inner hatched area between 
the proteins represents the lipid moiety in a rigid 
quasi-crystalline state, while the outer hatched area 
denotes the rather fluid bulk of the lipid matrix.
CAfter Sackman & Stier, 1973).
Kallner, 1976; Zannoni, 1977) have stressed the effects of 
ascorbic acid deficiency on this important rate limiting 
enzyme in cholesterol biosynthesis and these recent results 
CHolloway & Rivers, 1981) may explain some of the anomalies 
seen in the literature concerning the effects of large doses 
of ascorbic acid on cholesterol metabolism. Some authors 
have reported that large doses of ascorbic acid result in 
increases in the blood cholesterol concentration in normal 
individuals (Anderson et al, 1972b; Morin, 1972) and in young 
male baboons CKotze et al, 1975), whilst other authors have 
supported the view that ascorbic acid, when taken in large 
quantities, is capable of reducing pre-existing hypercholesterol- 
aemia (fillis, 1954; Ginter et al, 1977; Kothari et al, 1977; 
Noxden et al, 1977) and decreasing bloodt cholesterol concen­
trations in young adults (Spittle, 1973). This discrepancy 
in effect of the vitamin might be attributable to a dose- 
dependent response as seen with cytochrome P450 concentration 
and ascorbic acid in the guinea pig.
Th_e membranes of the endoplasmic reticulum are a 
frequent site of damage under the influence of a variety of 
pathological conditions.and, of the various components of the 
membranes, the mixed function oxidase system and related 
haemoprotein, cytochrome P450, are particularly sensitive 
to attack. A decreased activity of the system, with loss of 
the cytochrome, is encountered after the administration of a 
range of drugs, in cholestasis and under conditions where the 
liver haem concentration is depleted through accelerated 
turnover, such as in iron overload and starvation (De Matteis, 
1978b). There are a number of reasons why the endoplasmic 
reticulum is so sensitive to a wide range of damaging agents:
i) The organelle contains the mixed function 
oxidases and hence is the site of deactivation 
of chemicals and also the site where some are 
changed into reactive intermediates.
ii) The mixed function oxidases are dependant for 
their activity on the integrity of the membranes, 
which explains the preferential loss of activity
in the presence of lipid peroxidation and compounds 
with detergent properties e.g. bile acids.
iii) Any agent causing an increased t u r n o v e r : '
of hepatic haem will provoke a decrease in 
cytochrome P450 concentration and a subsequent 
loss of function of the mixed function oxidase 
system.
It is of interest that cholestatis is one of the causes 
of loss of cytochrome P450 activity since change in activity of 
7— a-hydroxylation of cholesterol has been linked with both 
excess and deficiency of ascorbic acid. McLuen and Fouts (1961) 
first reported a depression in liver drug metabolism in rabbits 
with obstructive jaundice due to ligation of their bile ducts.
De Matteis (1978b) has reviewed the literature on cholestasis 
and loss of mixed function oxidase activity, and it would appear 
that the effect on drug metabolism is roughly proportional to 
the degree of histological damage and the extent of cholestasis, 
with severe damage being associated with membrane hypertrophy 
and liver enlargement, an interesting observation since animals 
treated for 28 days with 300mg/day ascorbic acid had liver 
enlargement which was not apparent in the animals treated for 
only 4 days.
Denk: et al (1971) concluded that the functional 
alterations of the endoplasmic reticulum observed in cholestasis 
could be ascribed in part to bile acids, themselves, acting as 
competitive inhibitors of drug metabolism and in part to the 
detergent action of bile acids on the endoplasmic reticulum, 
with subsequent disruption of its drug metabolising system.
Dietary extremes of ascorbic acid resulted in lower 
cholesterol 7- a -hydroxylase activity, lower bile acid turnover 
rate, prolonged bile acid half-life and increased plasma and 
liver cholesterol concentrations in guinea pigs (Holloway & 
Rivers, 1981). Both groups also exhibited lower biliary 
cholesterol saturation than controls and urinary bile acid 
excretion was 2-3 fold higher in guinea pigs treated with large 
doses of ascorbic acid. These results tend to suggest that 
ascorbic acid, indeed, can exert some influence over bile salt 
metabolism and excretion and thus the possibility that an effect 
on hepatic drug metabolism may occur secondary to this.
It may be relevant to note that among several steroids 
tested, those found to be most active in reducing bile acid 
flow have also been reported to be more active in causing 
microsomal damage (De Matteis, 1978b). Whether thes'e chemicals 
also inhibit the microsomal hydroxylation of bile acids, or some 
other microsomal system directly involved in biliary secretion 
is yet to be determined.
With regard to the mechanism of action, there is no 
conclusive evidence for any particular mode of action of the 
vitamin. Nevertheless, based on this study and other published 
data concerned with the interactions of deficient and large 
quantities of ascorbic acid with the mixed function oxidase 
system of the guinea pig, the following list of possible paths 
of action of the vitamin can be arrived at.
i) An effect on the synthesis of the apoprotein
or its combination with haem to form cytochrome P450.
ii) An effect through the oxygenation of substrates, 
mediated by cytochrome P450, through a decreased 
availability of superoxide anions due to ascorbic 
acid acting as a scavenger of this anion.
iii) Lipid peroxidation, stimulated by ascorbic acid, 
resulting in an increased degradation of cytochrome 
P450 haem.
iv) An effect, possibly mediated by trace element 
interactions, on the availability of ferrous iron 
to be chelated with protoporphyrin IX to produce 
haem.
v) A shift in the oxidation state of iron from the 
ferrous to the ferric form, resulting in a decreased 
availability of ferrous ions for haem synthesis.
vi) An increased requirement for other haemoproteins, 
such as catalase, possibly via cytochrome P450’s 
ability to utilise hydroperoxides, leading to 
competition for haem at the expense of the 
microsomal cytochromes.
Evidence for the first hypothesis is found in the 
work of Rikans et' al (1978) with gel electrophoresis, where 
polypeptides, thought to represent species of cytochrome P450 
(Guengerich, 1979), were altered in concentration in ascorbic 
acid treated guinea pigs. A similar effect on a band of 
molecular weight 52,000 daltons was found in the present study.
It is perhaps significant that Rikans et a!L (1978) found a 
similar decrease in a polypeptide of this molecular weight, 
together with two other polypeptides in ascorbic acid deficient 
guinea pigs. An improperly formed apoprotein of cytochrome P450 
may not be capable of binding with haem to form an active 
cytochrome, or if it does bind, it may not prove suitable for 
binding to endoplasmic reticulum membranes.
Superoxide anions are thought to be intermediates 
in the formation of an active oxygen species, possibly an oxene 
involved in cytochrome P450-mediated oxygenation of substrates 
(Coon et al, 1977; O ’Brien, 1978; White & Coon, 1980) .Ascorbic 
acid is known to scavenge superoxide anions (Nishikimi, 1975; 
Halliwell & Foyer, 1976), thus emulating the natural superoxide 
dismutase. Hence it is feasible that excess quantities of 
ascorbic acid might result in a decreased availability of 
superoxide ions. These ions, besides acting as an intermediate 
active oxygen species, may also serve as electron donors. By 
deactivating the superoxide anion, the ascorbic acid is thought 
to form an ascorbic free-radical, a form of the vitamin with 
equal reducing powers to its parent compound, which is efficiently 
reconverted to ascorbic acid by ascorbate free-radical reductase 
and is thought to be the first oxidation product of many ascorbate- 
dependent metabolic reactions, whereas dehydroascorbic acid is the 
second product, whose reductase appears to play a secondary role. 
(Arrfgoni' et al, 1981) .
Ascorbic acid has been reported to stimulate lipid 
peroxidation, especially when in the presence of ferrous ions 
(Wills, 1965; Schaefer Jet' al, 1975). Nevertheless, other 
reports indicate that, perhaps via its antioxidant properties 
ascorbic acid can protect against lipid peroxidation (Jayanthi 
Bai et al, 1979). One of the ways by which haem breakdown can
occur is through lipid peroxidation (De Matteis, 1978a), 
resulting in the formation of uncharacterised compounds, known 
as green pigments. No effects of lipid peroxidation was found 
in the present study. However, an insensitive method was used 
and it would be of interest to repeat the study using a more 
sensitive method, since the effects seen with the peroxidation 
of lipids, such as membrane disruption and loss of haem, could 
explain the results seen with large doses of ascorbic acid on 
some membrane bound enzymes and the microsomal cytochromes.
Ascorbic acid is known to have a profound effect on 
iron absorption and disruption (Bothwell et_ al, 1979) and hence 
it is not unlikely that it might also alter the availability 
of iron for incorporation into haem by ferrochelatase. Sato 
and Zannoni (1976) reported a 2:1 ratio of ascorbic acid to 
cytochrome F450 in the microsomes of both deficient and control 
animals. This ratio was maintained even after partial purifi­
cation, suggesting an association of the vitamin with the cyto­
chrome, possibly through the ferrous iron (Sato & Zannoni, 1976).
It is also significant that large doses of the vitamin (300mg/day) 
were incapable of significantly increasing the microsomal 
ascorbic acid concentration of ascorbic acid, in spite of the. 
fact that total liver and cytosolic concentrations of the 
vitamin were significantly raised in the treated guinea pigs. 
Ascorbic acid also affects the absorption of various other trace 
elements, including copper (Carlton & Henderson, 1965) and hence 
an alteration in the proportion of trace elements might affect 
the ability of iron to bind with haem. Finally, other metals, 
such as cobalt are known to act as substrates for ferrochelatase, 
although, cobalt porphyrins lack the activity of their ferrous 
counterparts (Labbe & Hubbard, 1961). Sulphydryl agents, such 
as heavy metals, can convert cytochrome P450 to cytochrome P420 
(Murakami & Mason 1976), an unstable derivative with less affinity 
for haem (Maines'set al, 1974), yet another way by which drug 
metabolism could be affected.
Also involved in the distribution of iron is cerulo­
plasmin, which has an opposing action to ascorbic acid, being 
a ferroreductase (Bothwell et al, 1979). Omaye and Turnbull (1980)
suggested that, in ascorbic acid deficient animals, a shift 
occurs in the balance of ferrous and ferric ions due to the 
allosteric regulation of copper and ceruloplasmin, both of 
which are increased in concentration in such animals (Milne & 
Omaye, 1979). When guinea pigs were given pharmacological 
doses of the vitamin, the reverse was seen, with ceruloplasmin 
and copper concentrations both being decreased (Milne & Omaye, 
1979). Studies with guinea pigs treated with 300mg/day ascorbic 
acid also revealed an insignificant decrease in both cerulo­
plasmin and copper. Since opposing actions of ceruloplasmin 
and ascorbic acid are ubiquitious in reactions involving iron, 
it is perhaps not unlikely that an effect of ascorbic acid is 
also involved in the formation of haem. It should be noted 
that, like ascorbic acid, ceruloplasmin is also an augmentor 
of superoxide dismutase activity (Goldstein et_ al, 1979).
Finally, since the haem of the microsomal cytochromes 
form only a part of the total liver haem, it is possible that 
if other haemoproteins were to be required in increased quantities 
due to the presence of large quantities of ascorbic acid in the 
liver, competition might occur for haem, resulting in a decreased 
availability of haem for cytochrome P450 formation and a conser­
vation on the part of the endoplasmic reticulum as indicated 
by a decreased breakdown of existing haem. Cytochrome P450 is 
known to be capable of bypassing the normal procedures for 
cytochrome P450-mediated oxygenations by utilising hydroperoxides 
a process which results in its own destruction (Hrycay & O ’Brien, 
1971). The production of large quantities of hydrogen peroxide 
would require catalase for its removal, perhaps resulting in 
an increased requirement for catalase. Such a process could 
explain the decreased availability of the cytochromes and also 
of haem for P450 and b,_ synthesis, since the more cytochrome P450 
broken down by this system, the greater the need for catalase 
would be.
Central to this discussion is the fact that, in 
addition to regulating its own synthesis at the level of delta- 
amino laevulinic acid synthetase, haem can control its own 
-degradation by regulating the activity of haem oxygenase, for 
which it can act as an inducer. Hence two separate feed-back
mechanisms are dperating in opposite directions (De Matteis 
1978b).
Maines and Kappas (1976) suggested that induction 
of haem oxygenase synthesis can occur via ways other than through 
haem. They hypothesised that cobalt and other metals may 
function by complexing SH groups on a liver repressor molecule, 
resulting in haem oxygenase synthesis.
None of the above arguments is strong enough to draw 
a .positive conclusion as to the mode of action of dietary 
extremes of ascorbic acid on the hepatic mixed function oxidase 
system. Due to the nature of the compound under consideration, 
a vitamin, it is unlikely that the effect is a direct one, but 
due to the wide-ranging activities of ascorbic acid in the 
body, it is difficult to pin-point a single indirect mechanism 
whicEL could result in the effects seen.
Nevertheless, the fact still remains that potentially 
detrimental effects of large doses of the vitamin on the mixed 
function oxidase system are seen in the guinea pigs and these 
studies- can be related to effects seen with a small number of 
clinical studies. Hence it is important that the situation 
regarding the prophylactic use of large doses of ascorbic acid 
should be reviewed since some groups of individuals might be 
particularly at risk, including infants and growing children, 
the elderly and those on multi-drug regimens. Of special 
concern is the use of large doses of the vitamin in conjunction 
with drugs which are extensively sulphated during the first pass 
through the intestinal wall and the liver eg. isoproterenol 
(Houston, 1977). In the case of this drug, sulphation renders 
tho drug inactive but competition for sulphate could result in 
significant increases in the blood level of unmetabolised drug 
resulting in drug overdose.
It is perhaps significant that a number of recurring 
associations with ascorbic acid.exist in the literature,these can 
be illustrated by transition metal interaction^ involvement 
with thiol and sulphate groups, associations with oxygen economy, 
histamine release and the processes of regeneration and healing. 
In addition, there are links with a number of copper-containing
enzymes, including cytochrome^' oxidase, superoxide dismutase, 
ceruloplasmin, uricase, dopamine- 3-hydroxylase and tryptophan 
hydroxylase (O’Dell, 1976). The functions of most of these 
enzymes have been discussed previously, but to complete the 
picture, cytochrome oxidase is associated with the mitochondrial 
respiratory chain, dopamine- 3 -hydroxylase is a mono-oxygenase 
that catalyses the oxidation of the beta carbon of dopamine, 
to form norepinephrine in the presence of ascorbic acid and 
tryptophan hydroxylase catalyses the production of 5-hydroxy- 
tryptophan (O’Dell, 1976).
The studies detailed in this thesis have centred around 
the effects of large doses of ascorbic acid on the hepatic drug 
metabolising enzymes. However, it should not be forgotten as 
was discussed in the Introduction, that other adverse effects 
of large doses of the vitamin have been reported in the literature 
and two of these, the effects of oxalate and uric acid excretion, 
have also been investigated, using human volunteers receiving 
3gyday ascorbic acid as three divided doses over a period of 
one week.
Individual variation was apparent in the excretion 
of both oxalate and uric acid but no consistent effect of large 
doses of ascorbic acid was evident. These effects are contrary 
to those reported earlier (Lamden & Chrystowski, 1954; Briggs 
et'.'al, 1973; Stein et ;al, 1976) . However, recent reports on the 
effects of large doses of the vitamin on the excretion of oxalate 
(Schmidt" et' al, 1981; Gaskill, personal communication) and uric 
acid (Mitcb eb al, 1981) have reached the conclusion that large 
doses of ascorbic acid do not generally increase the excretion 
of either oxalate or uric acid.
In the past, the effects of ascorbic acid on the 
excretion of these two compounds has been used to counter the 
claim that large doses of the vitamin are totally innocuous.
These arguments are no longer valid. However, this thesis provide 
strong new evidence, that the use of large doses of ascorbic acid 
is not necessarily without risk.
In conclusion, large doses of ascorbic acid, when given 
to guinea pigs, appeared to interfere in some way with the normal
status quo found in the liver, with specific effects on the 
mixed function oxidase system of the endoplasmic reticulum.
Hence, large doses of the vitamin cannot be viewed as wholly 
beneficial, especially when multi-drug therapy is being 
simultaneously practised, since competition has been shown 
to occur for essential molecules (Houston & Levy, 1975).and 
for binding sites.
The administration of large doses of ascorbic acid 
to infants and young children may also be contraindicated 
because of their rapid growth rate and the consequent increased 
risk of depletion of essential nutrients. In such instances, 
effects of large doses of the vitamin may be more than dose 
related. Pregnant women are another risk group for as Cochrane 
(1965) reported, infants born to women who had taken ascorbic 
acid supplements during pregnancy had an increased requirement 
for the vitamin, which resulted in scurvy when supplements of 
the vitamin in addition to the diet- were not forthcoming.
Using animal experimentation as a basis, it is 
difficult to reach any conclusions regarding the optimal dose 
-of the vitamin to be recommended for man. However, since 
Xallner et elL (1979) reported that maximal body turnover of 
ascorbic acid is reached with a dose of lOOmg/day, it could be 
argued that unless the basal requirement of the vitamin is 
increased due to concomitant use of, for example, drugs that 
interact with the vitamin, doses of ascorbic acid much larger 
than lOOmg/day cannot be utilised fully and are mainly excreted 
unchanged, and indeed doses significantly larger than this, of 
gram quantities, may well interact with normal hepatic drug 
metabolism in such a way as to increase the risk of drug toxicity, 
at least in some individuals.
Finally, on the basis of these results, it can no 
longer be assumed that gram quantities of ascorbic acid are 
totally without harmful effect, at least in the guinea pig and 
consequently, large doses of the vitamin should not be used 
indiscriminantly in the possibly vain hope that protection against 
the common cold will be achieved. However, therapeutic use of the 
vitamin in the treatment of chronic conditions, such as cancer 
and rheumatoid arthritis pose different questions and therefore,
the risks and benefits must be weighed carefully for each 
individual case.
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